EP2187893A2 - Boron-containing small molecules as anti-inflammatory agents - Google Patents
Boron-containing small molecules as anti-inflammatory agentsInfo
- Publication number
- EP2187893A2 EP2187893A2 EP09700012A EP09700012A EP2187893A2 EP 2187893 A2 EP2187893 A2 EP 2187893A2 EP 09700012 A EP09700012 A EP 09700012A EP 09700012 A EP09700012 A EP 09700012A EP 2187893 A2 EP2187893 A2 EP 2187893A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- exemplary embodiment
- compound
- substituted
- unsubstituted
- member selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052796 boron Inorganic materials 0.000 title description 21
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 title description 16
- 229940121363 anti-inflammatory agent Drugs 0.000 title description 2
- 239000002260 anti-inflammatory agent Substances 0.000 title description 2
- 150000003384 small molecules Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 514
- 238000000034 method Methods 0.000 claims abstract description 125
- 125000000217 alkyl group Chemical group 0.000 claims description 251
- -1 -(CH2)2CH3 Chemical group 0.000 claims description 217
- 102000004127 Cytokines Human genes 0.000 claims description 114
- 108090000695 Cytokines Proteins 0.000 claims description 114
- 150000003839 salts Chemical class 0.000 claims description 114
- 125000003118 aryl group Chemical group 0.000 claims description 76
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 66
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 54
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 54
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 53
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims description 52
- 201000004681 Psoriasis Diseases 0.000 claims description 52
- 125000001072 heteroaryl group Chemical group 0.000 claims description 51
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 50
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 49
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 49
- 229910052757 nitrogen Inorganic materials 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
- 229910052736 halogen Inorganic materials 0.000 claims description 46
- 150000002367 halogens Chemical class 0.000 claims description 43
- 102000019034 Chemokines Human genes 0.000 claims description 41
- 108010012236 Chemokines Proteins 0.000 claims description 41
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 41
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 41
- 201000010099 disease Diseases 0.000 claims description 41
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 41
- 241001465754 Metazoa Species 0.000 claims description 32
- 238000009472 formulation Methods 0.000 claims description 31
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 31
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 28
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 28
- 230000003247 decreasing effect Effects 0.000 claims description 28
- 239000002552 dosage form Substances 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 26
- 230000002401 inhibitory effect Effects 0.000 claims description 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 24
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 24
- 230000000699 topical effect Effects 0.000 claims description 21
- 239000000460 chlorine Substances 0.000 claims description 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 20
- 201000006417 multiple sclerosis Diseases 0.000 claims description 19
- 108010002350 Interleukin-2 Proteins 0.000 claims description 18
- 102000000588 Interleukin-2 Human genes 0.000 claims description 18
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 17
- 108090001005 Interleukin-6 Proteins 0.000 claims description 17
- 102000004889 Interleukin-6 Human genes 0.000 claims description 17
- 102100037850 Interferon gamma Human genes 0.000 claims description 16
- 108010074328 Interferon-gamma Proteins 0.000 claims description 16
- 102000013264 Interleukin-23 Human genes 0.000 claims description 15
- 108010065637 Interleukin-23 Proteins 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 102000004388 Interleukin-4 Human genes 0.000 claims description 14
- 108090000978 Interleukin-4 Proteins 0.000 claims description 14
- 108090001007 Interleukin-8 Proteins 0.000 claims description 12
- 102000004890 Interleukin-8 Human genes 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 101001039702 Escherichia coli (strain K12) Methyl-accepting chemotaxis protein I Proteins 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
- 102000013462 Interleukin-12 Human genes 0.000 claims description 10
- 108010065805 Interleukin-12 Proteins 0.000 claims description 10
- 108010002616 Interleukin-5 Proteins 0.000 claims description 10
- 102000000743 Interleukin-5 Human genes 0.000 claims description 10
- 206010003246 arthritis Diseases 0.000 claims description 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 10
- 229960002986 dinoprostone Drugs 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 claims description 7
- 206010019280 Heart failures Diseases 0.000 claims description 7
- 108010002386 Interleukin-3 Proteins 0.000 claims description 7
- 102000000646 Interleukin-3 Human genes 0.000 claims description 7
- 108010002586 Interleukin-7 Proteins 0.000 claims description 7
- 102000000704 Interleukin-7 Human genes 0.000 claims description 7
- 108010002335 Interleukin-9 Proteins 0.000 claims description 7
- 102000000585 Interleukin-9 Human genes 0.000 claims description 7
- 206010028703 Nail psoriasis Diseases 0.000 claims description 7
- 208000026935 allergic disease Diseases 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims description 6
- 102000001327 Chemokine CCL5 Human genes 0.000 claims description 6
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 6
- 108010014419 Chemokine CXCL1 Proteins 0.000 claims description 6
- 102000016950 Chemokine CXCL1 Human genes 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 101000577064 Lymnaea stagnalis Molluscan insulin-related peptide 1 Proteins 0.000 claims description 6
- 101000737895 Mytilus edulis Contraction-inhibiting peptide 1 Proteins 0.000 claims description 6
- 206010037575 Pustular psoriasis Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 206010006895 Cachexia Diseases 0.000 claims description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 5
- 208000001640 Fibromyalgia Diseases 0.000 claims description 5
- 108090000171 Interleukin-18 Proteins 0.000 claims description 5
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 5
- 208000007502 anemia Diseases 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 108050003558 Interleukin-17 Proteins 0.000 claims description 4
- 102000013691 Interleukin-17 Human genes 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 4
- 206010018797 guttate psoriasis Diseases 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 208000003017 Aortic Valve Stenosis Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010015278 Erythrodermic psoriasis Diseases 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 206010024229 Leprosy Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 206010002906 aortic stenosis Diseases 0.000 claims description 3
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 208000016097 disease of metabolism Diseases 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 206010063094 Cerebral malaria Diseases 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 description 71
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 54
- 229940079593 drug Drugs 0.000 description 45
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 39
- 238000004519 manufacturing process Methods 0.000 description 38
- 210000003491 skin Anatomy 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 238000011282 treatment Methods 0.000 description 33
- 125000004429 atom Chemical group 0.000 description 32
- 230000002757 inflammatory effect Effects 0.000 description 32
- 210000000282 nail Anatomy 0.000 description 31
- 239000002585 base Substances 0.000 description 30
- 125000001424 substituent group Chemical group 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- 102000000589 Interleukin-1 Human genes 0.000 description 23
- 108010002352 Interleukin-1 Proteins 0.000 description 23
- 239000013543 active substance Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- 229940124597 therapeutic agent Drugs 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 210000004209 hair Anatomy 0.000 description 21
- 210000000003 hoof Anatomy 0.000 description 21
- 239000004480 active ingredient Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 210000000078 claw Anatomy 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 20
- 150000003254 radicals Chemical class 0.000 description 20
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 19
- 239000000651 prodrug Substances 0.000 description 19
- 229940002612 prodrug Drugs 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 125000004093 cyano group Chemical group *C#N 0.000 description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 18
- 239000003921 oil Substances 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- 230000004054 inflammatory process Effects 0.000 description 16
- 238000010992 reflux Methods 0.000 description 16
- 239000003981 vehicle Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 240000000662 Anethum graveolens Species 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 15
- 125000001153 fluoro group Chemical group F* 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 125000005842 heteroatom Chemical group 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- 239000002775 capsule Substances 0.000 description 13
- 239000006071 cream Substances 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 13
- 231100000252 nontoxic Toxicity 0.000 description 13
- 230000003000 nontoxic effect Effects 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
- ASCHNMXUWBEZDM-UHFFFAOYSA-N chloridodioxygen(.) Chemical compound [O]OCl ASCHNMXUWBEZDM-UHFFFAOYSA-N 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 230000000770 proinflammatory effect Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 239000003883 ointment base Substances 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- 102000003814 Interleukin-10 Human genes 0.000 description 10
- 108090000174 Interleukin-10 Proteins 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 125000001309 chloro group Chemical group Cl* 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 239000006186 oral dosage form Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 10
- 208000024827 Alzheimer disease Diseases 0.000 description 9
- 206010009900 Colitis ulcerative Diseases 0.000 description 9
- 208000011231 Crohn disease Diseases 0.000 description 9
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 9
- 208000018737 Parkinson disease Diseases 0.000 description 9
- 201000006704 Ulcerative Colitis Diseases 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 239000003995 emulsifying agent Substances 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 230000035515 penetration Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000013638 trimer Substances 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 7
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 208000037976 chronic inflammation Diseases 0.000 description 7
- 230000006020 chronic inflammation Effects 0.000 description 7
- 239000002270 dispersing agent Substances 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 125000004430 oxygen atom Chemical group O* 0.000 description 7
- 125000003386 piperidinyl group Chemical group 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
- 229910052701 rubidium Inorganic materials 0.000 description 7
- 235000015424 sodium Nutrition 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 229940083542 sodium Drugs 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- 239000000375 suspending agent Substances 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000011200 topical administration Methods 0.000 description 7
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 108010008165 Etanercept Proteins 0.000 description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000008064 anhydrides Chemical class 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 206010009887 colitis Diseases 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 239000003974 emollient agent Substances 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- OHENQANLQNOMAO-UHFFFAOYSA-N oxaborole Chemical class O1B=CC=C1 OHENQANLQNOMAO-UHFFFAOYSA-N 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 5
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000003435 antirheumatic agent Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 5
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 125000004474 heteroalkylene group Chemical group 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000003018 immunosuppressive agent Substances 0.000 description 5
- 229940125721 immunosuppressive agent Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 235000019271 petrolatum Nutrition 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 235000011181 potassium carbonates Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000000664 rectum Anatomy 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 235000017550 sodium carbonate Nutrition 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 4
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 108090000177 Interleukin-11 Proteins 0.000 description 4
- 102000003815 Interleukin-11 Human genes 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 239000004264 Petrolatum Substances 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 125000004103 aminoalkyl group Chemical group 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 229940093476 ethylene glycol Drugs 0.000 description 4
- 229940028334 follicle stimulating hormone Drugs 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000003349 gelling agent Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229960002900 methylcellulose Drugs 0.000 description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 4
- 229940066842 petrolatum Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 4
- 229950005741 rolipram Drugs 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 150000003431 steroids Chemical group 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 125000003944 tolyl group Chemical group 0.000 description 4
- 239000012049 topical pharmaceutical composition Substances 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000037317 transdermal delivery Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 201000002661 Spondylitis Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229960002964 adalimumab Drugs 0.000 description 3
- 229960002459 alefacept Drugs 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 229960002170 azathioprine Drugs 0.000 description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 208000010247 contact dermatitis Diseases 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003596 drug target Substances 0.000 description 3
- 229940073621 enbrel Drugs 0.000 description 3
- 201000002491 encephalomyelitis Diseases 0.000 description 3
- 229960000403 etanercept Drugs 0.000 description 3
- 235000019000 fluorine Nutrition 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 229940048921 humira Drugs 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 229960000598 infliximab Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 229940054136 kineret Drugs 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 229940116176 remicade Drugs 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- DRPHIMYWMOWYFI-UHFFFAOYSA-N 2-amino-6-chloropyridine-3-carbonitrile Chemical class NC1=NC(Cl)=CC=C1C#N DRPHIMYWMOWYFI-UHFFFAOYSA-N 0.000 description 2
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 2
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 2
- UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- DQTBPANHSUIJIF-UHFFFAOYSA-N 6-amino-2-chloropyridine-3-carbonitrile Chemical class NC1=CC=C(C#N)C(Cl)=N1 DQTBPANHSUIJIF-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108091007914 CDKs Proteins 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000014997 Crohn colitis Diseases 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- 229930195711 D-Serine Natural products 0.000 description 2
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 2
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 2
- 101100351286 Dictyostelium discoideum pdeE gene Proteins 0.000 description 2
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 101001098805 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4A Proteins 0.000 description 2
- 101000988423 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4C Proteins 0.000 description 2
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101150098694 PDE5A gene Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 229920003072 Plasdone™ povidone Polymers 0.000 description 2
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 2
- 101000935814 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Periplasmic beta-glucosidase Proteins 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 229940123155 T cell inhibitor Drugs 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000006177 alkyl benzyl group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 229960004238 anakinra Drugs 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 125000005002 aryl methyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102100037092 cAMP-specific 3',5'-cyclic phosphodiesterase 4A Human genes 0.000 description 2
- 102100029169 cAMP-specific 3',5'-cyclic phosphodiesterase 4C Human genes 0.000 description 2
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 2
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960000878 docusate sodium Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 229960000284 efalizumab Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- HDCXQTPVTAIPNZ-UHFFFAOYSA-N n-({[4-(aminosulfonyl)phenyl]amino}carbonyl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1=CC=C(S(N)(=O)=O)C=C1 HDCXQTPVTAIPNZ-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000011236 particulate material Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 101150037969 pde-6 gene Proteins 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- RRRUXBQSQLKHEL-UHFFFAOYSA-N piclamilast Chemical compound COC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OC1CCCC1 RRRUXBQSQLKHEL-UHFFFAOYSA-N 0.000 description 2
- 229950005184 piclamilast Drugs 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001987 poloxamine Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 2
- 229960002586 roflumilast Drugs 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- XOQABDOICLHPIS-UHFFFAOYSA-N 1-hydroxy-2,1-benzoxaborole Chemical class C1=CC=C2B(O)OCC2=C1 XOQABDOICLHPIS-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 229940044613 1-propanol Drugs 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- UHDLEJVYHQTSNL-UHFFFAOYSA-N 2,1-benzoxaborol-3-ol Chemical compound C1=CC=CC2=BOC(O)=C21 UHDLEJVYHQTSNL-UHFFFAOYSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- LFCADBSUDWERJT-UHFFFAOYSA-N 2,6-dichloropyridine-3-carbonitrile Chemical compound ClC1=CC=C(C#N)C(Cl)=N1 LFCADBSUDWERJT-UHFFFAOYSA-N 0.000 description 1
- AJPKQSSFYHPYMH-UHFFFAOYSA-N 2,6-dichloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1Cl AJPKQSSFYHPYMH-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- GYHDXQOBNIWTIE-UHFFFAOYSA-N 4-[(1-hydroxy-3H-2,1-benzoxaborol-3-yl)oxy]benzene-1,2-dicarbonitrile Chemical compound OB1OC(Oc2ccc(C#N)c(c2)C#N)c2ccccc12 GYHDXQOBNIWTIE-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-M 4-bromobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-M 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- GDLZBTJCRPGKTG-UHFFFAOYSA-N 4-ethoxy-6-[3-formyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyridine-3-carbonitrile Chemical compound C1=C(C#N)C(OCC)=CC(OC=2C=C(C=O)C(B3OC(C)(C)C(C)(C)O3)=CC=2)=N1 GDLZBTJCRPGKTG-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- JBKBUWWMEKKWJH-UHFFFAOYSA-N 5-phenoxy-1,2-benzoxaborole Chemical class C=1C=C2OB=CC2=CC=1OC1=CC=CC=C1 JBKBUWWMEKKWJH-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000037539 Acute peripheral arterial occlusion Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010001939 Aminoaciduria Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010003880 Axillary vein thrombosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241001416153 Bos grunniens Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 101100243082 Caenorhabditis elegans pde-1 gene Proteins 0.000 description 1
- 101100135858 Caenorhabditis elegans pde-2 gene Proteins 0.000 description 1
- 101100135867 Caenorhabditis elegans pde-3 gene Proteins 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 description 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 102000004308 Carboxylic Ester Hydrolases Human genes 0.000 description 1
- 108090000863 Carboxylic Ester Hydrolases Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 206010057254 Connective tissue inflammation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010064769 Dactylitis Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 101100407340 Drosophila melanogaster Pde8 gene Proteins 0.000 description 1
- 101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 206010058838 Enterocolitis infectious Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102100033495 Glycine dehydrogenase (decarboxylating), mitochondrial Human genes 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- 229920003115 HPC-SL Polymers 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical group ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 208000021342 Isolated sulfite oxidase deficiency Diseases 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001233242 Lontra Species 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000009564 MELAS Syndrome Diseases 0.000 description 1
- 201000009035 MERRF syndrome Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920003102 Methocel™ E4M Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 101100407337 Mus musculus Pde8a gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010069825 Myoclonic epilepsy and ragged-red fibres Diseases 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-methylmorpholine Substances CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000035544 Nonketotic hyperglycinaemia Diseases 0.000 description 1
- 241000272458 Numididae Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000006187 Onycholysis Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000283011 Rangifer Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010068956 Respiratory tract inflammation Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004163 Spermaceti wax Substances 0.000 description 1
- 206010072005 Spinal pain Diseases 0.000 description 1
- 208000007156 Spondylarthritis Diseases 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108700036932 Sulfite oxidase deficiency Proteins 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical class OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000010984 Type 7 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037622 Type 7 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047095 Vascular pain Diseases 0.000 description 1
- 208000012346 Venoocclusive disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000004143 Waterhouse-Friderichsen Syndrome Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- AKLXKTAAJGZRGR-UHFFFAOYSA-N [4-[(1-hydroxy-3h-2,1-benzoxaborol-5-yl)oxy]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1OC1=CC=C(B(O)OC2)C2=C1 AKLXKTAAJGZRGR-UHFFFAOYSA-N 0.000 description 1
- CLWILBGKFRYOCY-UHFFFAOYSA-N [6-(2,1-benzoxaborol-5-yloxy)pyridin-3-yl]methanol Chemical compound N1=CC(CO)=CC=C1OC1=CC2=COB=C2C=C1 CLWILBGKFRYOCY-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- SPTSIOTYTJZTOG-UHFFFAOYSA-N acetic acid;octadecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O SPTSIOTYTJZTOG-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 230000007000 age related cognitive decline Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000005238 alkylenediamino group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940031955 anhydrous lanolin Drugs 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005165 aryl thioxy group Chemical group 0.000 description 1
- 108010009043 arylesterase Proteins 0.000 description 1
- 102000028848 arylesterase Human genes 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000019664 bone resorption disease Diseases 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005792 cardiovascular activity Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 201000008240 chemical colitis Diseases 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- USZAGAREISWJDP-UHFFFAOYSA-N crisaborole Chemical compound C=1C=C2B(O)OCC2=CC=1OC1=CC=C(C#N)C=C1 USZAGAREISWJDP-UHFFFAOYSA-N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000001987 diarylethers Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- CITHEXJVPOWHKC-UHFFFAOYSA-N dimyristoyl phosphatidylcholine Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UHFFFAOYSA-N 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000011979 disease modifying therapy Methods 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 201000008243 diversion colitis Diseases 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 229940089666 egg yolk phosphatides Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 201000011205 glycine encephalopathy Diseases 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 description 1
- 125000005378 heteroarylthioxy group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- XSEOYPMPHHCUBN-FGYWBSQSSA-N hydroxylated lecithin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCC[C@@H](O)[C@H](O)CCCCCCCC XSEOYPMPHHCUBN-FGYWBSQSSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 208000023399 hyperprolinemia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000027139 infectious colitis Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000008222 ischemic colitis Diseases 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 208000008275 microscopic colitis Diseases 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- FXKQNFKNXHQWSU-UHFFFAOYSA-N n-benzyl-4-[(1-hydroxy-3h-2,1-benzoxaborol-5-yl)oxy]benzamide Chemical compound C=1C=C2B(O)OCC2=CC=1OC(C=C1)=CC=C1C(=O)NCC1=CC=CC=C1 FXKQNFKNXHQWSU-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 206010036784 proctocolitis Diseases 0.000 description 1
- 208000017048 proctosigmoiditis Diseases 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 201000010914 pustulosis of palm and sole Diseases 0.000 description 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000202 sensitizing Toxicity 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- AAYACJGHNRIFCT-YRJJIGPTSA-M sodium glycochenodeoxycholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)CC1 AAYACJGHNRIFCT-YRJJIGPTSA-M 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 description 1
- UDWXLZLRRVQONG-UHFFFAOYSA-M sodium hexanoate Chemical compound [Na+].CCCCCC([O-])=O UDWXLZLRRVQONG-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045845 sodium myristate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- IJRHDFLHUATAOS-DPMBMXLASA-M sodium ricinoleate Chemical compound [Na+].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O IJRHDFLHUATAOS-DPMBMXLASA-M 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
- 229960000776 sodium tetradecyl sulfate Drugs 0.000 description 1
- WDFRNBJHDMUMBL-OICFXQLMSA-M sodium;(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 WDFRNBJHDMUMBL-OICFXQLMSA-M 0.000 description 1
- WDFRNBJHDMUMBL-FUXQPCDDSA-M sodium;(4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 WDFRNBJHDMUMBL-FUXQPCDDSA-M 0.000 description 1
- WYPBVHPKMJYUEO-NBTZWHCOSA-M sodium;(9z,12z)-octadeca-9,12-dienoate Chemical compound [Na+].CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O WYPBVHPKMJYUEO-NBTZWHCOSA-M 0.000 description 1
- UNZSHUCNBUBSGW-IFNWOZJISA-M sodium;(9z,12z,15z)-octadeca-9,12,15-trienoate Chemical compound [Na+].CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O UNZSHUCNBUBSGW-IFNWOZJISA-M 0.000 description 1
- AQADNICIQOBXGR-CFYXSCKTSA-M sodium;(z)-hexadec-9-enoate Chemical compound [Na+].CCCCCC\C=C/CCCCCCCC([O-])=O AQADNICIQOBXGR-CFYXSCKTSA-M 0.000 description 1
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 1
- IYPNVUSIMGAJFC-HLEJRKHJSA-M sodium;2-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)CC1 IYPNVUSIMGAJFC-HLEJRKHJSA-M 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- JUQGWKYSEXPRGL-UHFFFAOYSA-M sodium;tetradecanoate Chemical compound [Na+].CCCCCCCCCCCCCC([O-])=O JUQGWKYSEXPRGL-UHFFFAOYSA-M 0.000 description 1
- UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 235000019385 spermaceti wax Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 229940036234 tazorac Drugs 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- JJXOIFHXNBFRNV-UHFFFAOYSA-N tert-butyl (2-methylpropan-2-yl)oxycarbonyl carbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C JJXOIFHXNBFRNV-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 150000003527 tetrahydropyrans Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Definitions
- Irregular inflammation is a major component of a wide range of human diseases. People suffering from degenerative disorders often exhibit excess levels of pro-inflammatory regulators in their blood.
- pro-inflammatory regulators include cytokines including IL- l ⁇ , ⁇ , IL-2, IL-3, IL-6, IL-7, IL-9, IL- 12, IL- 17, IL-18, IL-23, TNF- ⁇ , LT, LIF, Oncostatin, and IFNcl ⁇ , ⁇ , ⁇ .
- a non-limiting list of common medical problems that are directly caused by inflammatory cytokines include: arthritis where inflammatory cytokines can lead to lesions in the synovial membrane and destruction of joint cartilage and bone; kidney failure where inflammatory cytokines restrict circulation and damage nephrons; lupus where inflammatory cytokines exacerbate immune complex deposition and damage; asthma where inflammatory cytokines close the airway; psoriasis where inflammatory cytokines induce dermatitis; pancreatitis where inflammatory cytokines induce pancreatic cell injury; allergy where inflammatory cytokines induce vasopermeability and congestion; fibrosis where inflammatory cytokines attack traumatized tissue; surgical complications where inflammatory cytokines prevent healing; anemia where inflammatory cytokines attack erythropoietin production; and fibromyalgia where inflammatory cytokines are elevated in fibromyalgia patients.
- Other diseases associated with chronic inflammation include cancer; heart attack where chronic inflammation contributes to coronary atherosclerosis; Alzheimer's disease where chronic inflammation destroys brain cells; congestive heart failure where chronic inflammation causes heart muscle wasting; stroke where chronic inflammation promotes thrombo-embolic events; and aortic valve stenosis where chronic inflammation damages heart valves.
- Arteriosclerosis, osteoporosis, Parkinson's disease, infection, inflammatory bowel disease including Crohn's disease and ulcerative colitis as well as multiple sclerosis (a typical autoimmune inflammatory-related disease) are also related to inflammation (Bebo, B.
- IBD Inflammatory bowel disease
- CD Crohn's disease
- UC ulcerative colitis
- IBD can involve either small bowel, large bowel, or both.
- CD can involve any part of the gastrointestinal tract, but most frequently involves the distal small bowel and colon. It either spares the rectum, or causes inflammation or infection with drainage around the rectum.
- UC usually causes ulcers in the lower part of the large intestine, often starting at the rectum.
- Patients with IBD have defective intestinal epithelial barrier function,which allows bacterial colonization of the epithelia.
- bacterial products and pro-inflammatory cytokines cause persistent inflammatory stimulation.
- Bacterial antigens are introduced into the immune system by mucosal dendritic cells and macrophases.
- intestinal phagocytes mainly monocytes and neutrophils
- Symptoms vary but may include diarrhea, fever, and pain.
- Patients with prolonged UC are at an increased risk of developing colon cancer. There is currently no satisfactory treatment, as the cause for IBD remains unclear although infectious and immunologic mechanisms have been proposed.
- IBD treatments aim at controlling inflammatory symptoms, conventionally using corticosteroids, aminosalicylates and standard immunosuppressive agents such as azathioprine (6- mercaptopurine), methotrexate and ciclosporine.
- standard immunosuppressive agents such as azathioprine (6- mercaptopurine), methotrexate and ciclosporine.
- the only disease- modifying therapies are the immunosuppressive agents azathioprine and methotrexate, both of which have a slow onset of action and only a moderate efficacy.
- Long-term therapy may cause liver damage (fibrosis or cirrhosis) and bone marrow suppression. Also patients often become refractory to such treatment.
- Other therapeutic regimes merely address symptoms (Rutgeerts, P. A, J Gastroenterol Hepatol, 17 Suppl: S176-185 (2002); Rutgeerts, P., Aliment Pharmacol Ther, 17: 185- 192
- Psoriasis is one of the most common immune -mediated chronic skin diseases that comes in different forms and varied levels of severity, affecting approximately 2% of the population or more than 4.5 million people in the United States of which 1.5 million are considered to have a moderate to severe form of the disease.
- Ten to thirty percent of patients with psoriasis also develop a form of arthritis— psoriatic arthritis, which damages the bone and connective tissue around the joints.
- Psoriasis appears as patches of raised red skin covered by a flaky white buildup. It may also have a pimple-ish (pustular psoriasis) or burned (erythrodermic) appearance. Psoriasis may also cause intense itching and burning. Patients suffer psychologically as well as physically.
- Plaque psoriasis ⁇ psoriasis vulgaris
- Plaque psoriasis typically appears as raised areas of inflamed skin covered with silvery white scaly skin. These areas are called plaques.
- Flexural psoriasis (inverse psoriasis) appears as smooth inflamed patches of skin. It occurs in skin folds, particularly around the genitals (between the thigh and groin), the armpits, under an overweight stomach (pannus), and under the breasts (inframammary fold). It is aggravated by friction and sweat, and is vulnerable to fungal infections.
- Guttate psoriasis is characterized by numerous small oval (teardrop-shaped) spots. These numerous spots of psoriasis appear over large areas of the body, such as the trunk, limbs, and scalp. Guttate psoriasis is associated with streptococcal throat infection.
- Pustular psoriasis appears as raised bumps that are filled with non-infectious pus (pustules). The skin under and surrounding pustules is red and tender. Pustular psoriasis can be localised, commonly to the hands and feet (palmoplantar pustulosis), or generalised with widespread patches occurring randomly on any part of the body. Nail psoriasis produces a variety of changes in the appearance of finger and toe nails. These changes include discolouring under the nail plate, pitting of the nails, lines going across the nails, thickening of the skin under the nail, and the loosening (onycholysis) and crumbling of the nail. Psoriatic arthritis involves joint and connective tissue inflammation.
- Psoriatic arthritis can affect any joint but is most common in the joints of the fingers and toes. This can result in a sausage-shaped swelling of the fingers and toes known as dactylitis. Psoriatic arthritis can also affect the hips, knees and spine (spondylitis). About 10-15% of people who have psoriasis also have psoriatic arthritis. Erythrodermic psoriasis involves the widespread inflammation and exfoliation of the skin over most of the body surface. It may be accompanied by severe itching, swelling and pain. It is often the result of an exacerbation of unstable plaque psoriasis, particularly following the abrupt withdrawal of systemic treatment. This form of psoriasis can be fatal, as the extreme inflammation and exfoliation disrupt the body's ability to regulate temperature and for the skin to perform barrier functions.
- drugs prescribed for psoriasis include TNF- ⁇ inhibitors initially used for rheumatoid arthritis (RA) treatment, ENBREL® (etanercept), REMICADE® (infliximab) and HUMIRA® (adalimumab), and T-cell inhibitor AMEVIVE® (alefacept) from Biogen approved in 2002 and RAPTIV A® (efalizumab) from Genentech/Xoma approved in 2003 (Weinberg, J.
- AMEVIVE® (alefacept) is an immunoglobulin fusion protein composed of the first extracellular domain of human LFA-3 fused to the hinge, C(H)2 and C(H)3 domains of human IgG(I). It inhibits T cell proliferation through NK cells (Cooper, J. C, Eur J Immunol, 33: 666-675, (2003)).
- RAPTIV A® is also known as anti- CDl Ia, a humanized monoclonal antibody which targets the T cell adhesion molecule, leukocyte function-associated antigen-1 (LFA-I).
- RAPTIV A® is an immunosuppressive agent. Immunosuppressive agents have the potential to increase the risk of infection, reactivate latent, chronic infections or increase the risk of cancer development.
- Rheumatoid arthritis represents another example of troublesome inflammatory disorders. It is a common chronic inflammatory-related disease characterized by chronic inflammation in the membrane lining (the synovium) of the joints and/or other internal organs. The inflammatory cells can also invade and damage bone and cartilage. The joint involved can lose its shape and alignment, resulting in loss of movement. Patients with RA have pain, stiffness, warmth, redness and swelling in the joint, and other systemic symptoms like fever, fatigue, and anemia. Approximately 1% of the population or 2.1 million in the U.S. are currently affected, of which more are women (1.5 million) than men (0.6 million).
- RA pathology of RA is not fully understood although the cascade of improper immunological reactions has been postulated as a mechanism.
- Conventional treatment is unfortunately inefficient in RA (Bessis, N., J Gene Med, 4: 581-591, (2002)) (29).
- the disease does not respond completely to symptomatic medications including corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) used since the 1950s. Also, these medications carry a risk of serious adverse effects.
- NSAIDs non-steroidal anti-inflammatory drugs
- DMARDs disease-modifying antirheumatic drugs
- MTX Methotrexate
- IL-I plays a pivotal role in the pathogenesis and the clinical manifestations of RA (54).
- the ability of IL-I to drive inflammation and joint erosion and to inhibit tissue repair processes has been clearly established in in vitro systems and in animal models, and alleviation of inflammatory symptoms in RA patients has been achieved by blockage of IL-I (Bresnihan, B., Arthritis Rheum, 41 : 2196-2204, (1998)).
- IL-6 is a multifunctional cytokine that regulates the immune response, hematopoiesis, the acute phase response, and inflammation. Deregulation of IL-6 production is implicated in the pathology of several diseases including RA.
- IL-6 is an anti-inflammatory cytokine.
- Expressing IL-10 has been shown to prevent arthritis or ameliorate the disease in animal models (57, 58). While it is obvious that cytokines such as TNF- ⁇ , IL-I, IL-6 and IL-10 have independent roles, they act in concert in mediating certain pathophysiological processes in RA. The finding of a class of molecules described in this invention, which are able to modulate these different cytokines, will result in dramatic therapeutic progress in the treatment of RA.
- a new class of biologic DMARDs (disease-modifying antirheumatic drugs) for the treatment of RA has recently been developed based on an understanding of the role of cytokines, TNF- ⁇ and IL-I, in the inflammatory process.
- the FDA has approved several such DMARDs including ENBREL® (etanercept) from
- REMICADE® infliximab
- HUMIRA® adalimumab
- KINERET® anakinra
- ENBREL® is a soluble TNF receptor (TNFR) recombinant protein.
- REMICADE® is a humanized mouse (chimeric) anti- TNF- ⁇ monoclonal antibody.
- HUMIRA® is a fully human anti-TNF monoclonal antibody created using phage display technology resulting in an antibody with human- derived heavy and light chain variable regions and human IgGl :k constant regions.
- KINERET® is a recombinant IL-I receptor antagonist, which is similar to native human IL-IRa, except for the addition of a single methionine residue at its amino terminus. KINERET® blocks the biologic activity of IL-I by competitively inhibiting IL-I binding to the IL-I type I receptor (IL-IRI) and consequently reducing the pro-inflammatory effects of IL-I.
- IL-IRI IL-I type I receptor
- MS Multiple Sclerosis
- chemokines IL-8 family members
- TNF proinflammatory cytokines
- IL-I receptor antagonist moderates the induction of experimental autoimmune encephalomyelitis (EAE). Increased risk of MS has been seen in individuals with High IL-I (3 over IL-IRa production ratio and high TNF over IL-10 production ratio (de Jong, B. A., J Neuroimmunol, 126: 172-179, (2002)). Common symptoms of MS include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremors and depression.
- AD Alzheimer's disease
- PK Parkinson's disease
- PK is a progressive disorder of the central nervous system affecting over 1.5 million people in the United States. Clinically, the disease is characterized by a decrease in spontaneous movements, gait difficulty, postural instability, rigidity and tremor. PK is caused by the degeneration of the pigmented neurons in the substantia nigra of the brain, resulting in decreased dopamine availability. The causes of these neurodegenerative disorders are unknown and there is currently no cure for the disease.
- Radiation damage related inflammatory diseases to the rectum and sigmoid colon are most common complications with radiation therapy for cancers in the pelvic region, which include cancers of the cervix, uterus, prostate, bladder, and testes. Radiation proctosigmoiditis is the most common clinically apparent form of colonic damage after pelvic irradiation with an incidence of 5% to 20%. Patients typically exhibit symptoms of tenesmus, bleeding, low- volume diarrhea, and rectal pain. Rarely, low-grade obstruction or fistulous tracts into adjacent organs may develop.
- Cytokines can be generally classified into 3 types: pro-inflammatory (IL-I ⁇ , ⁇ , IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, IL-23, TNF- ⁇ , LT, LIF, Oncostatin, and IFNc 1 ⁇ , ⁇ , ⁇ ); anti-inflammatory (IL-4, IL- 10, IL- 11 , W- 13 and TGF- ⁇ ); and chemokines (IL-8, Gro- ⁇ , MIP-I, MCP-I, ENA-78, and RANTES).
- pro-inflammatory IL-I ⁇ , ⁇ , IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, IL-23, TNF- ⁇ , LT, LIF, Oncostatin, and IFNc 1 ⁇ , ⁇ , ⁇
- anti-inflammatory IL-4, IL- 10, IL- 11 , W-
- TNF- ⁇ Tumor necrosis factor- ⁇
- IL-I interleukin-1
- RA rheumatoid arthritis
- Crohn's disease inflammatory bowel disease
- multiple sclerosis multiple sclerosis
- endotoxin shock osteoporosis
- Alzheimer's disease congestive heart failure
- psoriasis among others
- TNF- ⁇ also referred to as TNFa
- IL-Ib interleukin-1 ⁇
- the cyclic nucleotide specific phosphodiesterases represent a family of enzymes that catalyze the hydrolysis of various cyclic nucleoside monophosphates (including cAMP and cGMP). These cyclic nucleotides act as second messengers within cells, and as messengers, carry impulses from cell surface receptors having bound various hormones and neurotransmitters. PDEs act to regulate the level of cyclic nucleotides within cells and maintain cyclic nucleotide homeostasis by degrading such cyclic mononucleotides resulting in termination of their messenger role.
- PDEs cyclic nucleotide specific phosphodiesterases
- PDE enzymes can be grouped into eleven families according to their specificity toward hydrolysis of cAMP or cGMP, their sensitivity to regulation by calcium, calmodulin or cGMP, and their selective inhibition by various compounds.
- PDE 1 is stimulated by Ca 2+ /calmodulin.
- PDE 2 is cGMP-dependent, and is found in the heart and adrenals.
- PDE 3 is cGMP-dependent, and inhibition of this enzyme creates positive inotropic activity.
- PDE 4 is cAMP specific, and its inhibition causes airway relaxation, antiinflammatory and antidepressant activity.
- PDE 5 appears to be important in regulating cGMP content in vascular smooth muscle, and therefore PDE 5 inhibitors may have cardiovascular activity. Since the PDEs possess distinct biochemical properties, it is likely that they are subject to a variety of different forms of regulation.
- PDE4 is distinguished by various kinetic properties including low Michaelis constant for cAMP and sensitivity to certain drugs.
- the PDE4 enzyme family consists of four genes, which produce 4 iso forms of the PDE4 enzyme designated PDE4A, PDE4B, PDE4C, and PDE4D [See: Wang et al, Expression, Purification, and Characterization of human cAMP-Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D, Biochem. Biophys. Res. Comm., 234, 320 324 (1997)]
- PDE4A PDE4A
- PDE4B PDE4C
- PDE4D PDE4D
- PDE4 isoenzymes are localized in the cytosol of cells and are unassociated with any known membranous structures. PDE4 isoenzymes specifically inactivate cAMP by catalyzing its hydrolysis to adenosine 5 '-monophosphate (AMP).
- AMP adenosine 5 '-monophosphate
- cAMP activity is important in many biological processes, including inflammation and memory.
- Inhibitors of PDE4 isoenzymes such as rolipram, piclamilast, CDP-840 and ariflo are powerful antiinflammatory agents and therefore may be useful in treating diseases where inflammation is problematic such as asthma or arthritis. Further, rolipram improves the cognitive performance of rats and mice in learning paradigms. [0024] Compounds which can inhibit the biological moieties described above, or treat diseases involving those biological moieties, would be a significant advance in the art.
- the invention provides a compound of the invention.
- the compound is described herein or a pharmaceutically acceptable salt thereof.
- the compound is according to a formula described herein.
- the compound is a member selected from Dl, D2, D3, D4, D5, D6, D7, D8, D9, DlO, DIl, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D
- the invention provides a compound, and salts thereof, having a structure according to the formula: wherein R* is a member selected from H, a negative charge and a positively charged counterion.
- X is a member selected from CR a , CR b and N.
- R a is a member selected from CN, -C(O)NR 1 R 2 , and -C(O)OR 3 .
- R b and R c are members independently selected from H, OR 4 , NR 4 R 5 , SR 4 , -S(O)R 4 , -S(O) 2 R 4 , -S(O) 2 NR 4 R 5 , -C(O)R 4 ,
- R 1 , R 2 , R 4 and R 5 are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, wherein each R 1 , R 2 , R 4 and R 5 are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- R 3 is a member selected from H and substituted or unsubstituted alkyl.
- R 1 and R 2 together with the atoms to which they are attached, are optionally combined to form a 5- to 7-membered substituted or unsubstituted heterocycloalkyl ring.
- R 4 and R 5 together with the atoms to which they are attached, are optionally combined to form a 5- to 7-membered substituted or unsubstituted heterocycloalkyl ring.
- R b and R c cannot both be H.
- R a and R b are optionally joined to form a 5- to 8-membered ring comprising two oxo moieties.
- the invention also provides pharmaceutical formulations, and methods of making and using the compounds described herein.
- FIG. 1 displays exemplary compounds of the invention.
- FIG. 2 displays exemplary compounds of the invention.
- FIG. 3 displays exemplary compounds of the invention.
- FIG. 5 displays exemplary compounds of the invention.
- FIG. 6 displays exemplary compounds of the invention.
- FIG. 7 displays exemplary compounds of the invention. DETAILED DESCRIPTION OF THE INVENTION
- an active agent includes a single active agent as well as two or more different active agents in combination. It is to be understood that present teaching is not limited to the specific dosage forms, carriers, or the like, disclosed herein and as such may vary.
- Compound of the invention refers to the compounds discussed herein, salts (such as pharmaceutically acceptable salts), prodrugs, solvates and hydrates of these compounds.
- Moiety refers to the radical of a molecule that is attached to another moiety.
- V ⁇ /V P indicates the point at which the displayed moiety is attached to the remainder of the molecule.
- alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e. Ci-Cio means one to ten carbons).
- the term “alkyl” means a straight or branched chain, or combinations thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals.
- saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl,
- cyclohexyl (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n- pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
- An unsaturated alkyl group is one having one or more double bonds or triple bonds.
- unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2- (butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3- butynyl, and the higher homologs and isomers.
- unsubstituted alkyl encompasses straight or branched chain saturated hydrocarbon radicals.
- saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t- butyl, isobutyl, sec-butyl, n-pentyl.
- alkylene by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified, but not limited, by - CH 2 CH 2 CH 2 CH 2 -, and further includes those groups described below as “heteroalkylene.”
- an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention.
- a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
- alkoxy alkylamino and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
- heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom.
- the term “heteroalkyl,” by itself or in combination with another term means a stable straight or branched chain, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom.
- the heteroatoms can be selected from the group consisting of B, O, N and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
- the heteroatom(s) B, O, N and S may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule.
- heteroalkylene by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH 2 -CH 2 -S-CH 2 -CH 2 - and -CH 2 -S-CH 2 -CH 2 -NH-CH 2 -.
- heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like).
- cycloalkyl and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
- heterocycloalkyl examples include, but are not limited to, 1 -(1,2,5,6- tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3- morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1 -piperazinyl, 2-piperazinyl, and the like.
- halo or halogen
- haloalkyl by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
- terms such as “haloalkyl,” are meant to include monohaloalkyl and polyhaloalkyl.
- halo(Ci-C 4 )alkyl is mean to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
- aryl means, unless otherwise stated, a polyunsaturated, aromatic, substituent that can be a single ring or multiple rings (preferably from 1 to 3 rings), which are fused together or linked covalently.
- heteroaryl refers to aryl groups (or rings) that contain from one to four heteroatoms.
- the heteroatom is selected from B, N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
- a heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
- Non- limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3- pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4- oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2- pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-
- aryl when used in combination with other terms (e.g. , aryloxy, arylthioxy, arylalkyl) includes those radicals in which an aryl group is attached through the next moiety to the rest of the molecule.
- arylalkyl is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, l-(3-nitrophenyl)ethyl and the like).
- a substituent such as benzyl or l-(3-nitrophenyl)ethyl can also be represented by 'substituted alkyl' wherein the ethyl radical is substituted with a 3-nitrophenyl moiety.
- aryloxy is meant to include those radicals in which an aryl group is attached to an oxygen atom.
- aryloxyalkyl is meant to include those radicals in which an aryl group is attached to an oxygen atom which is then attached to an alkyl group (e.g., phenoxymethyl, 3-(l-naphthyloxy)propyl, and the like).
- heteroaryl when used in combination with other terms (e.g., hetero aryloxy, heteroarylthioxy, heteroarylalkyl) includes those radicals in which a heteroaryl group is attached through the next moiety to the rest of the molecule.
- heteroarylalkyl is meant to include those radicals in which a heteroaryl group is attached to an alkyl group (e.g., pyridylmethyl and the like).
- heteroaryloxy is meant to include those radicals in which a heteroaryl group is attached to an oxygen atom.
- heteroaryloxyalkyl is meant to include those radicals in which an aryl group is attached to an oxygen atom which is then attached to an alkyl group, (e.g., 2-pyridyloxymethyl and the like).
- R', R", R'", R" and R'" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, e.g. , aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups.
- each of the R groups is independently selected as are each R', R", R'", R"" and R'"" groups when more than one of these groups is present.
- R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
- -NR'R is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl.
- alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF 3 and -CH 2 CF 3 ) and acyl (e.g., - C(O)CH 3 , -C(O)CF 3 , -C(O)CH 2 OCH 3 , and the like).
- haloalkyl e.g., -CF 3 and -CH 2 CF 3
- acyl e.g., - C(O)CH 3 , -C(O)CF 3 , -C(O)CH 2 OCH 3 , and the like.
- substituents for the aryl and heteroaryl groups are generically referred to as "aryl group substituents.”
- Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(0)-(CRR') q -U-, wherein T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer of from 0 to 3.
- two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula - A-(CH 2 VB-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O) 2 -, -S(O) 2 NR'- or a single bond, and r is an integer of from 1 to 4.
- One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
- two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula - (CRR')s-X-(CR"R'")d-, where s and d are independently integers of from O to 3, and X is -O-, -NR'-, -S-, -S(O)-, -S(O) 2 -, or -S(O) 2 NR'-.
- the substituents R, R', R" and R'" are preferably independently selected from hydrogen or substituted or unsubstituted (Ci-C6)alkyl.
- Ring means a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- a ring includes fused ring moieties. The number of atoms in a ring is typically defined by the number of members in the ring. For example, a "5- to 7-membered ring" means there are 5 to 7 atoms in the encircling arrangement. Unless otherwise specified, the ring optionally includes a heteroatom.
- the term “5- to 7-membered ring” includes, for example phenyl, pyridinyl and piperidinyl.
- the term “ring” further includes a ring system comprising more than one "ring”, wherein each "ring” is independently defined as above.
- heteroatom includes atoms other than carbon (C) and hydrogen (H). Examples include oxygen (O), nitrogen (N) sulfur (S), silicon (Si), germanium (Ge), aluminum (Al) and boron (B).
- R is a general abbreviation that represents a substituent group that is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted heterocycloalkyl groups.
- effective amount of a drug, formulation, or permeant is meant a sufficient amount of a active agent to provide the desired local or systemic effect.
- a “Topically effective,” “Cosmetically effective,” “pharmaceutically effective,” or “therapeutically effective” amount refers to the amount of drug needed to effect the desired therapeutic result.
- Topicically effective refers to a material that, when applied to the skin, nail, hair, claw or hoof produces a desired pharmacological result either locally at the place of application or systemically as a result of transdermal passage of an active ingredient in the material.
- Cosmetically effective refers to a material that, when applied to the skin, nail, hair, claw or hoof, produces a desired cosmetic result locally at the place of application of an active ingredient in the material.
- salts or “a salt thereof are meant to include salts of the compounds of the invention which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
- pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p- tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
- inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66: 1-19 (1977)).
- Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- the neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compounds in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
- the present invention provides compounds which are in a prodrug form.
- Prodrugs of the compounds or complexes described herein readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment.
- Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
- Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are encompassed within the scope of the present invention.
- the graphic representations of racemic, ambiscalemic and scalemic or enantiomerically pure compounds used herein are taken from Maehr, J. Chem. Ed. 1985, 62: 114-120. Solid and broken wedges are used to denote the absolute configuration of a stereocenter unless otherwise noted.
- the compounds described herein contain olefmic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are included.
- Compounds of the invention can exist in particular geometric or stereoisomer ⁇ forms.
- the invention contemplates all such compounds, including cis- and trans -isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, as falling within the scope of the invention.
- Additional asymmetric carbon atoms can be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- Optically active (R)- and (5)-isomers and d and / isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If, for instance, a particular enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis, or by derivatization with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
- diastereomeric salts can be formed with an appropriate optically active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means known in the art, and subsequent recovery of the pure enantiomers.
- separation of enantiomers and diastereomers is frequently accomplished using chromatography employing chiral, stationary phases, optionally in combination with chemical derivatization (e.g., formation of carbamates from amines).
- the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
- the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine- 125 ( 125 I) or carbon- 14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
- pharmaceutically acceptable carrier or “pharmaceutically acceptable vehicle” refers to any formulation or carrier medium that provides the appropriate delivery of an effective amount of an active agent as defined herein, does not interfere with the effectiveness of the biological activity of the active agent, and that is sufficiently non-toxic to the host or patient.
- Representative carriers include water, oils, both vegetable and mineral, cream bases, lotion bases, ointment bases and the like. These bases include suspending agents, thickeners, penetration enhancers, and the like. Their formulation is well known to those in the art of cosmetics and topical pharmaceuticals. Additional information concerning carriers can be found in Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005) which is incorporated herein by reference.
- pharmaceutically acceptable carrier or “pharmaceutically acceptable vehicle” refers to any formulation or carrier medium that provides the appropriate delivery of an effective amount of a active agent as defined herein, does not interfere with the effectiveness of the biological activity of the active agent, and that is sufficiently non-toxic to the host or patient.
- Representative carriers include water, oils, both vegetable and mineral, cream bases, lotion bases, ointment bases and the like. These bases include suspending agents, thickeners, penetration enhancers, and the like. Their formulation is well known to those in the art of cosmetics and topical pharmaceuticals. Additional information concerning carriers can be found in Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005) which is incorporated herein by reference.
- “Pharmaceutically acceptable topical carrier” and equivalent terms refer to pharmaceutically acceptable carriers, as described herein above, suitable for topical application.
- An inactive liquid or cream vehicle capable of suspending or dissolving the active agent(s), and having the properties of being nontoxic and non-inflammatory when applied to the skin, nail, hair, claw or hoof is an example of a pharmaceutically- acceptable topical carrier. This term is specifically intended to encompass carrier materials approved for use in topical cosmetics as well.
- compositions refers to preservatives, antioxidants, fragrances, emulsifiers, dyes and excipients known or used in the field of drug formulation and that do not unduly interfere with the effectiveness of the biological activity of the active agent, and that is sufficiently non-toxic to the host or patient.
- Additives for topical formulations are well-known in the art, and may be added to the topical composition, as long as they are pharmaceutically acceptable and not deleterious to the epithelial cells or their function. Further, they should not cause deterioration in the stability of the composition.
- inert fillers for example, inert fillers, anti- irritants, tackif ⁇ ers, excipients, fragrances, opacifiers, antioxidants, gelling agents, stabilizers, surfactant, emollients, coloring agents, preservatives, buffering agents, other permeation enhancers, and other conventional components of topical or transdermal delivery formulations as are known in the art.
- the terms “enhancement,” “penetration enhancement” or “permeation enhancement” relate to an increase in the permeability of the skin, nail, hair, claw or hoof to a drug, so as to increase the rate at which the drug permeates through the skin, nail, hair, claw or hoof.
- the enhanced permeation effected through the use of such enhancers can be observed, for example, by measuring the rate of diffusion of the drug through animal skin, nail, hair, claw or hoof using a diffusion cell apparatus.
- a diffusion cell is described by Merritt et al. Diffusion Apparatus for Skin Penetration, J of Controlled Release, 1 (1984) pp. 161-162.
- the term “permeation enhancer” or “penetration enhancer” intends an agent or a mixture of agents, which, alone or in combination, act to increase the permeability of the skin, nail, hair or hoof to a drug.
- excipients is conventionally known to mean carriers, diluents and/or vehicles used in formulating drug compositions effective for the desired use.
- an "effective amount” of one active of the combination is the amount of that active that is effective to provide the desired effect when used in combination with the other active of the combination.
- the amount that is “effective” will vary from subject to subject, depending on the age and general condition of the individual, the particular active agent or agents, and the appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
- active ingredient means a chemical entity which can be effective in treating a targeted disorder, disease or condition.
- phrases "pharmaceutically acceptable” means moieties or compounds that are, within the scope of medical judgment, suitable for use in humans without causing undesirable biological effects such as undue toxicity, irritation, allergic response, and the like, for example.
- oral dosage form means any pharmaceutical composition administered to a subject via the oral cavity, in which one or more antiplatelet agents and one or more acid inhibitors are administered concurrently in combination, optionally with one or more additional drugs.
- exemplary oral dosage forms include tablets, capsules, films, powders, sachets, granules, solutions, solids, suspensions or as more than one distinct unit (e.g., granules, tablets, and/or capsules containing different actives) packaged together for co-administration, and other formulations known in the art.
- An oral dosage form can be one, two, three, four, five or six units. When the oral dosage form has multiple units, all of the units are contained within a single package, (e.g.
- the oral dosage form is a single unit, it may or may not be in a single package.
- the oral dosage form is one, two or three units. In a particularly preferred embodiment, the oral dosage form is one unit.
- the dosage form includes a compound of the invention in one capsule. This is a single unit. In some embodiments, the dosage form includes a compound of the invention as part of a therapeutically effective dosage of a cream or ointment. This is also a single unit. In some embodiments, the dosage form includes a compound of the invention and another active ingredient contained within one capsule, or as part of a therapeutically effective dosage of a cream or ointment or lotion. This is a single unit, whether or not the interior of the capsule includes multiple discrete granules of the active ingredient.
- the dosage form includes a compound of the invention in one capsule, and the active ingredient in a second capsule.
- This is a two unit dosage form, such as two capsules or tablets, and so such units are contained in a single package.
- the term 'unit' refers to the object which is administered to the animal, not to the interior components of the object.
- prodrug as defined herein, is a biologically inactive derivative of a parent drug molecule that exerts its pharmacological effect only after chemical and/or enzymatic conversion to its active form in vivo. Prodrugs include those designed to circumvent problems associated with delivery of the parent drug.
- prodrugs may include improved chemical stability, absorption, and/or PK properties of the parent carboxylic acids. Prodrugs may also be used to make drugs more "patient friendly,” by minimizing the frequency (e.g., once daily) or route of dosing (e.g., oral), or to improve the taste or odor if given orally, or to minimize pain if given parenterally .
- the prodrugs effect a "slow-release" of the active drug, thereby changing the time-course of D-serine increase in a manner that improves the efficacy of the parent compound.
- compounds of the invention that extend D-serine level increases demonstrate improved efficacy in animal models of cognition (e.g., Contextual Fear Conditioning or Novel Object Recognition).
- the prodrugs are chemically more stable than the active drug, thereby improving formulation and delivery of the parent drug, compared to the drug alone.
- Prodrugs for carboxylic acid analogs of the invention may include a variety of esters.
- the pharmaceutical compositions of the invention include a carboxylic acid ester.
- the prodrug is suitable for treatment /prevention of those diseases and conditions that require the drug molecule to cross the blood brain barrier.
- the prodrug enters the brain, where it is converted into the active form of the drug molecule.
- a prodrug is used to enable an active drug molecule to reach the inside of the eye after topical application of the prodrug to the eye.
- a prodrug can be converted to its parent compound by chemical or biochemical methods in an ex vivo environment.
- a prodrug can be slowly converted to its parent compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- substrate means pharmaceutically acceptable particulate materials such as beads, particles, granules, pellets, and the like, in an oral dosage form.
- substantially free refers to a composition which contains none of the substance or less than a therapeutically effective amount of the substance for any known purpose for which the composition is intended.
- Topical administration refers to the application of a pharmaceutical agent to the external surface of the skin, nail, hair, claw or hoof, such that the agent crosses the external surface of the skin, nail, hair, claw or hoof and enters the underlying tissues.
- Topical administration includes application of the composition to intact skin, nail, hair, claw or hoof, or to an broken, raw or open wound of skin, nail, hair, claw or hoof.
- Topical administration of a pharmaceutical agent can result in a limited distribution of the agent to the skin and surrounding tissues or, when the agent is removed from the treatment area by the bloodstream, can result in systemic distribution of the agent.
- Transdermal delivery refers to the diffusion of an agent across the barrier of the skin, nail, hair, claw or hoof resulting from topical administration or other application of a composition.
- stratum corneum acts as a barrier and few pharmaceutical agents are able to penetrate intact skin.
- the epidermis and dermis are permeable to many solutes and absorption of drugs therefore occurs more readily through skin, nail, hair, claw or hoof that is abraded or otherwise stripped of the stratum corneum to expose the epidermis.
- Transdermal delivery includes injection or other delivery through any portion of the skin, nail, hair, claw or hoof or mucous membrane and absorption or permeation through the remaining portion.
- Absorption through intact skin, nail, hair, claw or hoof can be enhanced by placing the active agent in an appropriate pharmaceutically acceptable vehicle before application to the skin, nail, hair, claw or hoof.
- Passive topical administration may consist of applying the active agent directly to the treatment site in combination with emollients or penetration enhancers.
- transdermal delivery is intended to include delivery by permeation through or past the integument, i.e. skin, nail, hair, claw or hoof.
- substrates means pharmaceutically acceptable particulate materials such as beads, particles, granules, pellets, and the like, in an oral dosage form.
- substantially free refers to a composition which contains none of the substance or less than a therapeutically effective amount of the substance for any known purpose for which the composition is intended.
- microbial infection refers to any infection of a host tissue by an infectious agent including, but not limited to, viruses, bacteria, mycobacteria, fungus and parasites (see, e.g., Harrison's Principles of Internal Medicine, pp. 93-98 (Wilson et al., eds., 12th ed. 1991); Williams et al, J. of Medicinal Chem. 42:1481-1485 (1999), herein each incorporated by reference in their entirety).
- Bio medium refers to both in vitro and in vivo biological milieus.
- exemplary in vitro “biological media” include, but are not limited to, cell culture, tissue culture, homogenates, plasma and blood. In vivo applications are generally performed in mammals, preferably humans.
- a "human nail unit”, as defined herein, can be the nail plate, the nail bed, proximal nail fold, lateral nail fold and combinations thereof.
- the term "leaving group” means a functional group or atom which can be displaced by another functional group or atom in a substitution reaction, such as a nucleophilic substitution reaction.
- representative leaving groups include triflate, chloro, bromo and iodo groups; sulfonic ester groups, such as mesylate, tosylate, brosylate, nosylate and the like; and acyloxy groups, such as acetoxy, trifluoroacetoxy and the like.
- amino-protecting group means a protecting group suitable for preventing undesired reactions at an amino nitrogen.
- Representative amino-protecting groups include, but are not limited to, formyl; acyl groups, for example alkanoyl groups, such as acetyl, trichloroacetyl or trifluoroacetyl; alkoxycarbonyl groups, such as tert-butoxycarbonyl (Boc); arylmethoxycarbonyl groups, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl groups, such as benzyl (Bn), trityl (Tr), and l,l-di-(4'-methoxyphenyl)methyl; silyl groups, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS); and the like.
- hydroxy-protecting group means a protecting group suitable for preventing undesired reactions at a hydroxy group.
- Representative hydroxy- protecting groups include, but are not limited to, alkyl groups, such as methyl, ethyl, and tert-butyl; acyl groups, for example alkanoyl groups, such as acetyl; arylmethyl groups, such as benzyl (Bn), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm), and diphenylmethyl (benzhydryl, DPM); silyl groups, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS); and the like.
- alkyl groups such as methyl, ethyl, and tert-butyl
- acyl groups for example alkanoyl groups, such as acetyl
- arylmethyl groups such as benzyl (Bn), p-methoxy
- Dative bonds are usually weaker than covalent bonds.
- a boron atom is covalently bonded to at least one oxygen, sulfur or nitrogen, and is at the same time datively bonded to an oxygen, sulfur or nitrogen, respectively, the dative bond and covalent bond between the boron and the two identical heteroatoms can interconvert or be in the form of a resonance hybrid.
- the structures supplied are not intended to include any and all possible bonding scenarios between boron and the atom to which it is bound. Non limiting examples of these bonds are as follows:
- Salt counterion refers to positively charged ions that associate with a compound of the invention when the boron is fully negatively or partially negatively charged.
- salt counterions include H + , H 3 O + , ammonium, potassium, calcium, magnesium and sodium.
- the compounds comprising a boron bonded to a carbon and three heteroatoms can optionally contain a fully negatively charged boron or partially negatively charged boron, due to the nature of the dative bond between the boron and one of the oxygens. Due to the negative charge, a positively charged counterion may associate with this compound, thus forming a salt.
- positively charged counterions include H + , H 3 O + , calcium, sodium, ammonium, potassium. The salts of these compounds are implicitly contained in descriptions of these compounds.
- the present invention also encompasses compounds that are poly- or multi-valent species, including, for example, species such as dimers, trimers, tetramers and higher homo logs of the compounds of use in the invention or reactive analogues thereof.
- dimers of oxaboroles can form under the following conditions:
- the present invention also encompasses compounds that are anhydrides of the cyclic boronic esters are synthesized by subjecting these compounds to dehydrating conditions. Examples of these anhydrides are provided below:
- trimers of the compounds of the invention are also produced.
- trimers of acyclic boronic esters can be formed as follows:
- trimers of acyclic boronic esters can be formed as follows:
- Also of use in the present invention are compounds that are poly- or multivalent species, including, for example, species such as dimers, trimers, tetramers and higher homo logs of the compounds of use in the invention or reactive analogues thereof.
- the poly- and multi-valent species can be assembled from a single species or more than one species of the invention.
- a dimeric construct can be "homo-dimeric" or "heterodimeric.”
- poly- and multi-valent constructs in which a compound of the invention or a reactive analogue thereof, is attached to an oligomeric or polymeric framework e.g., polylysine, dextran, hydroxyethyl starch and the like
- the framework is preferably polyfunctional (i.e. having an array of reactive sites for attaching compounds of use in the invention).
- the framework can be derivatized with a single species of the invention or more than one species of the invention.
- the present invention includes the use of compounds within the motif set forth in the formulae contained herein, which are functionalized to afford compounds having water-solubility that is enhanced relative to analogous compounds that are not similarly functionalized.
- any of the substituents set forth herein can be replaced with analogous radicals that have enhanced water solubility.
- additional water solubility is imparted by substitution at a site not essential for the activity towards the editing domain of the compounds set forth herein with a moiety that enhances the water solubility of the parent compounds.
- Methods of enhancing the water-solubility of organic compounds are known in the art. Such methods include, but are not limited to, functionalizing an organic nucleus with a permanently charged moiety, e.g., quaternary ammonium, or a group that is charged at a physiologically relevant pH, e.g. carboxylic acid, amine.
- Other methods include, appending to the organic nucleus hydroxyl- or amine- containing groups, e.g. alcohols, polyols, polyethers, and the like.
- Representative examples include, but are not limited to, polylysine, polyethyleneimine, poly(ethyleneglycol) and poly(propyleneglycol).
- Suitable functionalization chemistries and strategies for these compounds are known in the art. See, for example, Dunn, R. L., et al, Eds. POLYMERIC DRUGS AND DRUG DELIVERY SYSTEMS, ACS Symposium Series Vol. 469, American Chemical Society, Washington, D.C. 1991.
- the present invention has multiple aspects. These aspects include inventions directed to compounds, pharmaceutical formulations, methods of treating a condition, enhancing an effect, increasing the production of a cytokine and/or chemokine, decreasing the production of a cytokine and/or chemokine, increasing the release of a cytokine and/or chemokine, decreasing the release of a cytokine and/or chemokine, or inhibiting a phosphodiesterase. ///. Compounds Ilia.
- the invention is a compound of the invention.
- the invention is a compound decribed herein.
- the compound is according to a formula described herein.
- the compound is a member selected from D2, D3, D4, D5, D6, D7, D8, D9, DlO, DIl, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D
- R* is a member selected from H, a negative charge and a positively charged counterion.
- X is a member selected from CR a , CR b and N.
- R a is a member selected from CN, -C(O)NR 1 R 2 , and -C(O)OR 3 .
- R b and R c are members independently selected from H, OR 4 , NR 4 R 5 , SR 4 , -S(O)R 4 , -S(O) 2 R 4 , -S(O) 2 NR 4 R 5 , -C(O)R 4 , -C(O)OR 4 , -C(O)NR 4 R 5 , nitro, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, wherein each R 1 , R 2 , R 4 and R 5 are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or
- R 3 is a member selected from H and substituted or unsubstituted alkyl.
- R 1 and R 2 together with the atoms to which they are attached, are optionally combined to form a 5- to 7-membered substituted or unsubstituted heterocycloalkyl ring.
- R 4 and R 5 together with the atoms to which they are attached, are optionally combined to form a 5- to 7-membered substituted or unsubstituted heterocycloalkyl ring.
- R b and R c cannot both be H.
- R a and R b are optionally joined to form a 5- to 8-membered ring comprising two oxo moieties.
- X is N. In an exemplary embodiment, X is CH. In an exemplary embodiment, X is CR b . [0111] In an exemplary embodiment, R* is H.
- R b and R c is a member selected from F and Cl.
- at least one of R b and R c is substituted or unsubstituted alkyl, which is a member selected from unsubstituted alkyl, hydroxyalkyl, haloalkyl, trihaloalkyl, substituted or unsubstituted aminoalkyl, - CH 2 C(O)OR 6 , -CH 2 NHC(O)R 6 , -CH 2 NR 6 R 7 , wherein each R 6 and R 7 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted heteroaryl, with the proviso that R 6 and R 7 , together with the atoms to which they are attached, are optionally combined to form a 5- to 7-membered substituted or unsubstituted
- R b is H.
- R c is H.
- R c is H, and R b is a member selected from halogen, unsubstituted alkyl, halogen substituted alkyl, unsubstituted alkoxy.
- R c is H, and R b is a member selected from methyl and ethyl.
- R c is H, and R b is a member selected from unsubstituted C 3 alkyl, unsubstituted C 4 alkyl, unsubstituted C5 alkyl and unsubstituted C 6 alkyl.
- R b is H, and R c is trifluoromethyl.
- R c is H, and R b is a member selected from methoxy, ethoxy, unsubstituted C3 alkoxy, unsubstituted C 4 alkoxy, unsubstituted C5 alkoxy and unsubstituted C 6 alkoxy.
- R b and R c is a member selected from -CH 2 C(O)OR 6 , -CH 2 NHC(O)R 6 , -CH 2 NR 6 R 7 , wherein each R 6 and R 7 are members independently selected from H, methyl, trifluoromethyl, ethyl, propyl, butyl, t-butyl, -C(O)H, wherein R 6 and R 7 , together with the together with nitrogen to which they are attached, are optionally combined to form a member selected from 4- methylpiperazinyl, piperidinyl, morpholino and pyrrolidinyl.
- At least one of R b and R c is methyl, trifluoromethyl, -
- R b and R c is a member selected from -OR 4 , -C(O)R 4 , -C(O)OR 4 and -C(O)NR 4 R 5 , wherein each R 4 and R 5 are members independently selected from H, methyl, ethyl, methoxyethyl, cyclopropyl, - CH 2 C(O)OR 8 , -CH 2 C(O)NR 8 R 9 , 2-(dimethylamino)ethyl, 2-pyridinylmethyl, 2-(4- cyano)pyridinyl, with the proviso that R 8 and R 9 , together with the atoms to which they are attached, are optionally combined to form a 5- to 7-membered substituted or unsubstituted heterocycloalkyl ring.
- At least one of R b and R c is a member selected from -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 OCH 3 , -OCH 2 C(O)OH, -OCH 2 C(O)OCH 2 CH 3 , -OCH 2 C(O)OC(CH 3 ) 3 , -C(O)OCH 3 , -C(O)OH, -C(O)H, -
- R b and R c is a member selected from F, Cl, methyl, trifluoromethyl, -CH 2 OH, -CH 2 N(CH 3 ) 2 , -OH, -OCH 3 , - OCH 2 CH 3 , -OCH 2 CH 2 OCH 3 , -OCH 2 C(O)OH, -OCH 2 C(O)OCH 2 CH 3 , - OCH 2 C(O)OC(CH 3 ) 3 , -C(O)OCH 3 , -C(O)OH, -C(O)H, -OCH 2 C(O)N(CH 2 CH 3 ) 2 ,
- the compound has a structure according to the formula
- R b and R c is a member selected from halogen, haloalkyl, -C(O)R 4 , -C(O)OR 4 , -C(O)NR 4 R 5 , -CH 2 C(O)OR 4 , -CH 2 NHC(O)R 4 and OR 4 , wherein R 4 and R 5 are members independently selected from H and substituted or unsubstituted alkyl
- R b and R c is a member selected from F, Cl, methyl, trifluoromethyl, -CH 2 OH, -CH 2 N(CH 3 ) 2 , -OH, -OCH 3 , - OCH 2 CH 3 , -OCH 2 CH 2 OCH 3 , -OCH 2 C(O)OH, -OCH 2 C(O)OCH 2 CH 3 , - OCH 2 C(O)OC(CH 3 ) 3 , -C(O)OCH 3 , -C(O)OH, -C(O)H, -OCH 2 C(O)N(CH 2 CH 3 ) 2 ,
- the compound has a structure according to the formula:
- R b and R c are as described herein.
- at least one of R b and R c is a member selected from F, Cl, methyl, trifluoromethyl, -CH 2 OH, -CH 2 N(CH 3 ) 2 , -OH, -OCH 3 , - OCH 2 CH 3 , -OCH 2 C(O)OH, -OCH 2 CH 2 OCH 3 , -OCH 2 C(O)OCH 2 CH 3 , - OCH 2 C(O)OC(CH 3 ) 3 , -C(O)OCH 3 , -C(O)OH, -C(O)H, -OCH 2 C(O)N(CH 2 CH 3 ) 2 , * ⁇ ° vJ ?
- R c is H
- R b is a member selected from F, Cl, methyl, trifluoromethyl, -CH 2 OH, -CH 2 N(CH 3 ) 2 , -OH, -OCH 3 , -OCH 2 CH 3 , - OCH 2 C(O)OH, -OCH 2 CH 2 OCH 3 , -OCH 2 C(O)OCH 2 CH 3 , -OCH 2 C(O)OC(CH 3 ) 3 , - C(O)OCH 3 , -C(O)OH, -C(O)H, -OCH 2 C(O)N(CH 2 CH 3 ) 2 , . 5 * ° _ / ⁇ J
- the compound has a structure according to the formula:
- R b is a member selected from halogen and substituted or unsubstituted alkyl, C(O)R 4 , C(O)OR 4 , OR 4 , NR 4 R 5 , wherein R 4 and R 5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, with the proviso that R 4 and R 5 , together with the atoms to which they are attached, are optionally combined to form a 5- to 7- membered substituted or unsubstituted heterocycloalkyl ring, and salts thereof.
- R b is a member selected from OR 4 and NR 4 R 5 , wherein R 4 and R 5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, with the proviso that R 4 and R 5 , together with the atoms to which they are attached, are optionally combined to form a 5- to 7- membered substituted or unsubstituted heterocycloalkyl ring.
- R b is alkyl, optionally substituted with a member selected from halogen, OR 4a , C(O)OR 4a , NR 4a R 4b , substituted or unsubstituted heterocycloalkyl or unsubstituted heteroaryl, wherein R 4a and R 4b are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- R 4a is H or unsubstituted alkyl.
- R 4b is H or unsubstituted alkyl or C(O)H.
- R b is fluoro.
- R b is chloro.
- R b is OH.
- R b is OR 4 , wherein R 4 is alkyl is optionally substituted with at least one halogen, hydroxyl, ether, carboxy or ester moiety.
- R b is OR 4 , wherein R 4 is unsubstituted alkyl.
- R is OR 4 , wherein R 4 is unsubstituted Ci or C 2 or C 3 alkyl.
- Strukturrei* crustn i R ⁇ > 4 is unsubstituted C 4 or C 5 or Ce alkyl.
- R b is OR 4 , wherein R 4 is methyl or ethyl or propyl or isopropyl or isobutyl.
- R b is OR 4 , wherein R 4 is alkyl substituted with at least one halogen.
- R b is OR 4 , wherein R 4 is alkyl substituted with one or two or three halogen(s).
- R b is O(CH 2 ) m iR 31 , wherein ml is 1 or 2 or 3 or 4 or 5 or 6 and R 31 is a methyl moiety wherein at least one of the methyl hydrogens is substituted with a halogen.
- the halogen is chloro.
- the halogen is fluoro.
- R 31 is -CF 3 .
- R 31 is -CHF 2 .
- ml is 1 or 2 or 3.
- R b is -OCH 2 CF 3 .
- R b is - OCH 2 CHF 2 .
- R b is -O(CH 2 ) m iOC(O)R 4d , wherein ml is a number selected from 1 or 2 or 3 or 4 or 5 or 6 and R 4d is unsubstituted alkyl. In an exemplary embodiment, ml is 1 or 2 or 3. In an exemplary embodiment, ml is 2. In an exemplary embodiment, R 4d is unsubstituted Ci or C 2 or C 3 alkyl. In an exemplary e :mmbbodiment, R 4d is unsubstituted C 4 or C 5 or C 6 alkyl. In an exemplary embodiment, R 4d is methyl. In an exemplary embodiment, R b is -O(CH 2 ) 2 OC(O)CH 3 .
- R b is -O(CH 2 ) m iC(O)R 4d , wherein ml is a number selected from 1 or 2 or 3 or 4 or 5 or 6 and R 4d is unsubstituted alkyl. In an exemplary embodiment, ml is 2 or 3 or 4. In an exemplary embodiment, ml is 3. In an exemplary embodiment, R 4d is unsubstituted Ci or C 2 or C 3 alkyl. In an exemplary embodiment, R 4d is unsubstituted C 4 or C 5 or C 6 alkyl. In an exemplary embodiment, R 4d is methyl. In an exemplary embodiment, R b is -O(CH 2 ) 3 C(O)CH 3 .
- R b is -O(CH 2 ) m iC(O)OR 4d , wherein ml is a number selected from 1 or 2 or 3 or 4 or 5 or 6 and R 4d is H or unsubstituted alkyl.
- R b is -OCH 2 C(O)OR 4d , wherein R 4d is as described herein.
- R 4d is H or methyl or ethyl or t-butyl.
- R b is -0(CH 2 )C(O)OCH 2 CH 3 or -0(CH 2 )C(O)OH or - O(CH 2 )C(O)OC(CH 3 ) 3 .
- R b is OR 4 , wherein R 4 is alkyl substituted with a substituted or unsubstituted amino. In an exemplary embodiment, R b is -
- R 4e and R 4f are independently selected from H or unsubstituted alkyl, or R 4e and R , together with the nitrogen to which they are attached, are optionally joined to form a substituted or unsubstituted 4 to 8 membered ring.
- R b is -OCH 2 C(O)NR 4e R 4f , wherein R 4e and R 4f are as described herein.
- R 4e and R 4f are the same and are independently selected unsubstituted alkyl.
- R 4e and R 4f are different and are independently selected unsubstituted alkyl.
- R 4e is H.
- R 4f is H.
- R 4e and R 4f are ethyl.
- R 4e and R 4f together with the nitrogen to which they are attached, are joined to form piperazinyl, either unsubstituted or substituted with unsustituted alkyl on the nitrogen at the 4-position.
- R 4e and R 4f together with the nitrogen to which they are attached, are joined to form N-methyl piperazinyl.
- R 4e and R 4f together with the nitrogen to which they are attached, are joined to form piperidinyl, either unsubstituted or substituted with unsustituted alkyl.
- R 4e and R 4f together with the nitrogen to which they are attached, are joined to form 4-methyl piperidinyl.
- R 4e and R 4f together with the nitrogen to which they are attached, are joined to form unsubstituted morpholinyl.
- R b is OR 4 , wherein R 4 is unsubstituted alkyl. In an exemplary embodiment, R 4 is Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl. In an exemplary embodiment, R 4 is Ci alkyl. In an exemplary embodiment, R b is OR 4 , wherein R 4 is alkyl substituted with unsubstituted pyridinyl. In an exemplary embodiment, R b is ⁇ wherein m3 is 1 or 2 or 3 or 4 or 5 or 6. In an exemplary embodiment, m3 is 1.
- R b is OR 4 , wherein R 4 is substituted or unsubstituted cycloalkyl. In an exemplary embodiment, R b is OR 4 , wherein R 4 is unsubstituted cycloalkyl. In an exemplary embodiment, R b is OR 4 , wherein R 4 is cyclopenyl. In an exemplary embodiment, R 4 is unsubstituted cyclohexyl. [0136] In an exemplary embodiment, R b is OR 4 , wherein R 4 is alkyl substituted with unsubstituted alkoxy.
- R b is -O(CH2) m 5 ⁇ R 30 , wherein m5 is 1 or 2 or 3 or 4 or 5 or 6 and R 30 is H or unsubstituted alkyl or unsubstituted tetrahydropyran.
- R 30 is Ci or C 2 or C 3 or C 4 or C 5 or Ce alkyl.
- m5 is 1 or 2 or 3.
- m5 is 2.
- R 30 is Ci or C 2 or C 3 alkyl.
- R 30 is C 4 or C 5 or C 6 alkyl.
- R 30 is H.
- R 30 is methyl or isopropyl. In an exemplary embodiment, R 30 is 2-tetrahydropyran. In an exemplary embodiment, R b is -O(CH 2 )2 ⁇ C(CH 3 )2 or -O(CH 2 ) 2 OH or -O(CH 2 ) 2 O-THP (TetraHydroPyran). [0137] In an exemplary embodiment, R b is OR 4 , wherein R 4 is alkyl substituted with unsubstituted cycloalkyl.
- R b is -O(CH 2 ) m5 ⁇ R 30 , wherein m5 is 1 or 2 or 3 or 4 or 5 or 6 and R 30 is a 3-8 membered cycloalkyl.
- R 30 is a 3-6 membered cycloalkyl.
- R 30 is a member selected from cyclopropyl and cyclopentyl.
- m5 is 1 or 2 or 3.
- m5 is 1.
- R b is C(O)R 4 , wherein R 4 is unsubstituted alkyl.
- R 4 is Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl.
- R 4 is Ci alkyl.
- R b is C(O)H.
- R b is Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl.
- R b is Ci alkyl.
- R b is alkyl substituted with halogen.
- R b is alkyl substituted with at least one halogen.
- R b is alkyl substituted with at least one fluoro.
- R b is CF 3 .
- R b is alkyl substituted with hydroxy.
- R b is -(CH 2 ) m4 ⁇ H, wherein m4 is a number selected from 1 or 2 or 3 or 4 or 5 or 6. In an exemplary embodiment, m4 is 1.
- R b is alkyl substituted with carboxy or ester.
- R b is -(CH 2 ) m iC(O)OR 4a , wherein ml is a number selected from 1 or 2 or 3 or 4 or 5 or 6 and R 4a is H or unsubstituted alkyl.
- R b is -CH 2 C(O)OR 4a , wherein R 4a is as described herein.
- R 4a is H or methyl or ethyl or t-butyl.
- R b is alkyl substituted with amino.
- R b is -(CH 2 ) m7 NR 4a R 4b , wherein m7 is a number selected from 1 or 2 or 3 or 4 or 5 or 6 and R 4a and R 4b are members independently selected from H and unsubstituted alkyl and formyl, or R 4a and R 4b , together with the nitrogen to which they are attached, are optionally joined to form a substituted or unsubstituted 4 to 8 membered ring.
- R 4b is as described herein,R 4a is H.
- R 4a is as described herein, R 4b is H.
- R 4b is as described herein, R 4a is methyl. In an exemplary embodiment, R 4a is as described herein, R 4b is methyl. In an exemplary embodiment, m7 is 1. In an exemplary embodiment, R 4a and R 4b , together with the nitrogen to which they are attached, are joined to form piperazinyl, either unsubstituted or substituted with unsustituted alkyl on the nitrogen at the 4-position. In an exemplary embodiment, R 4a and R 4b , together with the nitrogen to which they are attached, are joined to form N-methyl piperazinyl.
- R 4a and R 4b together with the nitrogen to which they are attached, are joined to form piperidinyl, either unsubstituted or substituted with unsustituted alkyl.
- R 4a and R 4b together with the nitrogen to which they are attached, are joined to form 4-methyl piperidinyl.
- R 4a and R 4b together with the nitrogen to which they are attached, are joined to form unsubstituted morpholinyl.
- R b is NH 2 .
- R b is NR 4 R 5 wherein R 4 is a member selected from H and unsubstituted alkyl, and R 5 is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- R b is NR 4 R 5 , R 4 is as described herein, R 5 is unsubstituted alkyl.
- R b is NR 4 R 5 , wherein R 4 is H, R 5 is as described herein.
- R b is NR 4 R 5 , wherein R 4 is unsubstituted alkyl, R 5 is as described herein.
- R b is NR 4 R 5 , wherein R 5 is as described herein, R 4 is unsubstituted Ci or C 2 or C 3 or C 4 or C 5 or Ce alkyl.
- R b is NR 4 R 5 , wherein R 4 is unsubstituted Ci or C 2 or C3 alkyl and R 5 is as described herein.
- R b is NR 4 R 5 , wherein R 4 is methyl and R 5 is as described herein.
- R b is NR 4 R 5 , wherein R 4 is as described herein R 5 is unsubstituted Ci or C 2 or C3 or C 4 or C5 or C 6 alkyl.
- R b is NR 4 R 5 , wherein R 5 is a member selected from methyl and tert-butyl, and R 4 is as described herein.
- R b is NR 4 R 5 , wherein R 4 is as described herein, R 5 is alkyl, substituted with a member selected from OH, unsubstituted arylalkoxy, unsubstituted alkoxy, and unsubstituted aryl.
- R b is NR 4 R 5 , wherein R 5 is -(CH 2 ) m8 Ph.
- R b is NR 4 R 5 , wherein R 5 is -(CH 2 ) m8 OR 26 , wherein m8 is a number selected from 1 or 2 or 3 or 4 or 5 or 6 and R 26 is a member selected from H, unsubstituted or arylsubstituted Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl.
- m8 is 1 or 2 or 3.
- m8 is 2.
- R 26 is unsubstituted Ci or C 2 or C 3 or C 4 or C 5 or Ce alkyl.
- R 26 is methyl.
- R 26 is benzyl.
- R b is NR 4 R 5 , wherein R 4 is as described herein, R 5 is -(CH 2 ) m g0(CH 2 ) m9 Ph, wherein m8 and m9 are each independently selected from 1 or 2 or 3 or 4 or 5 or 6.
- R b is NR 4 R 5 , wherein R 4 is as described herein R 5 is -(CH 2 ) m g0(CH 2 ) m9 Ph, wherein m8 and m9 are each independently selected from 1 or 2 or 3.
- R b is NR 4 R 5 , wherein R 4 is as described herein, R 5 is - (CH 2 ) m8 O(CH 2 )Ph. In an exemplary embodiment, R b is NR 4 R 5 , wherein R 4 is as described herein R 5 is -( CH 2 ) 2 ⁇ (CH 2 ) m9 Ph. In an exemplary embodiment, R b is NR 4 R 5 , wherein R 4 is as described herein R 5 is -(CH 2 ) 2 O(CH 2 )Ph.
- R b is a member selected from - NH(CH 2 ) 2 OH, -NH(CH 2 ) 2 OCH 3 , -NHCH 3 , -NHC(CH 3 ) 3 , -NH(CH 2 )Ph, - NH(CH 2 ) 2 O(CH 2 )Ph.
- R b is a member selected from -N(CH 3 ) 2 , - N(CH 3 )(CH 2 ) 2 OH, -N(CH 3 )(CH 2 ) 2 OCH 3 , -NHCH 3 , -NHC(CH 3 ) 3 , -NH(CH 2 )Ph, - NH(CH 2 ) 2 O(CH 2 )Ph.
- R b is -NR 4 R 5 , wherein R 4 and R 5 , together with the nitrogen to which they are attached, are joined to form a substituted or unsubstituted 4 to 8 membered ring.
- the only non- carbon atom which forms the ring is the nitrogen to which R 4 and R 5 are attached.
- R b is -NR 4 R 5 , wherein R 4 and R 5 , together with the nitrogen to which they are attached, are joined to form a member selected from substituted or unsubstituted pyrrolidinyl and substituted or unsubstituted piperidinyl.
- R b is -NR 4 R 5 , wherein R 4 and R 5 , together with the nitrogen to which they are attached, are joined to form a member selected from unsubstituted pyrrolidinyl and unsubstituted piperidinyl.
- the only non-carbon atom which forms the ring is nitrogen.
- the ring contains one nitrogen atom and one oxygen atom.
- the ring contains one nitrogen atom and one oxygen atom.
- R b is -NR 4 R 5 , wherein R 4 and R 5 , together with the nitrogen to which they are attached, are joined to form substituted or unsubstituted morpholinyl.
- R b is -NR 4 R 5 , wherein R 4 and R 5 , together with the nitrogen to which they are attached, are joined to form unsubstituted morpholinyl.
- the compound has a structure according to the following formula: and salts thereof, wherein R b is as described herein. [0150] In an exemplary embodiment, the compound has a structure according to the following formula: pH
- AAAX ⁇ and salts thereof, wherein R b is as described herein.
- the compound has a structure according to the following formula: pH
- the compound has a structure according to the following formula: and salts thereof, wherein R b is as described herein.
- the compound has a structure according to the following formula: and salts thereof, wherein R b is as described herein.
- the compound has a structure according to the following formula: and salts thereof, wherein R b is as described herein.
- the compound has a structure according to the following formula: and salts thereof, wherein R b is as described herein. [0156] In an exemplary embodiment, the compound has a structure according to the following formula:
- the compound is a member selected from D46, D86, D99, DlOO, D107, D108, D114, D122, D125, D126, D127, D128, D131, D140 and D141, and salts thereof.
- the compound is a member selected from D95, D96, D97, D102, DIlO, Dill, Dl 13, Dl 15, D121, D129, D130, D132, and salts thereof.
- the compound is a member selected from D47, D109, D116, D118, D119, D120, D123, and salts thereof.
- the compound is a member selected from D98, DlOl, D 106, and salts thereof.
- the compound is a member selected from DIl, D12, D37, D38, D39, D40, D41, D42, D43, D124, D142, D143, D146, and salts thereof.
- the compound is a member selected from D14, D15, D16, D17, D28, D29, D30, D31, D133, D134, D135, D144, D145, D147, and salts thereof.
- the compound has a structure which is a member selected from
- the compound has a structure according to the formula:
- R 3 is H.
- R 3 is unsubstituted alkyl.
- R 3 is methyl.
- R 3 is C 2 alkyl.
- R 3 is C 3 alkyl.
- R 3 is C 4 alkyl.
- R 3 is C 5 alkyl.
- R 3 is C 6 alkyl.
- R b and R c is a member selected from -C(O)NR 4 R 5 , -C(O)OR 4 , -CH 2 C(O)OR 4 , -CH 2 NHC(O)R 4 and OR 4 , wherein each R 4 and R 5 is a member independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted heteroaryl.
- R b and R c is a member selected from F, Cl, methyl, trifluoromethyl, -CH 2 OH, -CH 2 N(CH 3 ) 2 , -OH, -OCH 3 , - OCH 2 CH 3 , -OCH 2 C(O)OH, -OCH 2 C(O)OCH 2 CH 3 , -OCH 2 C(O)OC(CH 3 ) 3 , -C(O)OCH 3 , -C(O)OH, -C(O)H, -OCH 2 C(O)N(CH 2 CH 3 ) 2 ,
- the compound has a structure according to the formula:
- R 3 , X, R*, R b and R c are as described herein.
- at least one of R b and R c is a member selected from -C(O)NH 2 , -OH, -OCH 3 , cyclopropyloxy and 4-cyanopyridin-2-yloxy.
- R 3 , X, R* are as described herein, and at least one of R b and R c is a member selected from F, Cl, methyl, trifiuoromethyl, -CH 2 OH, -CH 2 N(CH 3 ) 2 , -OH, -OCH 3 , - OCH 2 CH 3 , -OCH 2 C(O)OH, -OCH 2 C(O)OCH 2 CH 3 , -OCH 2 C(O)OC(CH 3 ) 3 , - C(O)OCH 3 , -C(O)OH, -C(O)H, -OCH 2 C(O)N(CH 2 CH 3 ) 2 ,
- the invention provides an oxaborole which comprises an ester attached to its 5 -position moiety.
- These 5 -position oxaborole esters are metabolically stable in topical applications (such as the skin or nail) and exert their therapeutic action.
- the 5-position oxaborole ester is then hydrolyzed by an esterase. Esterases are classified broadly as cholinesterases (including acetylcholinesterases), carboxylesterases and arylesterases. The mechanism involved follows the general formula:
- R* is a member selected from H, a negative charge and a positively charged counterion.
- R 3 and R 4 are members independently selected from H, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- Each R 20 and R 21 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- R 3 and R 4 together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring.
- R 9 and R 10 together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring.
- R 10 and R 11 together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring.
- R 11 and R 12 together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring.
- R 20 and R 21 together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring.
- R 22 is H.
- R 22 is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- R 22 is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- R 22 is a member selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted butyl.
- the compound has a structure which is a member selected from:
- Y is a member selected from S and O;
- A is a member selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
- R a , R b and R c are members independently selected from H, OR 20 , NR 20 R 21 , SR 20 , -S(O)R 20 , -S(O) 2 R 20 , -S(O) 2 NR 20 R 21 , -C(O)R 20 , -C(O)NR 20 R 21 , -C(O)OR 22 , nitro, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, wherein each R 20 and R 21 are members
- the compound has a structure which is a member selected from:
- R*, R ,a a , n Rb and R c are as described herein.
- the compound has a structure according to the formula
- R h is a halogen.
- R h is fluoro.
- R h is chloro.
- the compound has a structure which is a member selected from:
- R* is as defined herein.
- the invention provides a compound having a structure according to the formula: wherein R is a member selected from H, a negative charge and a positively charged counterion, X is CH or N, and R d is aminosubstituted alkyl.
- R d is -(CR 10 R 11 ⁇ NR 12 R 13 in which n is a member selected from 1-10, and R 10 , R 11 , R 12 and R 13 are members independently selected from H, OR 14 , NR 14 R 15 , SR 14 , -S(O)R 14 , -S(O) 2 R 14 , -S(O) 2 NR 14 R 15 , - C(O)R 14 , -C(O)OR 14 , -C(O)NR 14 R 15 , nitro, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl wherein each R 14 and R 15 are members independently selected from H, nitro,
- R 10 and R 11 are H.
- R 12 and R 13 are H.
- n is a member selected from 1 to 5.
- n is a member selected from 1 to 3.
- n is 1.
- R d is -(CH 2 ) n NHR 13 in which n is a member selected from 1-10, and R 13 is -S(O) 2 R 14 , wherein R 14 is unsubstituted alkyl or substituted or unsubstituted aryl.
- R 14 is unsubstituted Ci or C 2 or C 3 alkyl.
- R 14 is unsubstituted C 4 or C 5 or Ce alkyl.
- R 14 is Ci alkyl.
- R d is -(CH 2 ) n NHR 13 in which n is a member selected from 1-10, and R , 1 1 3 3 is unsubstituted cycloalkyl.
- R 13 is unsubstituted C 3 -Cs cycloalkyl.
- R 13 is cyclopentyl or cyclohexyl or cycloheptyl.
- n is 1 or 2 or 3.
- n is 1.
- n is 1 and R 13 is cyclohexyl.
- R d is -(CH 2 ) n NHR 13 in which n is a member selected from 1-10, and R 13 is unsubstituted alkyl.
- R 13 is Ci or C 2 or C 3 alkyl.
- R 13 is C 4 or C 5 or C 6 alkyl.
- n is 1 or 2 or 3.
- n is 1.
- R d is -(CH 2 ) n NHCH 3 .
- R d is -(CH 2 )NHCH 3 .
- R d is -(CH 2 ) n NR 13a R 13 in which n is a member selected from 1-10, and R 13 and R 13a are each members independently selected unsubstituted alkyl. In an exemplary embodiment, R 13 and R 13a are each members independently selected from unsubstituted alkyl. In an exemplary embodiment, R 13 and R 13a are each members independently selected from Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl. In an exemplary embodiment, R 13 and R 13a are each members independently selected from Ci or C 2 or C 3 alkyl.
- R d is -(CH 2 )NR 13a R 13 , wherein R 13 and R 13a are each members independently selected from Ci or C 2 or C 3 alkyl.
- R d is -(CH 2 )N(CH 3 ),.
- R d is -(CH 2 )nNH(CH 2 )niR 16 in which n is a member selected from 1-10, nl is a member selected from 1-10, and R 16 is substituted or unsubstituted aryl.
- nl is 1 or 2 or 3 or 4 or 5.
- nl is 1.
- R 16 is phenyl substituted with nitro or cyano or unsubstituted alkoxy or unsubstituted alkyl.
- R 16 is ortho-cyanophenyl or meta-cyanophenyl or para-cyanophenyl.
- R 16 is ortho-nitrophenyl or meta-nitrophenyl or para-nitrophenyl.
- R d is -CH 2 NHCH 2 R 16 , wherein R 16 is ortho-cyanophenyl or meta-cyanophenyl or para-cyanophenyl or ortho-nitrophenyl or meta-nitrophenyl or para-nitrophenyl.
- R 16 is phenyl substituted with unsubstituted Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl.
- R 16 is ortho- methylphenyl or meta-methylphenyl or para-methylphenyl.
- RR dd i iss --CCHH 22 NNHHCCHH 22 RR 1166 , wherein R 16 is ortho-methylphenyl or meta- methylphenyl or para-methylphenyl.
- R 16 is phenyl substituted with unsubstituted Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyloxy.
- R 16 is ortho- methoxyphenyl or meta-methyloxyphenyl or para-methoxyphenyl.
- R d is -CH 2 NHCH 2 R 16 , wherein R 16 is ortho-methoxyphenyl or meta- methoxyphenyl or para-methoxyphenyl.
- R 16 is phenyl substituted with -NHC(O)-R 34 , wherein R 34 is unsubstituted Ci or C 2 or C3 or C 4 or C5 or C 6 alkyl.
- R 16 is phenyl substituted with -NHC(O)CH 3 .
- R d is -CH 2 NHCH 2 R 16 , wherein R 16 is ortho-(CH 3 C(O)NH-)phenyl or meta-(CH 3 C(O)NH-)phenyl or para-(CH 3 C(O)NH-)phenyl.
- R d is -(CH 2 ) n NHC(O)R 14 in which n is a member selected from 1-10, wherein R 14 is unsubstituted alkyl.
- R 14 is unsubstituted Ci or C 2 or C 3 alkyl.
- R 14 is unsubstituted C 4 or C 5 or C 6 alkyl.
- R 14 is methyl or ethyl or isopropyl or t-butyl or .
- R 14 is Ci alkyl.
- R d is -(CH 2 )NHC(O)CH 3 or -(CH 2 )NHC(O)CH 2 CH 3 or - (CH 2 )NHC(O)CH(CH 3 ) 2 or -(CH 2 )NHC(O)C(CH 3 ) 3 .
- R d is -(CH 2 ) n NHC(O)R 14 in which n is a member selected from 1-10, wherein R 14 is substituted or unsubstituted aryl. In an exemplary embodiment, R 14 is unsubstituted phenyl.
- R 14 is phenyl substituted with unsubstituted Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl.
- R 14 is ortho- methylphenyl or meta-methylphenyl or para-methylphenyl.
- R d is — CH 2 NHC(O)R 14 , wherein R 14 is ortho-methylphenyl or meta- methylphenyl or para-methylphenyl.
- R 14 is phenyl substituted with unsubstituted Ci or C 2 or C3 or C 4 or C5 or C 6 alkyloxy.
- R 14 is ortho- methoxyphenyl or meta-methyloxyphenyl or para-methoxyphenyl.
- R d is — CH 2 NHC(O)R 14 , wherein R 14 is ortho-methoxyphenyl or meta- methoxyphenyl or para-methoxyphenyl.
- R 14 is phenyl substituted with a halogen.
- R 14 is chloro or fluoro.
- R d is — CH 2 NHC(O)R 14 , wherein R 14 is ortho-fluorophenyl or meta-fluorophenyl or para- fluorophenyl.
- R 14 is phenyl substituted with haloalkyl.
- the halogen is chloro or fluoro.
- R 14 is phenyl substituted with alkyl substituted with three fluorines.
- R 14 is phenyl substituted with alkyl substituted with two fluorines.
- R 14 is ortho(trifluoromethyl)phenyl or meta(trifluoromethyl)phenyl or para(trifluoromethyl)phenyl.
- R d is -CH 2 NHC(O)R 14 , wherein R 14 is R 14 is ortho(trifluoromethyl)phenyl or meta(trifluoromethyl)phenyl or para(trifluoromethyl)phenyl.
- R d is -(CH 2 ) n NHC(O)(CR 40 R 41 ) n9 OC(O)R 42 in which n is a member selected from 1-10, wherein R 40 is unsubstituted alkyl, R 41 is unsubstituted alkyl, R 42 is unsubstituted alkyl.
- R 40 or R 41 or R 42 are each independently selected Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl.
- R 40 or R 41 or R 42 are each methyl.
- n9 is 1.
- R d is -(CH 2 ) n NHC(O)(CR 40 R 41 ) n9 OC(O)R 42 in which n is a member selected from 1-10, wherein R 40 is unsubstituted alkyl, R 41 is unsubstituted alkyl, R 42 is unsubstituted alkyl.
- R 40 or R 41 or R 42 are each independently selected Ci or C 2
- R d is - (CH 2 ) n NHC(O)(C(CH 3 )(CH 3 ))OC(O)R 42 , wherein R 42 is Ci or C 2 or C 3 or C 4 or C 5 or Ce alkyl.
- R d is - (CH 2 ) n NHC(O)(C(CH 3 )(CH 3 ))OC(O)CH 3 .
- R d is -(CH 2 ) n NHC(O)R 14 in which n is a member selected from 1-10, wherein R 14 is unsubstituted cycloalkyl.
- R d is -(CH 2 ) n NHC(O)R 14 in which n is a member selected from 1-10, wherein R 14 is unsubstituted heteroaryl.
- R 14 is unsubstituted furan.
- R 14 is unsubstituted 2-furan.
- R d is -(CH 2 ) n NHC(O)OR 14 in which n is a member selected from 1-10, wherein R 14 is unsubstituted alkyl.
- R 14 is Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl.
- R 14 is C 4 alkyl.
- R 14 is a member selected from n-butyl, isobutyl, sec-butyl and tert-butyl.
- R d is - (CH 2 )NHC(O)OR 14 , wherein R 14 is Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl. In an exemplary embodiment, R d is -(CH 2 )NHC(O)OC(CH 3 ) 3 .
- R d is -(CH 2 ) n NHC(O)NR 43 R 44 in which n is an integer selected from 1-10, wherein R 43 and R 44 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted aryl.
- R 43 and R 44 together with the nitrogen to which they are attached, are joined to form a 3 to 8 membered ring.
- R 43 and R 44 together with the nitrogen to which they are attached, are joined to form a 4 to 7 membered ring.
- R 43 and R 44 together with the nitrogen to which they are attached, are joined to form a 5 to 6 membered ring.
- n is 1 or 2 or 3.
- R d is
- R d is -(CH 2 ) n NHC(O)NHR 44 in which n is an integer selected from 1-10, wherein R 44 is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted aryl. In an exemplary embodiment, R 44 is unsubstituted aryl. In an exemplary embodiment, R 44 is unsubstituted phenyl. In an exemplary embodiment, R 44 is aryl, substituted with unsubstituted alkyl.
- R 44 is aryl, substituted with unsubstituted Ci or C 2 or C3 alkyl. In an exemplary embodiment, R 44 is aryl, substituted with unsubstituted C 4 or C5 or C 6 alkyl. In an exemplary embodiment, R 44 is phenyl, substituted with unsubstituted Ci or C 2 or C3 alkyl. In an exemplary embodiment, R 44 is ortho methylphenyl or meta methylphenyl or para methylphenyl. In an exemplary embodiment, R d is -(CH 2 )NHC(O)NHR 44 , wherein R 44 is para methylphenyl.
- R 44 is phenyl, substituted with NR 50 R 51 , wherein R 50 and R 51 are each independently selected from Ci or C 2 or C 3 alkyl. In an exemplary embodiment, R 44 is ortho (NR 50 R 5 ⁇ phenyl or meta (NR 50 R 5 ⁇ phenyl or para
- R 43 and R 44 together with the nitrogen to which they are attached, are joined to form a 4 to 7 membered ring. In an exemplary embodiment, R 43 and R 44 , together with the nitrogen to which they are attached, are joined to form a 5 to 6 membered ring.
- n is 1 or 2 or 3. In an exemplary embodiment, nlO is 1 or 2 or 3.
- R d is -(CH 2 NHC(O)(CH 2 ) DIO NR 43 R 44 [0214] In an exemplary embodiment, R d is -(CH 2 ) n NHC(O)NHR 44 in which n is an integer selected from 1-10, wherein R 44 is aryl, substituted with halogen. In an exemplary embodiment, R 44 is phenyl, substituted with halogen. In an exemplary embodiment, R 44 is ortho (halogen)phenyl or meta (halogen)phenyl or para (halogen)phenyl. In an exemplary embodiment, R 44 is ortho (chloro)phenyl or meta (chloro)phenyl or para (chloro)phenyl.
- R d is -(CH 2 ) n NHC(O)NHR 44 in which n is an integer selected from 1-10, wherein R 44 is unsubstituted aryl. In an exemplary embodiment, R 44 is unsubstituted phenyl. In an exemplary embodiment, R d is - (CH 2 )NHC(O)NHR 44 , wherein R 44 is unsubstituted phenyl.
- R d is -(CH 2 ) n NHC(O)NHR 44 in which n is an integer selected from 1-10, wherein R 44 is unsubstituted alkyl.
- R 44 is Ci or C 2 or C 3 alkyl.
- R d is - (CH 2 )NHC(O)NHR 44 , wherein R 44 is C 4 or C 5 or C 6 alkyl.
- R d is -(CH 2 )NHC(O)NHR 44 , wherein R 44 is ethyl.
- R d is -(CH 2 ) n NHC(O)(CR 52 R 53 ) n i 1NR 54 R 55 in which n is an integer selected from 1-10, nl 1 is an integer selected from 1-10, wherein R 52 and R 53 are independently selected from H and alkyl optionally substituted with aryl, and wherein R 54 and R 55 are independently selected from H, unsubstituted alkyl, and -C(O)OR 56 , wherein R 56 is unsubstituted alkyl.
- R d is -(CH 2 )NHC(O)(CH 2 ) n i 1 NR 54 R 55 in which nl 1 is an integer selected from 1-10, and wherein R 54 and R 55 are independently selected from H, unsubstituted alkyl, and -C(O)OR 56 , wherein R 56 is unsubstituted alkyl.
- R d is -(CH 2 )NHC(O)(CH 2 )NHR 55 and wherein R 55 is -C(O)OR 56 , wherein R 56 is unsubstituted alkyl.
- R d is -(CH 2 )NHC(O)(CH 2 )NHR 55 and wherein R 55 is -C(O)OR 56 , wherein R 56 is Ci or C 2 or C 3 alkyl.
- R d is - (CH 2 )NHC(O)(CH 2 )NHR 55 and wherein R 55 is -C(O)OR 56 , wherein R 56 is C 4 or C 5 or C 6 alkyl.
- R d is -(CH 2 )NHC(O)(CH 2 )NR 54 R 55 and wherein R 54 is unsubstituted alkyl, and R 55 is -C(O)OR 56 , wherein R 56 is unsubstituted alkyl.
- R d is - (CH 2 )NHC(O)(CH 2 )NR 54 R 55 and wherein R 54 is Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl, R 55 is -C(O)OR 56 , wherein R 56 is Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl.
- R d is -(CH 2 )NHC(O)(CH 2 )NR 54 R 55 and wherein R 54 is Ci alkyl, R 55 is -C(O)OR 56 , wherein R 56 is Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl.
- R d is -(CH 2 )NHC(O)(CH 2 )NR 54 R 55 and wherein R 54 is Ci or C 2 or C 3 alkyl, R 55 is -C(O)OR 56 , wherein R 56 is C 3 or C 4 or C 5 alkyl.
- R d is -(CH 2 )NHC(O)(CH 2 )NR 54 R 55 and wherein R 54 is C i alkyl, R 55 is -C(O)OR 56 , wherein R 56 is C 4 alkyl.
- R d is -(CH 2 ) n NHC(O)(CH 2 ) n i 1NR 54 R 55 in which n is an integer selected from 1-10, nl 1 is an integer selected from 1-10, and wherein R 54 and R 55 are independently selected from H and unsubstituted alkyl.
- R d is -(CH 2 ) n NHC(O)(CH 2 ) n nNH 2 .
- n is 1 or 2 or 3.
- nl 1 is 1 or 2 or 3.
- R d is -(CH 2 )NHC(O)(CH 2 )NH 2 .
- R d is -(CH 2 ) n NHC(O)(CH 2 ) n nNHR 55 in which n is an integer selected from 1-10, nl 1 is an integer selected from 1-10, and wherein R 55 is unsubstituted alkyl.
- R d is -(CH 2 )NHC(O)(CH 2 )NHR 55 in which R 55 is unsubstituted alkyl.
- R d is - (CH 2 )NHC(O)(CH 2 )NHR 55 in which R 55 is Ci or C 2 or C 3 alkyl.
- R d is -(CH 2 )NHC(O)(CH 2 )NHR 55 in which R 55 is C 4 or C 5 or C 6 alkyl. In an exemplary embodiment, R d is -(CH 2 )NHC(O)(CH 2 )NHCH 3 . [0221] In an exemplary embodiment, R d is -(CH 2 ) n NHC(O)(CH 2 ) n iiNR 54 R 55 in which n is an integer selected from 1-10, nl 1 is an integer selected from 1-10, and wherein R 54 and R 55 are independently selected unsubstituted alkyl.
- R 54 and R 55 are each members independently selected from Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl. In an exemplary embodiment, R 54 and R 55 are each members independently selected from Ci or C 2 or C 3 alkyl. In an exemplary embodiment, R d is -(CH 2 )NHC(O)(CH 2 )NR 54 R 55 , wherein R 54 and R 55 are each members independently selected from Ci or C 2 or C 3 alkyl. In an exemplary embodiment, R d is -(CH 2 )NHC(O)(CH 2 )N(CH 3 ) 2 .
- R d is -(CH 2 ) n NHC(O)(CHR 53 ) n i 1 NR 54 R 55 in which n is an integer selected from 1-10, nl 1 is an integer selected from 1-10, wherein R 53 is alkyl, and wherein R 54 and R 55 are independently selected from H, unsubstituted alkyl, and -C(O)OR 56 , wherein R 56 is unsubstituted alkyl.
- n is 1 or 2 or 3 and nl 1 is 1 or 2 or 3.
- n is 1 and nl 1 is 1.
- R d is - (CH 2 ) n NHC(O)(CHR 53 ) n iiNH 2 in which n is an integer selected from 1-10, nl 1 is an integer selected from 1-10, wherein R 53 is alkyl.
- R d is -(CH 2 )NHC(O)CH(R 53 )(NH 2 ) in which R 53 is alkyl.
- R 53 is Ci or C 2 or C3 or C 4 or C5 or C 6 alkyl.
- R 53 is Ci or C 2 or C 3 alkyl.
- R d is -(CH 2 )NHC(O)CH(R 53 )(NH 2 ) in which R 53 is Ci or C 2 or C 3 or C 4 alkyl.
- R d is - (CH 2 )NHC(O)CH(R 53 )(NH 2 ) in which R 53 is C 4 alkyl.
- R d is -(CH 2 )NHC(O)CH(CH 3 )(NH 2 ).
- R d is - (CH2)NHC(O)CH(NH2)(CH2CH(CH 3 )2).
- R d is -(CH 2 ) n NHC(O)R 58 in which n is an integer selected from 1-10, and R 58 is a member selected from wherein R 59 is H or unsubstituted alkyl or C(O)OR 56 , wherein R 56 is unsubstituted alkyl.
- R d is -(CH 2 ) n NHC(O)R 58 in which n is an integer selected from 1-10, and R 58 is a member selected from wherein R 59 is H or unsubstituted alkyl or C(O)OR 56 , wherein R 56 is unsubstituted alkyl.
- R d is -(CH 2 ) n NHC(O)R 58 in which n is an integer selected from 1-10, and R 58 is a member selected from wherein R 59 is H or unsubstituted alkyl or C(O)OR 56 , wherein R 56 is unsubstituted alky
- R d is -( CH 2 )NHC(O)R 58 in which R 58 is or
- R d is -(CH 2 ) n NHC(O)(CHR 53 ) n i 1 NH 2 in which n is an integer selected from 1-10, nl 1 is an integer selected from 1-10, wherein R 53 is unsubstituted alkyl, optionally substituted with aryl.
- n is 1 or 2 or 3 and nl 1 is 1 or 2 or 3.
- n is 1 and nl 1 is 1.
- R d is - (CH 2 ) n NHC(O)(CHR 53 ) n i iNH(C(O)OR 56 ) in which n is an integer selected from 1-10, nl 1 is an integer selected from 1-10, wherein R 56 is Ci or C 2 or C 3 or C 4 or C5 or C 6 alkyl, and R 53 is alkyl substituted with aryl.
- n is 1 or 2 or 3 and nl 1 is 1 or 2 or 3.
- n is 1 and nl 1 is 1.
- R d is -(CH 2 )NHC(O)(CHR 53 )NH(C(O)OR 56 ), wherein R 56 is C 4 alkyl, and R 53 is (CH 2 ) n i 2 -Ph, wherein ni 2 is an integer selected from 1-10.
- R d is -(CH 2 )NHC(O)CH((CH 2 )-Ph)(NH(C(O)OR 56 )).
- R d is -(CH 2 )NHC(O)CH(R 53 )(NH(C(O)OC(CH 3 ) 3 )).
- R d is -(CH 2 )NHC(O)CH((CH 2 )-Ph))(NH(C(O)OC(CH 3 ) 3 )).
- the compound has a structure according to the formula:
- R* is as defined herein.
- the compound has a structure according to the formula: wherein R* is as defined herein.
- the invention provides a compound having a structure according to the formula:
- R 20 and R 21 are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- R 20 and R 21 together with the atoms to which they are attached, are optionally combined to form a 5- to 7-membered substituted or unsubstituted heterocycloalkyl ring.
- compound has a structure according to the formula:
- R e is as defined herein.
- the compound has a structure according to the formula: wherein R* is as defined herein, and R e is C(O)H. In an exemplary embodiment, the compound has a structure which is
- R* is as described herein.
- the compound has a structure having the following formula: wherein R* is as defined herein, and with the proviso that both R 20 and R 21 are not both members selected from substituted or unsubstituted alkyl, and with the proviso that R 20 and R 21 , together with the atoms to which they are attached, are not optionally combined to form a substituted or unsubstituted morpholino ring. In an exemplary embodiment, there is the proviso that both R 20 and R 21 are not both members selected from unsubstituted alkyl. In an exemplary embodiment, there is the proviso that both R 20 and R 21 are not both ethyl.
- the compound has a structure according to the following formula:
- R 20 and R 21 are indepedently selected unsubstituted alkyl.
- each R 20 and R 21 is not unsubstituted C 4 -C 6 alkyl.
- each R 20 and R 21 is not unsubstituted C 1 -C 3 alkyl.
- there is a proviso that both R 20 and R 21 are not methyl.
- there is a proviso that both R 20 and R 21 are not ethyl.
- the compound is
- each R 20 and R 21 is unsubstituted C 4 -C 6 alkyl.
- each R 20 and R 21 is unsubstituted C1-C3 alkyl.
- there is a proviso that the compound is not , wherein both R 20 and R 21 are methyl.
- there is a proviso that the compound is not wherein both R 20 and R 21 are ethyl.
- there is a proviso that the compound is not
- the compound has a structure according to:
- R*, R , 20 and R 21 are as described herein.
- the compound is: , wherein R* is as described herein.
- the compound is: , wherein R* is as described herein.
- the compound does not have a structure according to the following formula: wherein R* is as described herein.
- the compound has a structure according to the following formula: wherein R* is as defined herein, R 20 is NH 2 . In an exemplary embodiment, the compound has a structure according to the following formula:
- R* is as defined herein.
- R* is as defined herein, R , 20 is tetrahydro-furan-2-ylmethyl.
- the compound has a structure according to:
- R , 20 is tetrahydro-furan-2-ylmethyl.
- the compound has a structure according to the following formula:
- R 20 is NC(O)OR 56 .
- R 56 is tert-butyl.
- the compound has a structure according to the following formula:
- R 61 is unsubstituted alkyl.
- R 61 is Ci or C 2 or C 3 alkyl.
- the compound has a structure according to:
- R 61 is as described herein.
- R 61 is methyl.
- the compound has a structure according to the formula:
- R* is as defined herein.
- the compound has a structure according to the formula:
- R* is as defined herein, and R e is NO 2 .
- the compound has a structure which is
- R* is as defined herein.
- R* is as defined herein, and R e is NH 2 .
- the compound has a structure which is
- the compound has a structure according to the formula:
- R* is as defined herein, -, wherein R 60 is unsubstituted alkyl.
- R 60 is methyl.
- the compound has a structure which is
- R* is as defined herein.
- the compound has a structure according to the formula:
- R* is as defined herein, and R f is substituted or unsubstituted alkyl.
- R f is unsubstituted alkyl.
- R f is unsubstituted Ci-C 6 alkyl.
- R f is unsubstituted Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl.
- R f is unsubstituted Ci or C 2 or C 3 alkyl.
- R is methyl or ethyl or isopropyl.
- the compound has a structure which is
- R* is as defined herein.
- the compound has a structure which is a member selected from:
- R 21 is a member selected from unsubstituted hydroxyalkyl, substituted or unsubstituted aminoalkyl, unsubstituted phenylalkyl, N-substituted aminoalkyl.
- R is H, and R is unsubstituted alkyl.
- R is H, and R 21 is unsubstituted Ci-C 6 alkyl.
- R 20 is H, and R 21 is Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl.
- R 20 and R 21 along with the nitrogen to which they are attached, are joined to form an unsubstituted piperazinyl ring.
- R 20 and R 21 along with the nitrogen to which they are attached, are joined to form a N-substituted piperazinyl ring.
- the N-substituted piperazinyl ring is substituted with unsubstituted Ci-C 6 alkyl and unsubstituted Ci-C 6 alkylcarbonyl.
- R 20 is H, and R 21 is a member selected from ortho-unsubstituted alkylbenzyl or meta-unsubstitutedalkylbenzyl or para-unsubstituted alkylbenzyl.
- R 20 is H, and R 21 is paramethylbenzyl.
- R 20 is H, and R 21 is a member selected from ortho-alkoxybenzyl or meta-alkoxybenzyl or para-alkoxybenzyl.
- R 20 is H, and R 21 is a member selected from ortho-methoxybenzyl or meta-methoxybenzyl or para- methoxybenzyl.
- R 20 is H, and R 21 is para- methoxybenzyl. In an exemplary embodiment, R 20 is H, and R 21 is phenyl. In an exemplary embodiment, R 20 is H, and R 21 is cycloalkyl. In an exemplary embodiment, R 20 is H, and R 21 is cyclopropyl. In an exemplary embodiment, R 20 is H, and R 21 is cyclobutyl. In an exemplary embodiment, R 20 is H, and R 21 is cyclopentyl. In an exemplary embodiment, R 20 is H, and R 21 is cyclohexyl. In an exemplary embodiment, R 20 is H, and R 21 is CH 3 . In an exemplary embodiment, R 20 is CH 3 , and R 21 is CH 3 .
- R e is a member selected from
- the compound is a member selected from N- Benzyl-4-(l -hydroxy- 1 ,3-dihydro-benzo[c] [ 1 ,2]oxaborol-5-yloxy)-benzamide,
- the compound has a structure according to the following formula: wherein X is a member selected from N, CH or C(O)R 22 , R 22 is a member selected from alkyl, optionally substituted with dialkylamino, and R* is as described herein.
- the compound has a structure according to:
- R 22 is unsubstituted alkyl, and R* is as described herein.
- R 22 is unsubstituted Ci-C 6 alkyl.
- R 22 is unsubstituted Ci or C 2 or C3 or C 4 or C5 or C 6 alkyl.
- R 22 is unsubstituted Ci alkyl.
- R 22 is unsubstituted C 2 alkyl.
- R 22 is unsubstituted C 3 alkyl.
- R 22 is isopropyl.
- R 22 is dialkylaminoalkyl.
- R 22 is dialkylaminoethyl.
- R 22 is dimethylaminoalkyl.
- R 22 is dimethylaminoethyl.
- the compound has a structure according to the following formula: wherein R 23 is halogen, and R* is as described herein.
- the compound has a structure according to:
- R , 23 is halogen, and R* is as described herein.
- the compound has a structure according to the following formula: wherein R , 24 is unsubstituted alkyl or halosubstituted alkyl, and R* is as described herein.
- the compound has a structure according to:
- R 24 is unsubstituted Ci-C 6 alkyl or halosubstituted Ci-C 6 alkyl. In an exemplary embodiment, R 24 is unsubstituted Ci or C 2 or C3 or C 4 or C5 or C 6 alkyl. In an exemplary embodiment, R 24 is halosubstituted Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl. In an exemplary embodiment, R 24 is fluorosubstituted Ci or C 2 or C3 or C 4 or C5 or C 6 alkyl. In an exemplary embodiment, R 24 is trifluoromethyl. In an exemplary embodiment, R 24 is methyl. [0257] In an exemplary embodiment, the compound is
- the compound is , wherein R* is as described herein.
- the compound is , wherein R* is as described herein.
- the compound has a structure according to the following formula: wherein R 28 or R 29 are independently selected unsubstituted alkyl, and R* is as described herein.
- the compound has a structure which
- R 2 8 R 29 is a member selected from: R 2 8 R 29 or or
- R 28 is ethyl. In an exemplary embodiment, R 29 is ethyl.
- the compound has a structure according to the following formula: wherein R , 3 M 0 1 is H and unsubstituted alkyl, and R* is as described herein. In an exemplary embodiment, the compound has a structure according to: wherein R is unsubstituted alkyl, and R* is as described herein. In an exemplary embodiment, R 30 is methyl. [0260] In an exemplary embodiment, the compound has a structure according to the following formula:
- the compound has a structure which is listed in FIG. 1, or a salt thereof.
- the compound has a structure which is listed in FIG. 2, or a salt thereof.
- the compound has a structure which is listed in FIG. 3, or a salt thereof.
- the compound has a structure which is listed in FIG. 4, or a salt thereof.
- the compound has a structure which is listed in FIG. 5, or a salt thereof.
- the compound has a structure which is listed in FIG. 6, or a salt thereof.
- the compound has a structure which is listed in FIG. 7, or a salt thereof.
- R is H.
- the invention provides poly- or mutli- valent species of the compounds of the invention. In an exemplary embodiment, the invention provides a dimer of the compounds described herein. In an exemplary embodiment, the invention provides a dimer of the compounds described herein.
- the invention provides a dimer of a compound which is a member selected from Dl, D2, D3, D4, D5, D6, D7, D8, D9, DlO, DIl, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79
- the invention provides an anhydride of the compounds described herein. In an exemplary embodiment, the invention provides an anhydride of the compounds described herein. In an exemplary embodiment, the invention provides an anhydride of a compound which is a member selected from Dl, D2, D3, D4, D5, D6, D7, D8, D9, DlO, DIl, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64,
- the invention provides a trimer of the compounds described herein. In an exemplary embodiment, the invention provides a trimer of the compounds described herein. In an exemplary embodiment, the invention provides a trimer of a compound which is a member selected from Dl, D2, D3, D4, D5, D6, D7, D8, D9, DlO, DIl, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64,
- the invention provides a compound described herein, or a salt, hydrate or solvate thereof, or a combination thereof.
- the invention provides a compound described herein, or a salt, hydrate or solvate thereof.
- the invention provides a compound described herein, or a salt thereof.
- the salt is a pharmaceutically acceptable salt.
- the invention provides a compound described herein, or a hydrate thereof.
- the invention provides a compound described herein, or a solvate thereof.
- the invention provides a compound described herein, or a prodrug thereof.
- the invention provides a salt of a compound described herein. In an exemplary embodiment, the invention provides a pharmaceutically acceptable salt of a compound described herein. In an exemplary embodiment, the invention provides a hydrate of a compound described herein. In an exemplary embodiment, the invention provides a solvate of a compound described herein. In an exemplary embodiment, the invention provides a prodrug of a compound described herein.
- alkyl is a member selected from linear alkyl and branched alkyl.
- heteroalkyl is a member selected from linear heteroalkyl and branched heteroalkyl.
- Step 1 The formyl group of compound 1 was protected as ethylene acetal with ethylene glycol in the presence of acid catalyst. Ethylene glycol was used in excess, typically from about 2 to about 10 equivalents to compound 1.
- acid catalysts sulfonic acids, such as para-toluene sulfonic acid or methanesulfonic acid, hydrogen chloride, hydrogen bromide, and the like are used at from about 1 to about 10 mol%.
- the solvent toluene, benzene, xylene are used. The reaction is carried out under azetropic condition with a Dean-Stark head at reflux. The reaction is typically complete in from about 1 to about 24 hours.
- Step 2 Compounds 2 and 3 are coupled in the presence of a base to give 4.
- a base carbonates, such as potassium carbonate, cesium carbonate, and sodium carbonate, sodium hydride, potassium tert-butoxide, and the like are used. The amount is between from about 1 to about 5 equivalent.
- Useful solvents include ⁇ /, ⁇ /-dimethylformamide, JV,iV-dimethylacetamide, dimethylsulfoxide, acetonitrile, and the like.
- the reaction is carried out at from about 70 to about 150 0 C and completed in from about 1 to about 24 hours.
- Step 3 Compound 4 is treated with acid to hydrolyze the acetal.
- Useful acids include hydrochloric acid, hydrobromic acid, para-toluenesulfonic acid, methansulfonic acid, acetic acid, and the like in amounts of from about 1 to about 50 equivalents.
- Useful solvents include methanol, ethanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, and the like. The reaction is carried out at room temperature to reflux. The reaction is complete in from about 1 to about 24 hours.
- Step 4 Compound 5 is subjected to Miyaura coupling to introduce boron atom.
- a mixture of compounds 5, 6, [1,1 '- bis(diphenylphosphino)ferrocene] dichloropalladium(II) complex with dichloromethane, and potassium carbonate in a solvent is stirred at about 50 0 C to reflux.
- the solvent is chosen from 1,4-dioxane, 1,2-dimethoxyethane, tetrahydrofuran, dimethylsulfoxide, dimethylformamide, toluene, and the like.
- the palladium catalyst is used at from about 1 to about 5 mol%, and the base is used from about 2 to about 5 equivalent. The reaction is completed in from about 1 to about 24 hours.
- Step 5 Compound 7 is treated with a reducing agent, such as sodium borohydride and lithium alminium hydride, in an inert solvent.
- Reducing agent is used from about 0.5 to about 2 equivalent.
- Inert solvent is methanol, ethanol, tetrahydrofuran, ether, and the like. The reaction is carried out at about 0 0 C to room temperature, and complete in from about 1 to about 12 hours. Pinacol is removed by washing with aqueous boric acid during the extraction, treating crude peoduct with water, or by freezedrying after purification.
- Some 2-alkoxy-6-chloronicotinonitriles (2a) are prepared as follows:
- Step 6 2,6-Dichloronicotinic acid (8) is converted into corresponding acid chloride using oxalyl chloride or thionyl chloride in inert solvent.
- solvent dichloromethane, 1 ,2-dichloroethane, tetrahydeofuran, are used.
- the reaction is carried out at about 0 0 C to reflux, and completes in from about 1 to about 24 hours. Small amount of ⁇ /, ⁇ /-dimethylformamide can be added to accelerate the reaction.
- the acid chloride formed is treated with ammonia to give compound 8.
- Step 7 Compound 10 is obtained by treating 8 with corresponding alkoxide.
- the alkoxide commercially available sodium methoxide or sodium ethoxide can be used. Otherwise, it is prepared in situ from alcohol (ROH) and a base, such as sodium, sodium hydride, potassium hydride, butyllithium, and the like.
- a base such as sodium, sodium hydride, potassium hydride, butyllithium, and the like.
- the solvent tetrahydrofuran, 1,4-dioxane, ⁇ /, ⁇ /-dimethylformamide, 1 ,2-dimethoxyethane, toluene, and the like are used. The reaction is carried out at about 0 0 C to room temperature for from about 1 to about 24 hours.
- Step 8 Compound 10 is treated with phosphorous oxy chloride and pyridine to give 2a.
- Phosphorous oxychloride and pyridine are used in about 3 to about 6 equivalent.
- the solvent is chosen from acetonitrile, tetrahydrofuran, toluene, and the like The reaction is carried out at room temperature to reflux and complete in from about 1 to about 24 hours.
- 2-alkoxy-6-chloronicotinonitriles (2a) and 6-alkoxy-2- chloronicotinonitriles (2b) are alternatively prepared as follows:
- Step 9 Compounds 2c and 2d are obtained by treating 11 with corresponding amines with or without a base.
- Amine is used from about 1 to about 10 equivalent.
- the base includes potassium carbonate, sodium carbonate, cesium carbonate, sodium hydride, potassium hydride, butyllithium, and the like.
- the solvent tetrahydrofuran, 1,4-dioxane, ⁇ /, ⁇ /-dimethylformamide, 1 ,2-dimethoxyethane, toluene, and the like are used.
- the reaction is carried out at about 0 0 C to reflux for from about 1 to about 24 hours.
- the mixture can be separated by silica gel column chromatography, preparative thin layer chromatography or high performance liquid chromatography.
- Step 10 (a) Compound 12 or 13 are treated with boron tribromide in dichloromethane. Boron tribromide is used from about 1 to about 3 equivalents. The reaction is carried out at about - 78 0 C to room temperature and complete in from about 1 to about 24 hours, (b) Alternatively, compound 12 or 13 are treated with 48% hydrobromic acid in acetic acid at from about 30 to about 100 0 C for from about 6 to about 72 hours.
- Strategy B is described below for the production of mono- or disubstituted 5-phenoxy derivatives: Strategy B: 2
- Strategy D is described below for the production of carboxy monosubstituted 5-phenoxy derivatives: Strategy D:
- Y CH , N , C-COOH , CC(O)NR 2 Reagents and conditions: EDCI, HOBt, DMAP, DMF, rt, overnight. Amide derivatives were synthesized from the carboxy derivative using regular EDC/HOBt conditions.
- Strategy F is described below for the production of ester monosubstituted 5- phenoxy derivatives:
- Reagents and conditions (a) ethylene glycol, p-TsOH, toluene, reflux, 6 h; (b) K 2 CO 3 , DMF, 10 O 0 C, overnight; (c) 3 M HCl, THF, reflux, 2 h; (d) NaBH 4 , MeOH, rt, 1 h; (e) 3,4-dihydro-2H-pyran, camphorsulfonic acid, CH 2 Cl 2 , rt, 2h; (f) (/-PrO) 3 B, n-BuLi, THF, -78 0 C to rt, 3h.
- These compounds are prepared by hydrogenation of corresponding cyano derivatives. Typical condition is using palladium on charcoal (5 to 10%) in ethanol, methanol, ethyl acetate, and the like, at room temperature to reflux at atmosphere pressure to about 50 psi for from about 1 to about 72 hours. Alternatively, these compounds are prepoared by lithium alminium hydride reduction in ether or tetrahydrofuran at about 0 ° C to reflux for from about 1 to about 24 hours.
- Alkylaminomethyl derivatives are prepared as follows: Strategy J
- Those compounds are prepared by regular reductive alkylration.
- the reducing agent sodium borohydride or sodium cyanoborohydride is typically used.
- the solvent methanol, ethanol, tetrahydrofuran, 1,4-dioxane, and the like are used. The reaction is carried out at from about 0 to about 50 0 C and complete in from about 1 to ahout 24 hours.
- These compounds are prepared by regular sulfonylation.
- the amine is treated with 1 to 10 equivalent of sulfonyl chloride.
- the base triethylamine, diisopropylethylamine, DBU, pyridine, 4- ⁇ /, ⁇ /-dimethylaminopyridine, sodium hydride, butyllithium, and the like are used.
- the solvents dichloromethane, 1 ,2-dichloroethane, tetrahydrofuran, acetonitrile, ⁇ /, ⁇ /-dimethylformamide, and the like are used.
- the reaction is carried out at from about 0 to ahout 50 0 C and complete in from about 1 to about 24 hours.
- These compounds are prepared from 5 -hydroxy derivative by regular alkylation with from about 1 to about 10 equivalent of alkyl halide (RX) and a base.
- RX alkyl halide
- the base potassium carbonate, sodium carbonate, cesium carbonate, sodium hydride, potassium ter t-butoxide, and the like are used.
- the solvent acetone, acetonitrile, tetrahydrofuran, dichloromethane, ⁇ /, ⁇ /-dimethylformamide, and the like are used..
- the reaction is carried out at from about 0 to about 100 0 C and complete in from about 1 to about 24 hours.
- the compounds of the invention can be converted into hydrates and solvates by methods similar to those described herein.
- the compounds of the invention may also be used in combination with additional therapeutic agents.
- the invention thus provides, in a further aspect, a combination comprising a compound described herein or a pharmaceutically acceptable salt thereof together with at least one additional therapeutic agent.
- the additional therapeutic agent is a compound of the invention.
- the additional therapeutic agent includes a boron atom.
- the additional therapeutic agent does not contain a boron atom.
- the additional therapeutic agent is a compound described in sections III a)-e).
- the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art. It will be appreciated that the amount of a compound of the invention required for use in treatment will vary with the nature of the condition being treated and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian.
- the additional therapeutic agent is an antiflammatory.
- the additional therapeutic agent is a steroid or cyclosporineor psoralen or UVA or retinoid or methotrexete or vitamin D 3 analog.
- the steroid is a systemic steriod or a topical steroid.
- the additional therapeutic agent is topical steroid or antihistamine or calcineurin inhibitor.
- the additional therapeutic agent is CC- 10004 or AWD- 12-281.
- the additional therapeutic agent is a corticosteroid or a NSAIDs.
- the additional therapeutic agent is a PDE4 inhibitor.
- the additional therapeutic agent is rolipram or roflumilast.
- the individual components of such combinations may be administered either simultaneously or sequentially in a unit dosage form.
- the unit dosage form may be a single or multiple unit dosage forms.
- the invention provides a combination in a single unit dosage form.
- An example of a single unit dosage form is a capsule wherein both the compound of the invention and the additional therapeutic agent are contained within the same capsule.
- the invention provides a combination in a two unit dosage form.
- An example of a two unit dosage form is a first capsule which contains the compound of the invention and a second capsule which contains the additional therapeutic agent.
- the term 'single unit' or 'two unit' or 'multiple unit' refers to the object which the patient ingests, not to the interior components of the object. Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.
- an exemplary embodiment of the invention is a pharmaceutical formulation comprising a) a compound of the invention; b) an additional therapeutic agent and c) a pharmaceutically acceptable excipient.
- the pharmaceutical formulation is a unit dosage form.
- the pharmaceutical formulation is a single unit dosage form.
- the pharmaceutical formulation is a two unit dosage form.
- the pharmaceutical formulation is a two unit dosage form comprising a first unit dosage form and a second unit dosage form, wherein the first unit dosage form includes a) a compound of the invention and b) a first pharmaceutically acceptable excipient; and the second unit dosage form includes c) an additional therapeutic agent and d) a second pharmaceutically acceptable excipient.
- the invention provides a method for decreasing the production of a cytokine and/or a chemokine, the method comprising: contacting a cell with a compound of the invention, wherein production of the cytokine and/or chemokine by the cell is decreased.
- the invention provides a method for decreasing the production of a cytokine and/or a chemokine, the method comprising: contacting a cell with a compound described herein or a pharmaceutically acceptable salt thereof, wherein production of the cytokine and/or chemokine by the cell is decreased.
- the compound of the invention is a compound decribed herein, or a pharmaceutically acceptable salt thereof.
- the compound of the invention is a compound decribed herein.
- the cell is contacted with a therapeutically effective amount of the compound.
- the compound is according to a formula described herein.
- the compound is a member selected from Cl, C2, C3, C4, C5, C6, C7, C8, C9, ClO, CIl, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62,
- the compound is a member selected from Dl, D2, D3, D4, D5, D6, D7, D8, D9, DlO, DIl, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82,
- the compound is C17. In another exemplary embodiment, the compound is C27. In another exemplary embodiment, the compound is C23 or C24. In another exemplary embodiment, the compound is C25. In another exemplary embodiment, the compound is C26. In another exemplary embodiment, the compound is C37. In an exemplary embodiment, the compound is a member selected from D46, D86, D99, DlOO, D107, D108, Dl 14, D122, D125, D126, D127, D128, D131, D140 and D141, and salts thereof.
- the compound is a member selected from D95, D96, D97, D 102, DIlO, Dill, D113, D115, D121, D129, D130, D132, and salts thereof.
- the compound is a member selected from D47, D109, Dl 16, Dl 18, Dl 19, D120, D123, and salts thereof.
- the compound is a member selected from D98, DlOl, D 106, and salts thereof.
- the compound is a member selected from DIl, D12, D37, D38, D39, D40, D41, D42, D43, D124, D142, D143, D146, and salts thereof.
- the compound is a member selected from D14, D15, D16, D17, D28, D29, D30, D31, D133, D134, D135, D144, D145, D147, and salts thereof.
- the method is for decreasing the production of a cytokine, which is a THl cytokine.
- a cytokine which is a THl cytokine.
- the THl cytokine is a member selected from IFN - ⁇ and IL-2.
- the method is for decreasing the production of a cytokine, which is a TH2 cytokine.
- the TH2 cytokine is a member selected from IL-4, IL-5 and IL-10.
- the method is for decreasing the production of a cytokine, which is a member selected from IL- l ⁇ , IL- l ⁇ , IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, IL-23, TNF- ⁇ , LT, LIF, Oncostatin, IFN ⁇ , IFN ⁇ and IFN- ⁇ .
- the cytokine is a member selected from IL- l ⁇ , IL- 2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-23, TNF- ⁇ , LT, LIF, Oncostatin, and IFN- ⁇ .
- the cytokine is a member selected from IL-I ⁇ , IL-2, IL-23, TNF- ⁇ and IFN- ⁇ .
- the cytokine is TNF- ⁇ .
- the method is for decreasing the release of a cytokine, which is a member selected from IL-l ⁇ , IL-2, IL-4, IL-5, IL-6, IL-8, IL-IO, IL- 12, IL-23, TNF- ⁇ and IFN- ⁇ .
- a cytokine which is a member selected from IL-l ⁇ , IL-2, IL-4, IL-5, IL-6, IL-8, IL-IO, IL- 12, IL-23, TNF- ⁇ and IFN- ⁇ .
- the method is for decreasing the production of a cytokine, which is a member selected from IL-4, IL-IO, IL-11, W-13 and TGF- ⁇ .
- the method is for decreasing the production of a chemokine, which is a member selected from IL-8, Gro- ⁇ , MIP-I, MCP-I, PGE2, ENA-78, and RANTES.
- a chemokine which is a member selected from IL-8, Gro- ⁇ , MIP-I, MCP-I, PGE2, ENA-78, and RANTES.
- the chemokine is a member selected from MCP-I and PGE2.
- the compound of the invention is present in an amount which will inhibit the production of a cytokine and/or a chemokine by at least about 5 to about 100%, or at least about 30 to about 100%, 40 to about 100%, or at least about 50 to about 100%, or at least about 60 to about 100%, or at least about 70 to about 100%, or at least about 80 to about 100%, or at least about 90 to about 100%, or at least about 30 to about 70%, or at least about 40 to about 90%, or at least about 45 to about 80%, or at least about 55 to about 75%, or at least about 75 to about 98%, or at least about 55 to about 99%, or at least about 5% to about 20% or at least about 10% to about 25%.
- the compound of the invention is a compound described herein. b) Increasing the production of a cytokine and/or a chemokine
- the invention provides a method for increasing the production of a cytokine and/or a chemokine, the method comprising: contacting a cell with a compound of the invention, wherein production of the cytokine and/or chemokine by the cell is increased.
- the compound is described herein or a pharmaceutically acceptable salt thereof.
- the compound of the invention is a compound described herein.
- the cell is contacted with a therapeutically effective amount of the compound.
- the compound is according to a formula described herein.
- the compound is a member selected from Cl, C2, C3, C4, C5, C6, C7, C8, C9, ClO, CIl, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75, C76, C77, C78, C79, C80, C81, C82, C
- the compound is a member selected from Dl, D2, D3, D4, D5, D6, D7, D8, D9, DlO, DIl, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82,
- the method is for increasing the production of a cytokine, which is a THl cytokine.
- a cytokine which is a THl cytokine.
- the THl cytokine is a member selected from IFN- ⁇ and IL-2.
- the method is for increasing the production of a cytokine, which is a TH2 cytokine.
- the TH2 cytokine is a member selected from IL-4, IL-5 and IL-10.
- the method is for increasing the production of a cytokine, which is a member selected from IL-4, IL-IO, IL-11, W-13 and TGF- ⁇ .
- the method is for increasing the production of a chemokine, which is a member selected from IL-8, Gro- ⁇ , MIP-I, MCP-I, PGE2, ENA-78, and RANTES.
- a chemokine which is a member selected from IL-8, Gro- ⁇ , MIP-I, MCP-I, PGE2, ENA-78, and RANTES.
- the chemokine is a member selected from MCP-I and PGE2.
- the compound of the invention is present in an amount which will increase the production of a cytokine and/or a chemokine by at least about 5 to about 100%, or at least about 30 to about 100%, 40 to about 100%, or at least about 50 to about 100%, or at least about 60 to about 100%, or at least about 70 to about 100%, or at least about 80 to about 100%, or at least about 90 to about 100%, or at least about 30 to about 70%, or at least about 40 to about 90%, or at least about 45 to about 80%, or at least about 55 to about 75%, or at least about 75 to about 98%, or at least about 55 to about 99%, or at least about 5% to about 20% or at least about 10% to about 25%.
- the compound of the invention is a compound described herein. c) Decreasing the release of a cytokine and/or chemokine
- the invention provides a method for decreasing the release of a cytokine and/or a chemokine, the method comprising: contacting a cell with a compound of the invention, wherein the release of the cytokine and/or chemokine by the cell is decreased.
- the compound of the invention is a compound described herein or a pharmaceutically acceptable salt thereof.
- the compound of the invention is a compound described herein.
- the cell is contacted with a therapeutically effective amount of the compound.
- the compound is according to a formula described herein.
- the compound is a member selected from Cl, C2, C3, C4, C5, C6, C7, C8, C9, ClO, CIl, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75, C76, C77, C78, C79, C80, C81, C82, C
- the compound is a member selected from Dl, D2, D3, D4, D5, D6, D7, D8, D9, DlO, DIl, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82,
- the compound is C17. In another exemplary embodiment, the compound is C27. In another exemplary embodiment, the compound is C23 or C24. In another exemplary embodiment, the compound is C25. In another exemplary embodiment, the compound is C26. In another exemplary embodiment, the compound is C37. In an exemplary embodiment, the compound is a member selected from D46, D86, D99, DlOO, D107, D108, D114, D122, D125, D126, D127, D128, D131, D140 and D141, and salts thereof.
- the compound is a member selected from D95, D96, D97, D102, DIlO, Dill, Dl 13, Dl 15, D121, D129, D130, D132, and salts thereof.
- the compound is a member selected from D47, D109, Dl 16, Dl 18, Dl 19, D120, D123, and salts thereof.
- the compound is a member selected from D98, DlOl, D 106, and salts thereof.
- the compound is a member selected from DIl, D12, D37, D38, D39, D40, D41, D42, D43, D124, D142, D143, D146, and salts thereof.
- the compound is a member selected from D14, D15, D16, D17, D28, D29, D30, D31, D133, D134, D135, D144, D145, D147, and salts thereof.
- the method is for decreasing the release of a cytokine, which is a THl cytokine.
- a cytokine which is a THl cytokine.
- the THl cytokine is a member selected from IFN- ⁇ and IL-2.
- the method is for decreasing the release of a cytokine, which is a TH2 cytokine.
- a cytokine which is a TH2 cytokine.
- the TH2 cytokine is a member selected from IL-4, IL-5 and IL-IO.
- the method is for decreasing the release of a cytokine, which is a member selected from IL- l ⁇ , IL- l ⁇ , IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, IL-23, TNF- ⁇ , LT, LIF, Oncostatin, IFN ⁇ , IFN ⁇ and IFN- ⁇ .
- the cytokine is a member selected from IL-I ⁇ , IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-23, TNF- ⁇ , LT, LIF, Oncostatin, and IFN- ⁇ .
- the cytokine is a member selected from IL-I ⁇ , IL-2, IL-23, TNF- ⁇ and IFN- ⁇ . In another exemplary embodiment, the cytokine is TNF- ⁇ . In another exemplary embodiment, the cytokine is IFN- ⁇ .
- the method is for decreasing the release of a cytokine, which is a member selected from IL-l ⁇ , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-23, TNF- ⁇ and IFN- ⁇ .
- a cytokine which is a member selected from IL-l ⁇ , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-23, TNF- ⁇ and IFN- ⁇ .
- the compound of the invention decreases the release of IL-l ⁇ , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-23, TNF- ⁇ and IFN- ⁇ .
- the compound is C17.
- the method is for decreasing the release of a cytokine, which is a member selected from IL-4, IL-10, IL-11, W- 13 and TGF- ⁇ .
- the method is for decreasing the release of a chemokine, which is a member selected from IL-8, Gro- ⁇ , MIP-I, MCP-I, PGE2, ENA-78, and RANTES.
- the chemokine is a member selected from MCP-I and PGE2.
- the compound is C17 and the chemokine is a member selected from MCP-I and PGE2.
- the compound of the invention decreases the release of TNF- ⁇ , IL-2, IFN ⁇ , IL-5, and IL-IO. In an exemplary embodiment, the compound of the invention does not substantially decrease the release of IL-I ⁇ , IL-6 and IL-8. In an exemplary embodiment, the compound of the invention does not substantially decrease the release of IL-I ⁇ . In an exemplary embodiment, the compound of the invention does not substantially decrease the release of IL-4. In an exemplary embodiment, the compound decreases the release of IL- 12 and IL-23. In an exemplary embodiment, the compound is C27.
- the compound of the invention is present in an amount which will decrease the release of a cytokine and/or a chemokine by at least about 5 to about 100%, or at least about 30 to about 100%, 40 to about 100%, or at least about 50 to about 100%, or at least about 60 to about 100%, or at least about 70 to about 100%, or at least about 80 to about 100%, or at least about 90 to about 100%, or at least about 30 to about 70%, or at least about 40 to about 90%, or at least about 45 to about 80%, or at least about 55 to about 75%, or at least about 75 to about 98%, or at least about 55 to about 99%, or at least about 5% to about 20% or at least about 10% to about 25%.
- the compound of the invention is a compound described herein or a pharmaceutically acceptable salt thereof. d) Increasing the release of a cytokine and/or a chemokine
- the invention provides a method for increasing the production of a cytokine and/or a chemokine, the method comprising: contacting a cell with a compound of the invention, wherein release of the cytokine and/or chemokine by the cell is increased.
- the compound of the invention is a compound described herein or a pharmaceutically acceptable salt thereof.
- the compound is described herein.
- the cell is contacted with a therapeutically effective amount of the compound.
- the compound is according to a formula described herein.
- the compound is a member selected from Cl, C2, C3, C4, C5, C6, C7, C8, C9, ClO, CIl, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75, C76, C77, C78, C79, C80, C81, C82, C
- the compound is a member selected from Dl, D2, D3, D4, D5, D6, D7, D8, D9, DlO, DIl, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82,
- the method is for increasing the release of a cytokine, which is a THl cytokine.
- the THl cytokine is a member selected from IFN- ⁇ and IL-2.
- the method is for increasing the release of a cytokine, which is a TH2 cytokine.
- a cytokine which is a TH2 cytokine.
- the TH2 cytokine is a member selected from IL-4, IL-5 and IL-10.
- the method is for increasing the release of a cytokine, which is a member selected from IL-4, IL-10, IL-11, W- 13 and TGF- ⁇ .
- the method is for increasing the release of a chemokine, which is a member selected from IL-8, Gro- ⁇ , MIP-I, MCP-I, PGE2, ENA-78, and RANTES.
- the chemokine is a member selected from MCP-I and PGE2.
- the compound of the invention is present in an amount which will increase release of a cytokine and/or a chemokine by at least about 5 to about 100%, or at least about 30 to about 100%, 40 to about 100%, or at least about 50 to about 100%, or at least about 60 to about 100%, or at least about 70 to about 100%, or at least about 80 to about 100%, or at least about 90 to about 100%, or at least about 30 to about 70%, or at least about 40 to about 90%, or at least about 45 to about 80%, or at least about 55 to about 75%, or at least about 75 to about 98%, or at least about 55 to about 99%, or at least about 5% to about 20% or at least about 10% to about 25%.
- the compound of the invention is a compound described herein or a pharmaceutically acceptable salt thereof.
- the invention provides a method for inhibiting a phosphodiesterase (PDE), the method comprising: contacting the phosphodiesterase with a compound of the invention, wherein the phosphodiesterase is inhibited.
- PDE phosphodiesterase
- the compound of the invention is a compound described herein or a pharmaceutically acceptable salt thereof.
- the compound of the invention is a compound described herein.
- the amount of the compound is a therapeutically effective amount.
- the compound is according to a formula described herein.
- the compound is according to the following formula:
- R 1 is a member selected from a negative charge, a salt counterion, H, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- M is a member selected from oxygen, sulfur and NR 2 .
- R 2 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- J is a member selected from (CR 3 R 4 ) n i and CR 5 .
- R 3 , R 4 , and R 5 are members independently selected from H, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- nl is an integer selected from 0 to 2.
- R 6 , R 7 , and R 8 are members independently selected from H, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- ml is an integer selected from 0 and 1.
- A is a member selected from CR 9 and N.
- D is a member selected from CR 10 and N.
- E is a member selected from CR 11 and N.
- G is a member selected from CR 12 and N.
- R 9 , R 10 , R 11 and R 12 are members independently selected from H, OR*, NR*R**, SR*, - S(O)R*, -S(O) 2 R*, -S(O) 2 NR*R**, -C(O)R*, -C(O)OR*, -C(0)NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, wherein each R* and R** are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cyclo
- the combination of nitrogens (A + D + E + G) is an integer selected from O to 3.
- a member selected from R 3 , R 4 and R 5 and a member selected from R 6 , R 7 and R 8 , together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring.
- R 3 and R 4 together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring.
- R 6 and R 7 together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring.
- R 9 and R 10 together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring.
- R 10 and R 11 together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring.
- R 11 and R 12 together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring.
- the compound is a member selected from Cl, C2, C3, C4, C5, C6, C7, C8, C9, ClO, CIl, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75, C76, C77, C78, C79, C80, C81,
- the compound is a member selected from Dl, D2, D3, D4, D5, D6, D7, D8, D9, DlO, DIl, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82,
- the compound is C17. In another exemplary embodiment, the compound is C27. In another exemplary embodiment, the compound is C23. In another exemplary embodiment, the compound is C24. In another exemplary embodiment, the compound is C25. In another exemplary embodiment, the compound is C26. In an exemplary embodiment, the compound is a member selected from D46, D86, D99, DlOO, D107, D108, D114, D122, D125, D126, D127, D128, D131, D140 and D141, and salts thereof.
- the compound is a member selected from D95, D96, D97, D102, DIlO, Dill, Dl 13, Dl 15, D121, D129, D130, D132, and salts thereof.
- the compound is a member selected from D47, D109, Dl 16, Dl 18, Dl 19, D120, D123, and salts thereof.
- the compound is a member selected from D98, DlOl, D 106, and salts thereof.
- the compound is a member selected from DIl, D12, D37, D38, D39, D40, D41, D42, D43, D124, D142, D143, D146, and salts thereof.
- the compound is a member selected from D14, D15, D16, D17, D28, D29, D30, D31, D133, D134, D135, D144, D145, D147, and salts thereof.
- the compound is a member selected from 5- (4-Cyanophenoxy)-l -hydroxy-2, 1 -benzoxaborole; 1 ,3-Dihydro- 1 -hydroxy-5-
- yloxy)-benzoic acid isopropyl ester ; 4-(l-Hydroxy-l,3- dihydro-benzo[c][l,2]oxaborol-5-yloxy)-benzoic acid 2-dimethylamino-ethyl ester ; N-Benzyl-4-(l-hydroxy-l,3-dihydro-
- the phosphodiesterase is a member selected from PDEl, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE8, PDE9, PDElO and PDEl 1.
- the phosphodiesterase is PDE4.
- the PDE4 is a member selected from PDE4A, PDE4B, PDE4C and PDE4D.
- the PDE4 is PDE4B.
- the phosphodiesterase is PDE7.
- the invention provides a method for inhibiting a phosphodiesterase4 (PD E4), but not significantly inhibiting at least one PDE which is a member selected from PDEl, PDE2, PDE3, PDE5 and PDE6, involving contacting a cell with a compound of the invention, thereby providing said inhibition.
- PD E4 phosphodiesterase4
- the compound is C27.
- the invention provides a method for inhibiting a phosphodiesterase4 (PDE4), the method comprising: contacting the phosphodiesterase with C 17, or a pharmaceutically acceptable salt thereof, wherein the phosphodiesterase4 (PDE4) is inhibited.
- PDE4 phosphodiesterase4
- the invention provides a method for inhibiting a phosphodiesterase? (PDE7), the method comprising: contacting the phosphodiesterase with C 17, or a pharmaceutically acceptable salt thereof, wherein the phosphodiesterase? (PDE7) is inhibited.
- the invention provides a method for inhibiting a phosphodiesterase4 (PDE4), the method comprising: contacting the phosphodiesterase with C27, or a pharmaceutically acceptable salt thereof, wherein the phosphodiesterase4 (PDE4) is inhibited.
- PDE4 phosphodiesterase4
- the invention provides a method for inhibiting a phosphodiesterase? (PDE7), the method comprising: contacting the phosphodiesterase with C27, or a pharmaceutically acceptable salt thereof, wherein the phosphodiesterase? (PDE7) is inhibited.
- the amount of the compound is a therapeutically effective amount.
- the invention provides a method for inhibiting a phosphodiesterase4 (PDE4), the method comprising: contacting the phosphodiesterase with C23 or C24 or C25, or a pharmaceutically acceptable salt thereof, wherein the phosphodiesterase4 (PDE4) is inhibited.
- PDE4 phosphodiesterase4
- the invention provides a method for inhibiting a phosphodiesterase4 (PDE4), the method comprising: contacting the phosphodiesterase with D46 or D86 or D99 or DlOO or D107 or D108 or Dl 14 or D122 or D125 or D126 or D127 or D128 or D131 or D140 and D141, or a pharmaceutically acceptable salt thereof, wherein the phosphodiesterase4 (PDE4) is inhibited.
- PDE4 phosphodiesterase4
- the invention provides a method for inhibiting a phosphodiesterase4 (PDE4), the method comprising: contacting the phosphodiesterase with D95 or D96 or D97 or D102 or DIlO or Dill or Dl 13 or Dl 15 or D121 or D129 or D130 or D132, and, or a pharmaceutically acceptable salt thereof, wherein the phosphodiesterase4 (PDE4) is inhibited.
- PDE4 phosphodiesterase4
- the invention provides a method for inhibiting a phosphodiesterase4 (PDE4), the method comprising: contacting the phosphodiesterase with D47 or D109 or Dl 16 or Dl 18 or Dl 19 or D120 or D123, and, or a pharmaceutically acceptable salt thereof, wherein the phosphodiesterase4 (PDE4) is inhibited.
- PDE4 phosphodiesterase4
- the invention provides a method for inhibiting a phosphodiesterase4 (PDE4), the method comprising: contacting the phosphodiesterase with D98 or DlOl or D106, and, or a pharmaceutically acceptable salt thereof, wherein the phosphodiesterase4 (PDE4) is inhibited.
- PDE4 phosphodiesterase4
- the invention provides a method for inhibiting a phosphodiesterase4 (PDE4), the method comprising: contacting the phosphodiesterase with DIl or D12 or D37 or D38 or D39 or D40 or D41 or D42 or D43 or D124 or D142 or D143 or D146, and, or a pharmaceutically acceptable salt thereof, wherein the phosphodiesterase4 (PDE4) is inhibited.
- PDE4 phosphodiesterase4
- the invention provides a method for inhibiting a phosphodiesterase4 (PDE4), the method comprising: contacting the phosphodiesterase with D14 or D15 or D16 or D17 or D28 or D29 or D30 or D31 or D133 or D134 or D135 or D144 or D145 or D147, and, or a pharmaceutically acceptable salt thereof, wherein the phosphodiesterase4 (PDE4) is inhibited.
- PDE4 phosphodiesterase4
- the of the invention is present in an amount which will inhibit a phosphodiesterase described herein by at least about 5 to about 100%, or at least about 30 to about 100%, 40 to about 100%, or at least about 50 to about 100%, or at least about 60 to about 100%, or at least about 70 to about 100%, or at least about 80 to about 100%, or at least about 90 to about 100%, or at least about 30 to about 70%, or at least about 40 to about 90%, or at least about 45 to about 80%, or at least about 55 to about 75%, or at least about 75 to about 98%, or at least about 55 to about 99%, or at least about 5% to about 20% or at least about 10% to about 25%.
- the compound of the invention is a compound described herein or a pharmaceutically acceptable salt thereof.
- the invention provides a method of treating and/or preventing a condition, and/or enhancing an effect, in an animal, the method comprising administering to the animal an effective amount of a compound of the invention, thereby treating and/or preventing the condition.
- the compound of the invention is a compound described herein.
- the compound of the invention is a pharmaceutically acceptable salt of a compound described herein.
- the effective amount is an amount effective to treat the condition.
- the effective amount is an amount effective to prevent the condition.
- the animal is not otherwise is need of treatment with the compound of the invention.
- the compound is according to a formula described herein.
- the invention provides a method of treating a condition in an animal in need of the treatment, the method comprising administering to the animal an amount of a compound of the invention, thereby treating the condition.
- the invention provides a method of treating a condition in an animal in need of the treatment, the method comprising administering to the animal a therapeutically effective amount of a compound of the invention, thereby treating the condition.
- the invention provides a method of preventing a condition, in an animal, the method comprising administering to the animal an amount of a compound of the invention, thereby preventing the condition.
- the invention provides a method of enhancing an effect, in an animal, the method comprising administering to the animal an effective amount of a compound of the invention, thereby enhancing the effect.
- the compound is according to a formula described in the section entitled "Inhibiting a phosphodiesterase”.
- the compound is a member selected from Cl, C2, C3, C4, C5, C6, C7, C8, C9, ClO, CIl, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75, C76, C77, C78, C79, C80, C81, C82, C
- the compound is a member selected from Dl, D2, D3, D4, D5, D6, D7, D8, D9, DlO, DIl, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82,
- the compound is C 17 or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is C27 or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is a member selected from D46, D86, D99, DlOO, D107, D108, Dl 14, D122, D125, D126, D127, D128, D131, D140 and D141, and salts thereof. In an exemplary embodiment, the compound is a member selected from D95, D96, D97, D102, DIlO, Dill, D113, D115, D121, D129, D130, D132, and salts thereof.
- the compound is a member selected from D47, D109, Dl 16, Dl 18, Dl 19, D120, D123, and salts thereof.
- the compound is a member selected from D98, DlOl, D 106, and salts thereof.
- the compound is a member selected from DIl, D12, D37, D38, D39, D40, D41, D42, D43, D124, D142, D143, D146, and salts thereof.
- the compound is a member selected from D14, D15, D16, D17, D28, D29, D30, D31, D133, D134, D135, D144, D145, D147, and salts thereof
- the condition is a disease. In an exemplary embodiment, the condition is an inflammatory-related condition. In an exemplary embodiment, the condition involves the increase of production of a cytokine and/or a chemokine. In an exemplary embodiment, the condition involves the decrease of production of a cytokine and/or a chemokine. In an exemplary embodiment, the condition involves the increase of release of a cytokine and/or a chemokine. In an exemplary embodiment, the condition involves the decrease of release of a cytokine and/or a chemokine. In an exemplary embodiment, the condition involves the inhibition of a phosphodiesterase.
- the compound is in an amount sufficient to treat the inflammatory-related disease by inhibiting proinflammatory cytokine expression or by stimulating anti-inflammatory cytokine expression, but the amount is less than sufficient to substantially inhibit cyclin dependent kinases.
- the condition is mediated by a cytokine.
- the condition is mediated by a chemokine.
- the condition is mediated by a neutrophil.
- the condition is mediated by a phosphodiesterase.
- the condition is mediated by a phosphodiesterase-4.
- the condition is mediated by a phosphodiesterase-7.
- the condition is a member selected from periodontitis, keratoconjuncitivitis sicca, rheumatoid arthritis, osteoarthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, traumatic arthritis, rubella arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis, graft versus host disease, systemic lupus erythematosus, cutaneous lupus erythematosus, toxic shock syndrome, irritable bowel syndrome, muscle degeneration, allograft rejections, pancreatitis, insulinitis, glomerulonephritis, diabetic nephropathy, renal fibrosis, chronic renal failure, gout, leprosy, acute synovitis, Reiter's syndrome, gouty arthritis, Behcet's disease, spondylitis, endometriosis, non-articular inflammatory conditions, such as intervertbral disk syndrome
- cytokine mediated diseases are allergy, a metabolic disease, a chemotherapy/radiation related complication; diabetes type I; diabetes type II; a liver disease; a gastrointestinal disorder; an ophthamological disease; allergic conjunctivitis; diabetic retinopathy; Sjogren's syndrome; uvetitis; a pulmonary disorder, a renal disease; dermatitis; HIV- related cachexia; cerebral malaria; ankylosing spondolytis; leprosy; anemia; fibromyalgia, kidney failure, stroke, chronic heart failure, endotoxemia, reperfusion injury, ischemia reperfusion, myocardial ischemia, restenosis, thrombosis, angiogenesis, Coronary Heart Disease, Coronary Artery Disease, acute coronary syndrome, Takayasu arteritis, cardiac failure such as heart failure, aortic valve stenosis, cardiomyopathy, myocarditis, vasculitis, vascular restenosis, valvular disease or
- the condition is a member selected from allergic conjunctivitis, uveitis, glaucoma, optic neuritis, retinal ischemia, diabetic retinopathy, laser induced optic damage, or surgery or trauma-induced proliferative vitreoretinopathy.
- the condition is a member selected from allergic rhinitis, asthma, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, emphysema, bronchitis, mucus hypersecretion, silicosis, SARS infection and respiratory tract inflammation.
- the condition is a member selected from psoriasis, eczema, atopic dermatitis, contact dermatitis, inflammatory alopecia or acne.
- the condition is a member selected from Guillain-Barre syndrome, Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis and other demyelinating diseases, viral and bacterial meningitis, CNS trauma, spinal cord injury, seizures, convulsions, olivopontocerebellar atrophy, AIDS dementia complex, MERRF and MELAS syndromes, Leber's disease, Wernicke's encephalophathy, Rett syndrome, homocysteinuria, hyperprolinemia, hyperhomocysteinemia, nonketotic hyperglycinemia, hydroxybutyric aminoaciduria, sulfite oxidase deficiency, combined systems disease, lead encephalopathy, Tourett's syndrome, hepatic encephalopathy, drug addiction, drug tolerance, drug dependency, depression, attention deficit disorder (ADD), anxiety and schizophrenia, aneurism, or epilepsy
- the condition is a member selected from bone resorption diseases, osteopetrosis, osteoporosis, or osteoarthritis.
- the condition is a member selected from diabetes, systemic cachexia, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), obesity, anorexia or bulimia nervosa.
- the condition is a member selected from sepsis, HIV, HCV, malaria, infectious arthritis, leishmaniasis, Lyme disease, cancer, including but not limited to breast cancer, colon cancer, lung cancer, prostate cancer, multiple myeloma, acute myelogenous leukemia, myelodysplastic syndrome, non-Hodgkins lymphoma, or follicular lymphoma, Castleman's disease, or drug resistance.
- the condition is a member selected from is bronchial asthma, rhinitis, influenza, stroke, myocardial infarction, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, acute glomerulonephritis, dermatoses with acute inflammatory components, acute purulent meningitis, hemodialysis, leukopheresis, granulocyte transfusion associated syndromes, or necrotizing enterocolitis.
- the condition is a member selected from inflammatory bowel disease (IBD), psoriasis, rheumatoid arthritis (RA), multiple sclerosis (MS), neurodegenerative disorder, cardiovascular disease (CVD) and atherosclerosis, and metabolic disease (the metabolic syndrome and diabetes) as well as infection-related inflammation.
- the condition is a neurodegenerative disorder which is a member selected from Alzheimer's disease and Parkinson disease.
- the condition is inflammatory bowel disease which is selected from the group consisting of: Crohn's disease or ulcerative colitis.
- the condition is a gastrointestinal complication.
- the condition is diarrhea.
- the condition is a member selected from celiac disease and non-specific colitis.
- the condition is a liver disease.
- the condition is a member selected from an autoimmune hepatitis, hepatitis C, primary biliary cirrhosis, primary sclerosing cholangitis, or fulminant liver failure.
- the condition is a bone disease.
- the condition is osteoporosis.
- the condition is a pulmonary disorder.
- condition is a member selected from: allergic rhinitis, asthma, chronic obstructive pulmonary disease, chronic granulomatous inflammation, cystic fibrosis, and sarcoidosis.
- condition is cardiovascular disease.
- the cardiovascular disease is a member selected from atheroscleotic cardiac disease, congestive heart failure and restenosis.
- condition is a renal disease.
- condition is a member selected from glomerulonephritis and vasculitis.
- condition is a member selected from post-radiotherapy related disease or atherosclerosis.
- condition is atopic dermatitis.
- the condition is actinic keratosis.
- the condition is a member selected from psoriasis, inflammatory arthritis, rheumatoid arthritis, asthma, chronic bronchitis, inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, colitis, esoniophilic granuloma, septic shock, reperfusion injury of the myocardium, reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, chronic obstruct
- the colitis is a member selected from ulcerative colitis, Crohn's colitis, diversion colitis, ischemic colitis, infectious colitis, fulminant colitis, chemical colitis, microscopic colitis, lymphocytic colitis, and atypical colitis.
- the colitis is a member selected from ulcerative colitis and Crohn's colitis.
- the condition is sunburn. In an exemplary embodiment, the condition is inflammation caused by sunburn.
- the condition is psoriasis.
- psoriasis is a member selected from plaque psoriasis, flexural psoriasis (inverse psoriasis), guttate psoriasis, pustular psoriasis, nail psoriasis, psoriatic arthritis and erythrodermic psoriasis.
- the psoriasis is a member selected from plaque psoriasis and nail psoriasis.
- the condition is psoriasis and the compound is C17.
- the condition is psoriasis and the compound is C27.
- the condition is plaque psoriasis or nail psoriasis and the compound is C17.
- the condition is plaque psoriasis or nail psoriasis and the compound is C27.
- the disorder is a member selected from cognition impairment or decline and memory impairment.
- the memory impairment is due to dementia.
- the patient is suffering from memory impairment due to Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld- Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia, an acute neuronal disease, age-related cognitive decline, HIV or a cardiovascular disease.
- the PDE4 inhibition is enhancing an effect, wherein the enhanced effect is cognition or memory.
- the invention provides a method for stimulating ovarian follicular growth in a female, comprising administering to a female a medicament comprising a compound of the invention, whereby ovarian follicular growth is stimulated in the female.
- the compound of the invention is a compound described herein or a pharmaceutically acceptable salt thereof.
- the female is undergoing ovulation induction.
- the female is undergoing controlled ovarian hyperstimulation.
- the medicament is administered simultaneously, separately or sequentially with follicle stimulating hormone (FSH), or an agent having FSH activity, or an agent that stimulates endogenous FSH release.
- FSH follicle stimulating hormone
- the invention also provides a method of treating an inflammatory-related disease associated with cytokine expression levels, which comprises administering to an animal in need of such treatment the compound of the invention.
- the compound is according to a formula described herein.
- the compound of the invention is a compound described herein or a pharmaceutically acceptable salt thereof.
- the invention provides a method of treating or preventing an inflammatory-related disease in an animal, the method comprising administering to the animal a therapeutically effective amount of a compound of the invention, wherein the compound is in an amount sufficient to treat the inflammatory- related disease by inhibiting pro-inflammatory cytokine expression or by stimulating anti-inflammatory cytokine expression, but the amount is less than sufficient to substantially inhibit cyclin dependent kinases.
- the compound of the invention is a compound described herein or a pharmaceutically acceptable salt thereof.
- the invention provides a method for inhibiting the production of an inflammatory cytokine by cells capable of producing the inflammatory cytokine, the method comprises contacting a cell with a therapeutic amount of compound of the invention, wherein production of the inflammatory cytokine by the cells is inhibited.
- the therapeutic amount is sufficient to inhibit the production of the inflammatory cytokine protein between about 50% and about 99%.
- the invention provides a method for inhibiting an inflammatory response in an animal, the method comprising: contacting the animal with a therapeutic amount of a compound of the invention, wherein the inflammatory response is inhibited.
- the animal is a member selected from human, cattle, deer, reindeer, goat, honey bee, pig, sheep, horse, cow, bull, dog, guinea pig, gerbil, rabbit, cat, camel, yak, elephant, ostrich, otter, chicken, duck, goose, guinea fowl, pigeon, swan, and turkey.
- the animal is a member selected from a human, cattle, goat, pig, sheep, horse, cow, bull, dog, guinea pig, gerbil, rabbit, cat, chicken and turkey.
- the animal is a human.
- a compound of the invention and/or a pharmaceutical formulation described herein can be used.
- the animal being administered the compound of the invention is not otherwise in need of treatment with the compound of the invention.
- the compound is a member selected from Cl, C2, C3, C4, C5, C6, C7, C8, C9, ClO, CIl, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C
- the compound is C17. In an exemplary embodiment, the compound is C27. In an exemplary embodiment, the compound is Dl. In an exemplary embodiment, the compound is D82. In an exemplary embodiment, the compound is D226. In an exemplary embodiment, the compound is D227.
- the method involves treating psoriasis by administering a compound of the invention to an animal not otherwise in need of treatment with the compounds of the invention.
- the method involves treating atopic dermatitis by administering a compound of the invention to an animal not otherwise in need of treatment with the compounds of the invention.
- the invention provides a pharmaceutical formulation comprising: (a) a compound of the invention and (b) a pharmaceutically acceptable excipient.
- the compound of the invention is a compound described herein or a pharmaceutically acceptable salt thereof.
- the compound of the invention is a compound described herein or a pharmaceutically acceptable salt thereof.
- the compound is according to a formula described herein.
- the compound is a member selected from Cl, C2, C3, C4, C5, C6, C7, C8, C9, ClO, CIl, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75, C76, C77, C78, C79, C80, C81, C82, C
- the compound is a member selected from Dl, D2, D3, D4, D5, D6, D7, D8, D9, DlO, DIl, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82,
- the compound is C17. In an exemplary embodiment, the compound is C27.
- the formulation is a unit dosage form. In an exemplary embodiment, the formulation is a member selected from an oral unit dosage form and a topical unit dosage form. In an exemplary embodiment, the topical unit dosage form is a member selected from a lotion, an ointment and a cream. In an exemplary embodiment, the formulation is for topical use.
- the compound of the invention is present in the pharmaceutical formulation in an amount of between about 0.0001% to about 60% (w/w). In an exemplary embodiment, the amount is between about 0.05% to about 0.2% (w/w). In an exemplary embodiment, the amount is between about 0.075% to about 0.15% (w/w). In an exemplary embodiment, the amount is between about 0.01% to about 10% (w/w). In an exemplary embodiment, the amount is between about 0.1% to about 10% (w/w). In an exemplary embodiment, the amount is between about 0.25% to about 6% (w/w). In an exemplary embodiment, the amount is between about 0.5% to about 5% (w/w).
- the amount is between about 0.1% and about 1.0% (w/w). In an exemplary embodiment, the amount is between about 0.25% and about 0.75% (w/w). In an exemplary embodiment, the amount is between about 0.4% and about 0.6% (w/w). In an exemplary embodiment, the amount is between about 1.0% and about 2.0% (w/w). In an exemplary embodiment, the amount is between about 1.3% and about 1.7% (w/w). In an exemplary embodiment, the amount is between about 2.0% and about 3.0% (w/w). In an exemplary embodiment, the amount is between about 3.0% and about 4.0% (w/w). In an exemplary embodiment, the amount is between about 4.0% and about 5.0% (w/w).
- the amount is between about 4.5% and about 5.5% (w/w). In an exemplary embodiment, the amount is between about 10% to about 20% (w/w). In an exemplary embodiment, the amount is between about 13% to about 17% (w/w). In an exemplary embodiment, the amount is between about 14% to about 16% (w/w). In an exemplary embodiment, the amount is a member selected from about 0.1%, 0.3, 0.5%, 1.0%, 1.5%, 2.0%, 5.0%, 10% and 15% (w/w).
- the pharmaceutical formulations of the invention can take a variety of forms adapted to the chosen route of administration. Those skilled in the art will recognize various synthetic methodologies that may be employed to prepare non-toxic pharmaceutical formulations incorporating the compounds described herein. Those skilled in the art will recognize a wide variety of non-toxic pharmaceutically acceptable solvents that may be used to prepare solvates of the compounds of the invention, such as water, ethanol, propylene glycol, mineral oil, vegetable oil and dimethylsulfoxide (DMSO).
- DMSO dimethylsulfoxide
- the pharmaceutical formulations of the invention may be administered orally, topically, ocularly, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. It is further understood that the best method of administration may be a combination of methods. Oral administration in the form of a pill, capsule, elixir, syrup, lozenge, troche, or the like is particularly preferred.
- parenteral as used herein includes subcutaneous injections, intradermal, intravascular (e.g., intravenous), intramuscular, spinal, intrathecal injection or like injection or infusion techniques.
- the pharmaceutical formulations containing compounds of the invention are preferably in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
- compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical formulations, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
- Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.
- excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia; lubricating agents, for example magnesium stearate, stearic acid or talc; and extenders and bulking agents, such as microcrystalline cellulose.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; and dispersing or wetting agents, which may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbito
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., EDTA
- suspending agent e.g., EDTA
- preservatives e.g., EDTA, EDTA
- PEG polyvinylpyrrolidone
- PVP polyvinylpyrrolidone
- carbohydrate-based dispersing agents such as, for example, hydroxypropylcellulose and hydroxypropylcellulose ethers (e.g., HPC, HPC-SL, and HPC-L), hydroxypropylmethylcellulose and hydroxypropylmethylcellulose ethers (e.g.
- HPMC KlOO, HPMC K4M, HPMC Kl 5M, and HPMC KlOOM carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), polyvinylpyrrolidone/vinyl acetate copolymer (Plasdone.RTM., e.g., S-630), 4-(l,l,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol), poloxamers (e.g., Pluronics F68.RTM., F88.RTM., and F108.RTM., which are block copolymers of ethylene oxide and propylene oxide); and poloxamines (e.g., Tetronic 9080, also known as Poloxamine 9080
- compositions of the invention may also be in the form of oil-in-water emulsions and water-in-oil emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth; naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol; anhydrides, for example sorbitan monooleate; and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, and flavoring and coloring agents.
- the pharmaceutical formulations may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents, which have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
- the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- the pharmaceutical formulations may also be administered in the form of suppositories, e.g., for rectal administration of the drug.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- Such materials are cocoa butter and polyethylene glycols.
- the pharmaceutical formulations can be administered parenterally in a sterile medium.
- the drug depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
- adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.
- the pharmaceutical formulations may be administered ocularly.
- the ophthalmic formulation contains a liquid vehicle.
- the compound depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
- Such ophthalmic formulations can then be administered to the eye in the form of a droplet.
- Suitable vehicles, and optional tear substitute components are known in the art.
- the composition containing the therapeutic compound may be added to the animal's feed or drinking water. Also, it will be convenient to formulate animal feed and drinking water products so that the animal takes in an appropriate quantity of the compound in its diet. It will further be convenient to present the compound in a composition as a premix for addition to the feed or drinking water. The composition can also added as a food or drink supplement for humans.
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the condition being treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.
- Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most disorders, a dosage regimen of 4 times daily or less is preferred.
- the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
- Preferred compounds of the invention will have desirable pharmacological properties that include, but are not limited to, oral bioavailability, low toxicity, low serum protein binding and desirable in vitro and in vivo half-lives. Penetration of the blood brain barrier for compounds used to treat CNS disorders is necessary, while low brain levels of compounds used to treat peripheral disorders are often preferred. [0395] Assays may be used to predict these desirable pharmacological properties. Assays used to predict bioavailability include transport across human intestinal cell monolayers, including Caco-2 cell monolayers. Toxicity to cultured hepatocytes may be used to predict compound toxicity. Penetration of the blood brain barrier of a compound in humans may be predicted from the brain levels of laboratory animals that receive the compound intravenously.
- Serum protein binding may be predicted from albumin binding assays. Such assays are described in a review by Oravcova, et al. (Journal of Chromatography B (1996) volume 677, pages 1-27).
- Compound half- life is inversely proportional to the frequency of dosage of a compound. In vitro half- lives of compounds may be predicted from assays of microsomal half-life as described by Kuhnz and Gieschen (Drug Metabolism and Disposition, (1998) volume 26, pages 1120-1127).
- compositions required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or clinician.
- the pharmaceutical composition described herein includes an additional active ingredient.
- the additional active ingredient is an immunosuppressive agent.
- the additional active ingredient is a member selected from corticosteroids, aminosalicylates, azathioprine (6-mercaptopurine), methotrexate and ciclosporine, etanercept, infliximab, adalimumab, alefacept, efalizumab and anakinra.
- the additional active ingredient is a member selected from cilostazol, rolipram, roflumilast, piclamilast, CDP-840 and ariflo.
- the additional active ingredient is a member selected from betamethasone, tacrolimus and pimecrolimus. In still another exemplary embodiment, the additional active ingredient is a member selected from an activated vitamin D analog and an arotinoid (an aromatic retinoic acid analog). In still another exemplary embodiment, the additional active ingredient is a member selected from carcipotriol, such as Tazorac (tazarotene). V. a) Topical formulations
- Topical administration includes for example, transmucosal, transdermal, ungual and transungual routes of administration.
- compositions of the present invention comprises fluid or semi-solid vehicles that may include but are not limited to polymers, thickeners, buffers, neutralizers, chelating agents, preservatives, surfactants or emulsifiers, antioxidants, waxes or oils, emollients, sunscreens, and a solvent or mixed solvent system.
- the solvent or mixed solvent system is important to the formation because it is primarily responsible for dissolving the drug.
- the best solvent or mixed solvent systems are also capable of maintaining clinically relevant levels of the drug in solution despite the addition of a poor solvent to the formulation.
- the topical compositions useful in the subject invention can be made into a wide variety of product types.
- product types can comprise several types of carrier systems including, but not limited to particles, nanoparticles, and liposomes.
- disintegrating agents can be added, such as the cross-linked polyvinyl pyrrolidone, agar or alginic acid or a salt thereof such as sodium alginate.
- the formulation can be selected to maximize delivery to a desired target site in the body.
- the formulations can also include various conventional colorants, fragrances, thickeners, preservatives, humectants, emollients, demulcents, solubilizing excipients, dispersants, penetration enhancers, plasticizing agents, preservatives, stabilizers, demulsif ⁇ ers, wetting agents, sunscreens, emulsifiers, moisturizers, astringents, deodorants, and the like, which can be added to provide additional benefits such as, for example, improving the feel and/or appearance of the topical preparation.
- Lotions which are preparations that are to be applied to the skin, nail, hair, claw or hoof surface without friction, are typically liquid or semi-liquid preparations in which finely divided solid, waxy, or liquid are dispersed. Lotions will typically contain suspending agents to produce better dispersions as well as compounds useful for localizing and holding the active agent in contact with the skin, nail, hair, claw or hoof, e.g., methylcellulose, sodium carboxymethyl-cellulose, or the like.
- Creams containing the active agent for delivery according to the present invention are viscous liquid or semisolid emulsions, either oil-in-water or water-in-oil.
- Cream bases are water- washable, and contain an oil phase, an emulsif ⁇ er and an aqueous phase.
- the oil phase is generally comprised of petrolatum or a fatty alcohol, such as cetyl- or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant.
- the emulsif ⁇ er in a cream formulation as explained in Remington: The Science and Practice of
- a lotion or cream may include a relatively large aqueous phase and a relatively small oil phase. Furthermore, the lotions and creams of the invention may include the active compound "all-in-solution" in the oil phase so that substantially none of the active compound crystallizes out at room temperature.
- the lotion or cream may comprise a biphasic system, that is, a system wherein a portion (from about 30 to about 75% by weight) of the active compound is in solution in the oil phase and the remainder is in suspension in the aqueous phase.
- Gel formulations can also be used in connection with the present invention. As will be appreciated by those working in the field of topical drug formulation, gels are semisolid. Single-phase gels contain organic macromolecules distributed substantially uniformly throughout the carrier liquid, which is typically aqueous, but also may be a solvent or solvent blend. In various embodiments, conventional gelling agents can be used. In an exemplary embodiment, cellulose or its derivatives are used. In an exemplary embodiment, hydroxypropyl methyl cellulose, such as Methocel E4M, is used.
- gelling agents include methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, cellulose acetate, ethyl cellulose, methyl hydroxy ethyl cellulose, hydroxy ethyl cellulose, and cellulose gum.
- Cellulose based gelling agents particularly hydroxymethylcellulose and hydroxypropyl methyl cellulose, are also useful in some embodiments.
- cross-linked acrylic polymers including Carbopol may be used.
- the formulation of the invention is viscous enough to form a firm gel. In one embodiment, the viscosity is in the range of 25,000-300,000 cps (centipoise) or 75,000-200,000 cps, based on Brookf ⁇ eld (LV) analysis.
- a speed-gel may be prepared by mixing lecithin organogel (L. O.), as a 1 :1 (m/m) mixture of lecithin and isopropyl myristate, with LID oil (a 1 :1 [m/m] mixture of L. O. and docusate sodium), dissolving additional docusate sodium powder into this mixture, and then adding aqueous urea.
- lecithin organogel L. O.
- LID oil a 1 :1 [m/m] mixture of L. O. and docusate sodium
- Ointments which are semisolid preparations, are typically based on petrolatum or other petroleum derivatives.
- the specific ointment base to be used is one that provides for optimum delivery for the active agent chosen for a given formulation, and, preferably, provides for other desired characteristics as well, e.g., emolliency or the like.
- an ointment base should be inert, stable, nonirritating and non- sensitizing. As explained in Remington: The Science and Practice of Pharmacy, 19th Ed.
- ointment bases may be grouped in four classes: oleaginous bases; emulsifiable bases; emulsion bases; and water-soluble bases.
- Oleaginous ointment bases include, for example, vegetable oils, fats obtained from animals, and semisolid hydrocarbons obtained from petroleum. Examples of oleaginous ointment bases include White Ointment USP, Yellow Ointment NF, Oleic Acid USP, Olive Oil USP, Paraffin USP, Petrolatum NF, White Petrolatum USP, Spermaceti Wax USP, Synthetic Spermaceti NF, Starch
- Emulsifiable ointment bases also known as absorbent ointment bases, contain little or no water and include, for example, hydroxystearin sulfate, anhydrous lanolin and hydrophilic petrolatum.
- Emulsion ointment bases are either water-in-oil (W/O) emulsions or oil-in- water (O/W) emulsions, and include, for example, cetyl alcohol, glyceryl monostearate, lanolin and stearic acid.
- Preferred water-soluble ointment bases are prepared from polyethylene glycols of varying molecular weight; again, reference may be had to Remington: The Science and Practice of Pharmacy, supra, for further information.
- Useful formulations of the invention also encompass sprays and aerosols.
- Sprays generally provide the active agent in an aqueous and/or alcoholic solution which can be misted onto the skin, nail, hair, claw or hoof for delivery.
- Such sprays include those formulated to provide for concentration of the active agent solution at the site of administration following delivery, e.g., the spray solution can be primarily composed of alcohol or other like volatile liquid in which the drug or active agent can be dissolved.
- the topical pharmaceutical compositions may also comprise suitable solid or gel phase carriers.
- suitable solid or gel phase carriers include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
- the topical pharmaceutical compositions may also comprise a suitable emulsifier which refers to an agent that enhances or facilitates mixing and suspending oil-in- water or water-in-oil.
- the emulsifying agent used herein may consist of a single emulsifying agent or may be a nonionic, anionic, cationic or amphoteric surfactant or blend of two or more such surfactants; preferred for use herein are nonionic or anionic emulsifiers.
- Such surface-active agents are described in
- Examples of useful ionic surfactants include sodium caproate, sodium caprylate, sodium caprate, sodium laurate, sodium myristate, sodium myristolate, sodium palmitate, sodium palmitoleate, sodium oleate, sodium ricinoleate, sodium linoleate, sodium linolenate, sodium stearate, sodium lauryl sulfate (dodecyl), sodium tetradecyl sulfate, sodium lauryl sarcosinate, sodium dioctyl sulfosuccinate, sodium cholate, sodium taurocholate, sodium glycocholate, sodium deoxycholate, sodium taurodeoxycholate, sodium glycodeoxycholate, sodium ursodeoxycholate, sodium chenodeoxycholate, sodium taurochenodeoxycholate, sodium glyco cheno deoxycholate, sodium cholylsarcosinate, sodium N-methyl taurocholate, egg yolk phosphatides, hydrogenated soy
- acyl isethionates acyl taurates
- alkyl glyceryl ether sulfonates sodium octyl sulfosuccinate, sodium undecylenamideo-MEA-sulfosuccinate, hexadecyl triammonium bromide, decyl trimethyl ammonium bromide, cetyl trimethyl ammonium bromide, dodecyl ammonium chloride, alkyl benzyldimethylammonium salts, diisobutyl phenoxyethoxydimethyl benzylammonium salts, alkylpyridinium salts, betaines (trialkylglycine), lauryl betaine (N-lauryl,N,N-dimethylglycine), and ethoxylated amines (polyoxyethylene-15 coconut amine).
- Typical counterions are provided above. It will be appreciated by one skilled in the art, however, that any bioacceptable counterion may be used.
- the fatty acids are shown as sodium salts, other cation counterions can also be used, such as, for example, alkali metal cations or ammonium.
- Formulations of the invention may include one or more of the ionic surfactants above.
- Preferred for use herein are high molecular weight alcohols such as cetearyl alcohol, cetyl alcohol, stearyl alcohol, emulsifying wax, glyceryl monostearate, and oleyl alcohol.
- the emulsifier is octyldodecanol.
- xanthan gum or a xanthan gum blend is used. Cholesterol and cholesterol derivatives may also be employed in externally used emulsions and promote w/o emulsions.
- nonionic emulsifying agents are those with hydrophile- lipophile balances (HLB) of about 3 to 6 for w/o system and 8 to 18 for o/w system as determined by the method described by Paul L. Lindner in "Emulsions and Emulsion", edited by Kenneth Lissant, published by Dekker, New York, N. Y., 1974, pages 188-190. More preferred for use herein are one or more nonionic surfactants that produce a system having HLB of about 8 to about 18.
- nonionic emulsif ⁇ ers include but are not limited to
- BIJ 72 the trade name for a polyoxyethylene (2) stearyl ether having an HLB of 4.9
- BMIJ 721 the trade name for a polyoxyethylene (21) stearyl ether having an HLB of 15.5, "Brij 30”, the trade name for polyoxyethylene lauryl ether having an HLB of 9.7
- Polyawax the trade name for emulsifying wax having an HLB of 8.0
- Span 60 the trade name for sorbitan monostearate having an HLB of 4.7
- Crodesta F-160 the trade name for sucrose stearate” having an HLB of 14.5.
- each emulsifying agent is present in amount from about 0.5 to about 2.5 wt%, preferably 0.5 to 2.0%, more preferably
- the emulsifying agent comprises a mixture of steareth 21 (at about 1.8 %) and steareth 2 (at about 1.0%).
- the topical pharmaceutical compositions may also comprise suitable emollients.
- Emollients are materials used for the prevention or relief of dryness, as well as for the protection of the skin, nail, hair, claw or hoof.
- Useful emollients include, but are not limited to, hydrocarbon oils, waxes, silicone, cetyl alcohol, isopropyl myristate, stearyl alcohol, oleyl alcohol, octyl hydroxystearate, glycerin, other fatty alcohols including short or medium chain fatty alcohols having a carbon length of up to 18, medium or short chain fatty acid triglycerides, esters such as fatty acid esters, lecithins and related polar compounds such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, lyso-phosphatidylcholine, lyso-phosphatidy
- emollients include triglyceride oils like vegetable oils such as wheat germ, maize, sunflower, karite, castor, sweet almond, macadamia, apricot, soybean, cottonseed, alfalfa, poppy, pumpkinseed, sesame, cucumber, rapeseed, avocado, hazelnut, grape seed, blackcurrant seed, evening primrose, millet, barley, quinoa, olive, rye, safflower, candlenut, soya, palm, passion flower, or musk rose oil; triglycerides of caprylic/capric acid, such as those sold under the tradenames MIGLYOL.RTM.
- fatty alcohols such as caprylic alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol, and stearyl alcohol; and fatty esters such as oleyl acetate, isotridecyl benzoate, diisooctyl sebacate, isopropyl myristate, cetyl octanoate, isopropyl palmitate, butyl stearate, hexyl laurate, myristyl myristate, decyl oleate, hexyldecyl dimethyloctanoate, cetyl lactate, myristyl lactate, lanoline acetate, isocetyl stearate, isocetyl isostearate, cholesteryl 12-hydroxystearate, dipentaerythritol fatty acid ester, and is
- emollients are known and can be used herein. See e.g., Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 32-43 (1972), and U.S. Pat. No. 4,919,934, to Deckner et al, issued Apr. 24, 1990, both of which are incorporated herein by reference in their entirety. These materials are available from Ruger Chemical Co, (Irvington, NJ).
- each emollient is present in an amount from about 0.1 to 15%, preferably 0.1 to about 3.0, more preferably 0.5, 1.0, or 2.5 wt%.
- the emollient is a mixture of cetyl alcohol, isopropyl myristate and stearyl alcohol in a 1/5/2 ratio.
- the emollient may also be a mixture of cetyl alcohol and stearyl alcohol in a 1 /2 ratio.
- the topical pharmaceutical compositions may also comprise suitable antioxidants, substances known to inhibit oxidation.
- Antioxidants suitable for use in accordance with the present invention include, but are not limited to, butylated hydroxytoluene, ascorbic acid, sodium ascorbate, calcium ascorbate, ascorbic palmitate, butylated hydroxyanisole, 2,4,5-trihydroxybutyrophenone, 4- hydroxymethyl-2,6-di-tert-butylphenol, erythorbic acid, gum guaiac, propyl gallate, thiodipropionic acid, dilauryl thiodipropionate, tert-butylhydroquinone and tocopherols such as vitamin E, and the like, including pharmaceutically acceptable salts and esters of these compounds.
- the antioxidant is butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, ascorbic acid, pharmaceutically acceptable salts or esters thereof, or mixtures thereof.
- the antioxidant is butylated hydroxytoluene.
- These materials are available from Ruger Chemical Co, (Irvington, NJ).
- Antioxidants that may be incorporated into the formulations of the invention include natural antioxidants prepared from plant extracts, such as extracts from aloe vera; avocado; chamomile; echinacea; ginko biloba; ginseng; green tea; heather; jojoba; lavender; lemon grass; licorice; mallow; oats; peppermint; St. John's wort; willow; wintergreen; wheat wild yam extract; marine extracts; and mixtures thereof.
- the topical formulations of the present invention contain at least one antioxidant
- the total amount of antioxidant present is from about 0.001 to 0.5 wt%, preferably 0.05 to about 0.5 wt%, more preferably 0.1%.
- the topical pharmaceutical compositions may also comprise suitable preservatives.
- Preservatives are compounds added to a pharmaceutical formulation to act as an anti-microbial agent.
- preservatives known in the art as being effective and acceptable in parenteral formulations are benzalkonium chloride, benzethonium, chlorohexidine, phenol, m-cresol, benzyl alcohol, methylparaben, propylparaben and other parabens, chlorobutanol, o-cresol, p-cresol, chlorocresol, phenylmercuric nitrate, thimerosal, benzoic acid, and various mixtures thereof. See, e.g., Wall Arbitr, K. -H., Develop.
- the preservative is selected from methylparaben, propylparaben and mixtures thereof. These materials are available from Inolex Chemical Co (Philadelphia, PA) or Spectrum Chemicals.
- the total amount of preservative present is from about 0.01 to about 0.5 wt%, preferably from about 0.1 to 0.5%, more preferably from about 0.03 to about
- the preservative is a mixture of methylparaben and proplybarben in a 5/1 ratio.
- the amount is usually 15 to 20%.
- the topical pharmaceutical compositions may also comprise suitable chelating agents to form complexes with metal cations that do not cross a lipid bilayer.
- chelating agents examples include ethylene diamine tetraacetic acid (EDTA), ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) and 8-Amino-2-[(2-amino-5-methylphenoxy)methyl]-6-methoxyquinoline- N 5 N 5 N', N '-tetraacetic acid, tetrapotassium salt (QUIN-2).
- the chelating agents are EDTA and citric acid.
- a chelating agent may comprise salts of the above, such as edetate disodium, for example. These materials are available from Spectrum Chemicals.
- the topical formulations of the present invention contain at least one chelating agent
- the total amount of chelating agent present is from about 0.005% to 2.0% by weight, preferably from about 0.05% to about 0.5 wt%, more preferably about 0.1% by weight.
- the topical pharmaceutical compositions may also comprise suitable neutralizing agents used to adjust the pH of the formulation to within a pharmaceutically acceptable range.
- neutralizing agents include but are not limited to trolamine, tromethamine, sodium hydroxide, hydrochloric acid, sodium carbonate, citric acid, acetic acid and corresponding acids or bases thereof. Such materials are available from are available from Spectrum Chemicals (Gardena, CA).
- the topical formulations of the present invention contain at least one neutralizing agent, the total amount of neutralizing agent present is from about 0.1 wt to about 10 wt %, preferably 0.1 wt % to about 5.0 wt%, and more preferably about 1.0 wt %.
- the neutralizing agent is generally added in whatever amount is required to bring the formulation to the desired pH.
- the pH is about 6.0 to about 8.0.
- the pH is about 3.0 to about 4.0.
- the topical pharmaceutical compositions may also comprise suitable thickening or viscosity increasing agents.
- These components are diffusible compounds capable of increasing the viscosity of a polymer-containing solution through the interaction of the agent with the polymer.
- CARBOPOL ULTREZ 10 polymethyl methacrylate (PMMA), and fumed silica may be used as a viscosity-increasing agent.
- PMMA polymethyl methacrylate
- fumed silica may be used as a viscosity-increasing agent.
- thickeners include monoglycerides and fatty alcohols, fatty acid esters of alcohols having from about 3 to about 16 carbon atoms. Examples of suitable monoglycerides are glyceryl monostearate and glyceryl monopalmitate.
- fatty alcohols are cetyl alcohol and stearyl alcohol.
- suitable esters are myristyl stearate and cetyl stearate.
- the monoglyceride also functions as an auxilliary emulsifier.
- Other emollients or oleaginous material which may be employed include petrolatum, glyceryl monooleate, myristyl alcohol, and isopropyl palmitate.
- the thickener is used in combination with an emulsifying agent.
- the total amount of viscosity increasing agent present is from about 0.25% to about 5.0% by weight, preferably from about 0.25% to about 1.0 wt%, and more preferably from about 0.4% to about 0.6% by weight.
- the topical pharmaceutical compositions may also comprise a disintegrating agent including starch, e.g., a natural starch such as corn starch or potato starch, a pregelatinized starch such as National 1551 or Amijele.RTM., or sodium starch glycolate such as Promogel.RTM. or Explotab.RTM.; a cellulose such as a wood product, microcrystalline cellulose, e.g., Avicel.RTM., Avicel.RTM. PHlOl, Avicel.RTM. PH102, Avicel.RTM. PH105, Elcema.RTM.
- a disintegrating agent including starch, e.g., a natural starch such as corn starch or potato starch, a pregelatinized starch such as National 1551 or Amijele.RTM., or sodium starch glycolate such as Promogel.RTM. or Explotab.RTM.; a cellulose such as a wood product, microcrystalline cellulose, e.g., Avicel
- the topical pharmaceutical compositions may also comprise suitable nail penetration enhancers.
- nail penetration enhancers include mercaptan compounds, sulfites and bisulfites, keratolytic agents and surfactants. Nail penetration enhancers suitable for use in the invention are described in greater detail in Malhotra et al., J. Pharm. Sci., 91:2, 312-323 (2002), which is incorporated herein by reference in its entirety.
- the topical pharmaceutical compositions may also comprise an anti- foaming anti-whitening agent that increases the elegancy of the cream or lotion and inhibits the formation of a white soapy look upon rubbing the cream or lotion on the skin.
- an anti- foaming anti-whitening agent that increases the elegancy of the cream or lotion and inhibits the formation of a white soapy look upon rubbing the cream or lotion on the skin.
- An example of such material includes silicone fluid.
- Other anti-foaming agents include simethicone, polyglycol, and sorbitan sesquioleate.
- the topical pharmaceutical compositions may also comprise a post- foaming agent.
- Post-foaming refers to a gel that remains a gel as it is expelled from a container but foams up after it is spread over the skin.
- Post-foaming agents include saturated aliphatic hydrocarbons having from 4-6 carbon atoms, such as butane, pentane and hexane (in particular is opentane and isobutene).
- Other suitable post- foaming agents include partially, or wholly halogenated hydrocarbons, such as trichlorofluroethane.
- mixtures of aliphatic and halogenated hydrocarbon propellants, or post-foaming agents can be used.
- suitable post- foaming agents are those substances that have a low solubility in water, for example less than about 20 cc of gas in 100 grams of water at one atmosphere and 20. degree. C.
- the topical pharmaceutical compositions may also comprise one or more suitable solvents.
- suitable solvents The ability of any solid substance (solute) to dissolve in any liquid substance (solvent) is dependent upon the physical properties of the solute and the solvent. When solutes and solvents have similar physical properties the solubility of the solute in the solvent will be the greatest. This gives rise to the traditional understanding that "like dissolves like.”
- Solvents can be characterized in one extreme as non-polar, lipophilic oils, while in the other extreme as polar hydrophilic solvents. Oily solvents dissolve other non-polar substances by Van der WaIs interactions while water and other hydrophilic solvents dissolve polar substances by ionic, dipole, or hydrogen bonding interactions.
- solvents can be listed along a continuum from the least polar, i.e. hydrocarbons such as decane, to the most polar solvent being water.
- a solute will have its greatest solubility in solvents having equivalent polarity.
- less polar solvents will provide improved solubility with the solvent having polarity nearly equivalent to the solute providing maximum solubility.
- Most drugs have intermediate polarity, and thus experience maximum solubility in solvents such as propylene glycol or ethanol, which are significantly less polar than water.
- the concentration of active ingredient in the formulation may be limited by the solubility of the active ingredient in the chosen solvent and/or carrier.
- Non-lipophilic drugs typically display very low solubility in pharmaceutically acceptable solvents and/or carriers.
- the solubility of some compounds in the invention in water is less than 0.00025% wt/wt.
- the solubility of the same compounds in the invention can be less than about 2% wt/wt in either propylene glycol or isopropyl myristate.
- solubilizing excipients include polyethoxylated fatty acids, PEG-fatty acid diesters, PEG-fatty acid mono-ester and di-ester mixtures, polyethylene glycol glycerol fatty acid esters, alcohol-oil transesterification products, polyglycerized fatty acids, propylene glycol fatty acid esters, mixtures of propylene glycol esters-glycerol esters, mono- and diglycerides, sterol and sterol derivatives, polyethylene glycol sorbitan fatty acid esters, polyethylene glycol alkyl ethers, sugar esters, polyethylene glycol alkyl phenols, polyoxyethylene-polyoxypropylene block copolymers, sorbitan fatty acid esters, lower alcohol fatty acid esters, ionic surfactants, tocopherol esters, and sterol esters.
- ethylhexyl hydroxystearate is the solvent used to dissolve the compounds described herein.
- diethylene glycol monoethyl ether DGME
- DGME diethylene glycol monoethyl ether
- the compounds in the invention useful in the present formulation are believed to have a solubility of from about 10% wt/wt to about 25% wt/wt in DGME.
- a DGME water cosolvent system is used to dissolve the compounds described herein.
- a DGME water cosolvent system is used to dissolve a compound of the invention.
- the solvent capacity of DGME drops when water is added; however, the DGME/water cosolvent system can be designed to maintain the desired concentration of from about 0.1 % to about 5% wt/wt active ingredient.
- the active ingredient is present from about 0.5 % to about 3% wt/wt, and more preferably at about 1% wt/wt, in the as-applied topical formulations. Because DGME is less volatile than water, as the topical formulation evaporates upon application, the active agent becomes more soluble in the cream formulation.
- the vehicle is lipophilic.
- Lipophilic materials include oleaginous material such as petrolatum, mineral oil thickened or gelled with polyethylene, high molecular weight paraffin waxes, mono and diglycerides of fatty acids gelled with high molecular weight fatty acids or polyamide complex of hydroxystearate, propylene glycol isostearate or isostearyl alcohol gelled with high molecular weight fatty acids, and mixtures thereof.
- Liquid forms such as lotions suitable for topical administration or suitable for cosmetic application, may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, thickeners, penetration enhancers, and the like.
- Solid forms such as creams or pastes or the like may include, for example, any of the following ingredients, water, oil, alcohol or grease as a substrate with surfactant, polymers such as polyethylene glycol, thickeners, solids and the like.
- Liquid or solid formulations may include enhanced delivery technologies such as liposomes, microsomes, microsponges and the like.
- the compounds can be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
- sustained-release materials have been established and are well known by those skilled in the art.
- at least two different dosage forms, each of which contains a compound of the inventon may be formulated for topical administration by including such dosage forms in an oil-in- water emulsion, or a water-in-oil emulsion.
- the delayed release dosage forms are in the continuous phase
- the delayed sustained release dosage form is in a discontinuous phase.
- the formulation may also be produced in a manner for delivery of three dosage forms as hereinabove described.
- an oil-in-water-in-oil emulsion with oil being a continuous phase that contains the third delayed sustained release component, water dispersed in the oil containing a first delayed release dosage form, and oil dispersed in the water containing a second delayed release dosage form.
- Topical treatment regimens according to the practice of this invention comprise applying the composition directly to the skin, nail, hair, claw or hoof at the application site, from one to several times daily.
- the pharmaceutical formulation includes a simple solution.
- the simple solution includes a polyether.
- the polyether is polyethylene glycol or polypropylene glycol.
- the simple solution includes an alcohol.
- the alcohol is methanol, ethanol, propanol, isopropanol or butanol.
- the simple solution includes a polyether and an alcohol.
- the simple solution includes a polypropylene glycol and ethanol.
- the simple solution is a member selected from about 10% polypropylene glycol and about 90% ethanol; about 20% polypropylene glycol and about 80% ethanol; about 30% polypropylene glycol and about 70% ethanol; about 40% polypropylene glycol and about 60% ethanol; about 50% polypropylene glycol and about 50% ethanol; about 60% polypropylene glycol and about 40% ethanol; about 70% polypropylene glycol and about 30% ethanol; about 80% polypropylene glycol and about 20% ethanol; about 90% polypropylene glycol and about 10% ethanol.
- the simple solution includes acetone.
- the simple solution includes acetone and an alcohol.
- the simple solution includes acetone and a member selected from methanol, ethanol, propanol, isopropanol or butanol.
- the simple solution includes acetone, an alcohol and a polyether.
- the simple solution includes acetone, an alcohol and a member selected from polyethylene glycol and polypropylene glycol.
- the simple solution includes acetone and ethanol.
- the simple solution is a member selected from about 10% acetone and about 90% ethanol; about 20% acetone and about 80% ethanol; about 30% acetone and about 70% ethanol; about 40% acetone and about 60% ethanol; about 50% acetone and about 50% ethanol; about 60% acetone and about 40% ethanol; about 70% acetone and about 30% ethanol; about 80% acetone and about 20% ethanol; about 90% acetone and about 10% ethanol.
- the pharmaceutical formulation is a lacquer.
- Anti-inflammatory agents include, but are not limited to, bisabolol, mentholatum, dapsone, aloe, hydrocortisone, and the like.
- Vitamins include, but are not limited to, Vitamin B, Vitamin E, Vitamin A, Vitamin D, and the like and vitamin derivatives such as tazarotene, calcipotriene, tretinoin, adapalene and the like.
- Anti-aging agents include, but are not limited to, niacinamide, retinol and retinoid derivatives, AHA, Ascorbic acid, lipoic acid, coenzyme Q lO, beta hydroxy acids, salicylic acid, copper binding peptides, dimethylaminoethyl (DAEA), and the like.
- Sunscreens and or sunburn relief agents include, but are not limited to, PABA, jojoba, aloe, padimate-O, methoxycinnamates, proxamine HCl, lidocaine and the like.
- Sunless tanning agents include, but are not limited to, dihydroxyacetone (DHA).
- Ultraviolet (UV) light blockers include, for example, amino benzoic acids, benzophenones, camphors, cinnamates, dibenzoyl methanes, salicylates, metal oxides, and mixtures thereof.
- Psoriasis-treating agents and/or acne-treating agents include, but are not limited to, salicylic acid, benzoyl peroxide, coal tar, selenium sulfide, zinc oxide, pyrithione (zinc and/or sodium), tazarotene, calcipotriene, tretinoin, adapalene and the like.
- Agents that are effective to control or modify keratinization including without limitation: tretinoin, tazarotene, and adapalene.
- compositions comprising an compound/active agent described herein, and optionally at least one of these additional agents, are to be administered topically.
- any one of the topically applied active agents may also be delivered systemically by transdermal routes.
- an additional cosmetically or pharmaceutically effective agent such as an anti-inflammatory agent, vitamin, anti-aging agent, sunscreen, and/or acne-treating agent, for example, is usually a minor component (from about 0.001 % to about 20% by weight or preferably from about 0.01 % to about 10% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
- Testins Preferred compounds for use in the present topical formulations will have certain pharmacological properties. Such properties include, but are not limited to, low toxicity, low serum protein binding and desirable in vitro and in vivo half-lives. Assays may be used to predict these desirable pharmacological properties. Assays used to predict bioavailability include transport across human intestinal cell monolayers, including Caco-2 cell monolayers. Serum protein binding may be predicted from albumin binding assays. Such assays are described in a review by Oravcova et al. (1996, J. Chromat. B677: 1-27). Compound half-life is inversely proportional to the frequency of dosage of a compound.
- Toxicity and therapeutic efficacy of such compounds can be determined by Standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD50 and ED50.
- Compounds that exhibit high therapeutic indices are preferred.
- the data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
- the dosage can vary within this range depending upon the dosage form employed and the route of administration utilized.
- the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See, e.g. Fingl et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1, p. 1). V. d) Administration
- the therapeutically effective dose can be estimated initially from cell culture assays, as disclosed herein.
- a dose can be formulated in animal models to achieve a circulating concentration range that includes the EC 50 (effective dose for 50% increase) as determined in cell culture, i.e., the concentration of the test compound which achieves a half-maximal inhibition of bacterial cell growth.
- EC 50 effective dose for 50% increase
- concentration of the test compound which achieves a half-maximal inhibition of bacterial cell growth i.e., the concentration of the test compound which achieves a half-maximal inhibition of bacterial cell growth.
- the compounds prepared by the methods, and from the intermediates, described herein will be administered in a therapeutically or cosmetically effective amount by any of the accepted modes of administration for agents that serve similar utilities. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination, the severity of the particular disease undergoing therapy and the judgment of the prescribing physician.
- the drug can be administered from once or twice a day, or up to 3 or 4 times a day.
- Dosage amount and interval can be adjusted individually to provide plasma levels of the active moiety that are sufficient to maintain bacterial cell growth inhibitory effects.
- Usual patient dosages for systemic administration range from 0.1 to 1000 mg/day, preferably, 1-500 mg/day, more preferably 10 - 200 mg/day, even more preferably 100 - 200 mg/day. Stated in terms of patient body surface areas, usual dosages range from 50-91 mg/m 2 /day.
- the amount of the compound in a formulation can vary within the full range employed by those skilled in the art.
- the formulation will contain, on a weight percent (wt%) basis, from about 0.01-10 wt% of the drug based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.
- the compound is present at a level of about 0.1-3.0 wt%, more preferably, about 1.0 wt%.
- the pharmaceutical formulation is an ointment, and comprises a compound of the invention.
- the pharmaceutical formulation is an ointment which includes C17.
- the pharmaceutical formulation is an ointment which includes C27.
- the pharmaceutical formulation includes C 17 and at least one surfactant described herein. In another exemplary embodiment, the pharmaceutical formulation includes C27 and at least one surfactant described herein. In another exemplary embodiment, the formulation comprises a hydroxystearate. In another exemplary embodiment, the hydroxystearate is a member selected from glyceryl monostearate, ethylhexyl hydroxystearate and octyl hydroxystearate .
- the pharmaceutical formulation includes C17 and an alcohol. In another exemplary embodiment, the pharmaceutical formulation includes C27 and an alcohol. In another exemplary embodiment, the alcohol is a long chain alcohol or a fatty alcohol. In another exemplary embodiment, the alcohol is a member selected from benzyl alcohol, octyldodecanol, stearyl alcohol, cetyl alcohol, oleyl alcohol.
- the formulation comprises a member selected from benzyl alcohol
- octyl comprises at least one compound which is a member selected from hydrocarbon oils, waxes, silicone, cetyl alcohol, isopropyl myristate, stearyl alcohol, oleyl alcohol, ethylhexyl hydroxystearate, octyl hydroxystearate, glycerin, other fatty alcohols hydroxystearate.
- the pharmaceutical formulation comprises a compound of the invention and at least one emollient described herein.
- the pharmaceutical formulation includes a compound of the invention, and petrolatum.
- the pharmaceutical formulation comprises C 17 and petrolatum. In an exemplary embodiment, the pharmaceutical formulation comprises C27 and petrolatum. In an exemplary embodiment, the pharmaceutical formulation comprises C17 and a member selected from hydrocarbon oils, waxes, silicone, cetyl alcohol, isopropyl myristate, stearyl alcohol, oleyl alcohol, ethylhexyl hydroxystearate, octyl hydroxystearate, glycerin, other fatty alcohols hydroxystearate.
- the pharmaceutical formulation comprises C27 and a member selected from hydrocarbon oils, waxes, silicone, cetyl alcohol, isopropyl myristate, stearyl alcohol, oleyl alcohol, ethylhexyl hydroxystearate, octyl hydroxystearate, glycerin, other fatty alcohols hydroxystearate.
- the pharmaceutical formulation comprises C 17 and ethylhexyl hydroxystearate and/or octyl hydroxystearate.
- the pharmaceutical formulation comprises C27 and ethylhexyl hydroxystearate and/or octyl hydroxystearate.
- the pharmaceutical formulation comprises C17, petrolatum and a member selected from hydrocarbon oils, waxes, silicone, cetyl alcohol, isopropyl myristate, stearyl alcohol, oleyl alcohol, ethylhexyl hydroxystearate, octyl hydroxystearate, glycerin, other fatty alcohols hydroxystearate. .
- the pharmaceutical formulation comprises C27, petrolatum and a member selected from hydrocarbon oils, waxes, silicone, cetyl alcohol, isopropyl myristate, stearyl alcohol, oleyl alcohol, ethylhexyl hydroxystearate, octyl hydroxystearate, glycerin, other fatty alcohols hydroxystearate.
- the pharmaceutical formulation comprises C 17, petrolatum, oleyl alcohol and ethylhexyl hydroxystearate.
- the pharmaceutical formulation comprises C27, petrolatum, oleyl alcohol and ethylhexyl hydroxystearate.
- the pharmaceutical formulation is a cream, and comprises a compound of the invention.
- the compound is C17.
- the compound is C27.
- the pharmaceutical formulation comprises a compound of the invention and a preservative.
- the preservative is a member selected from benzalkonium chloride, benzethonium, chlorohexidine, phenol, m-cresol, benzyl alcohol, methylparaben, propylparaben and other parabens, chlorobutanol, o-cresol, p-cresol, chlorocresol, phenylmercuric nitrate, thimerosal, benzoic acid, and various mixtures thereof.
- the compound is C17.
- the compound is C27.
- the perservative is a paraben.
- the perservative is a member selected from methyl paraben and propyl paraben.
- the pharmaceutical formulation comprises a compound of the invention and a chelating agent.
- the pharmaceutical formulation comprises C 17 and a chelating agent.
- the pharmaceutical formulation comprises C27 and a chelating agent.
- the chelating agent is edetate sodium.
- the invention provides a compound having a structure according to the formula:
- R a is a member selected from CN, C(O)NR 1 R 2 , C(O)OR 3 ; wherein R 3 is a member selected from H and substituted or unsubstituted alkyl, X is a member selected from N, CH and CR b , R b is a member selected from halogen and substituted or unsubstituted alkyl, C(O)R 4 , C(O)OR 4 , OR 4 , NR 4 R 5 , wherein R 1 , R 2 , R 4 and R 5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, with the proviso that R 1 and R 2 , together with the atoms
- R 3 is a member selected from H and unsubstituted alkyl.
- the compound has a structure according to the formula:
- the compound has a formula which is a member selected from:
- the compound has a formula which is a member selected from:
- the compound has a formula which is a member selected from:
- the compound has a formula which is a member selected from:
- the compound has a structure according to the formula:
- the compound has a formula which is a member selected from:
- the compound has a formula which is a member selected from:
- the compound has a formula which is a member selected from:
- the compound has a formula which is a member selected from:
- the compound has a structure according to the formula:
- the compound has a formula which is a member selected from:
- the compound has a formula which is a member selected from:
- the compound has a formula which is a member selected from:
- the compound has a formula which is a member selected from:
- R b is a member selected from fluorine and chlorine.
- R b is a member selected from OR 4 and NR 4 R 5 .
- R b is OR 4
- R 4 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- R b is OR 4 , and R 4 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted cycloalkyl.
- R b is OR 4 , and R 4 is unsubstituted Ci-C 6 alkyl.
- R b is OR 4
- R 4 is unsubstituted cycloalkyl.
- R b is OR 4
- R 4 is alkyl, substituted with a member selected from substituted or unsubstituted Ci-C 6 alkoxy.
- R b is OR 4
- R 4 is alkyl, substituted with at least one halogen.
- R b is OR 4 , and R 4 is alkyl, substituted with at least one oxo moiety.
- R b is OR 4 , and R 4 is a member selected from -CH 3 , -CH 2 CH 3 , -(CH 2 ) 2 CH 3 , - CH(CH 3 ) 2 , -CH 2 CF 3 , -CH 2 CHF 2 , -CH 2 CH 2 (OH), -CH 2 CH 2 (OCH 3 ), - CH 2 CH 2 (OC(CH 3 ) 2 ), -C(O)CH 3 , -CH 2 CH 2 OC(O)CH 3 , -CH 2 C(O)OCH 2 CH 3 , - CH 2 C(O)OC(CH 3 ) 3 , -(CH 2 ) 3 C(O)CH 3 , -CH 2 C(CH 2 ) 3 C(O)CH 3 , -CH 2 C(CH 2 ) 3 C(O)CH 3 , -CH
- R b is OR 4 , wherein R 4 is alkyl is optionally substituted with at least one halogen, hydroxyl, ether, carboxy or ester moiety.
- R b is OR 4 , wherein R 4 is unsubstituted alkyl.
- R b is OR 4 , wherein R 4 is unsubstituted Ci or C 2 or C 3 alkyl.
- R b is OR 4 , wherein R 4 is unsubstituted C 4 or Cs or C 6 alkyl.
- R b is OR 4 , wherein R 4 is methyl or ethyl or propyl or isopropyl or isobutyl.
- R b is -O(CH 2 ) m iOC(O)R 4d , wherein ml is a number selected from 1 or 2 or 3 or 4 or 5 or 6 and R 4d is unsubstituted alkyl.
- ml is 1 or 2 or 3.
- ml is 2.
- R 4d is unsubstituted Ci or C 2 or C 3 alkyl.
- R 4d is unsubstituted C 4 or Cs or Ce alkyl.
- R 4d is methyl.
- R b is -O(CH 2 ) 2 OC(O)CH 3 .
- R b is -O(CH 2 ) m iC(O)R 4d , wherein ml is a number selected from 1 or 2 or 3 or 4 or 5 or 6 and R 4d is unsubstituted alkyl.
- ml is 2 or 3 or 4.
- ml is 3.
- R 4d is unsubstituted Ci or C 2 or C 3 alkyl.
- R 4d is unsubstituted C 4 or C 5 or Ce alkyl.
- R 4d is methyl.
- R b is -O(CH 2 ) 3 C(O)CH 3 .
- R b is -O(CH 2 )miC(O)OR 4d , wherein ml is a number selected from 1 or 2 or 3 or 4 or 5 or 6 and R 4d is H or unsubstituted alkyl.
- R b is -OCH 2 C(O)OR 4d , wherein R 4d is as described herein.
- R 4d is H or methyl or ethyl or t-butyl.
- R b is -0(CH 2 )C(O)OCH 2 CH 3 or -0(CH 2 )C(O)OH or -O(CH 2 )C(O)OC(CH 3 ) 3 .
- R b is OR 4 , wherein R 4 is alkyl substituted with a substituted or unsubstituted amino.
- R b is wherein m2 is a number selected from 1 or 2 or 3 or 4 or 5 or 6, and R 4e and R 4f are independently selected from H or unsubstituted alkyl, or R 4e and R 4f , together with the nitrogen to which they are attached, are optionally joined to form a substituted or unsubstituted 4 to 8 membered ring.
- R b is OR 4 , wherein R 4 is substituted or unsubstituted cycloalkyl.
- R b is OR 4 , wherein R 4 is unsubstituted cycloalkyl.
- R b is -O(CH 2 ) m 5 ⁇ R 30 , wherein m5 is 1 or 2 or 3 or 4 or 5 or 6 and R 30 is H or unsubstituted alkyl or unsubstituted tetrahydropyran.
- X is N.
- X is CH.
- X is CR b .
- R b is NR 4 R 5 , wherein R 4 and R 5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- R b is NR 4 R 5 , wherein R 4 is H or unsubstituted alkyl; and R 5 is unsubstituted alkyl or alkyl substituted with a member selected from hydroxyl, phenyl, unsubstituted alkoxy and alkoxy substituted with a phenyl.
- R b is NR 4 R 5 .
- R 4 is a member selected from H or CH 3 .
- R b is NR 4 R 5 wherein R 4 and R 5 are each members independently selected from substituted or unsubstituted alkyl.
- R b is NR 4 R 5 , wherein R 5 is alkyl, substituted with a member selected from OH, unsubstituted arylalkoxy, unsubstituted alkoxy, and unsubstituted aryl.
- R b is NR 4 R 5 , wherein R 5 is -(CH 2 )msPh.
- R b is NR 4 R 5 , wherein R 5 is -(CH 2 ) m 8 ⁇ R 26 , wherein m8 is a number selected from 1 or 2 or 3 or 4 or 5 or 6 and R 26 is a member selected from H, unsubstituted or arylsubstituted Ci or C 2 or C 3 or C 4 or C 5 or C 6 alkyl.
- RR bb iiss NNRR 44 RR 55 ,, wwhheerreeiinn RR 55 iiss --((CCHH 22 )) mm88 OO((CCH 2 ) m9 Ph, wherein m8 and m9 are each independently selected from 1 or 2 or 3.
- R b is NR 4 R 5 , wherein R 4 is unsubstituted alkyl; and R 5 is substituted or unsubstituted alkyl.
- R b is NR 4 R 5 , wherein R 4 is unsubstituted alkyl; and R 5 is alkyl, substituted with a member selected from substituted or unsubstituted alkoxy and hydroxyl.
- R b is NR 4 R 5 , wherein R 4 is unsubstituted alkyl; and R 5 is alkyl, substituted with unsubstituted alkoxy.
- R b is a member selected fromN(CH 3 ) 2 , N(CH 3 )(CH 2 CH 2 (OCH 3 )), N(CH 3 )(CH 2 CH 2 OH), NH 2 , NHCH 3 , NH(CH 2 CH 2 (OCH 3 )), NH(CH 2 CH 2 (OCH 2 Ph), NH(CH 2 Ph), NH(C(CH 3 ) 3 ) and NH(CH 2 CH 2 OH).
- R b is NR 4 R 5 , wherein R 4 and R 5 , together with the nitrogen to which they are attached, are combined to form a 4- to 8-membered substituted or unsubstituted heterocycloalkyl ring.
- R b is NR 4 R 5 , wherein R 4 and R 5 , together with the nitrogen to which they are attached, are combined to form a 5- or 6-membered substituted or unsubstituted heterocycloalkyl ring.
- R b is a member selected from:
- the invention provides a pharmaceutical formulation comprising: (a) a compound according to any of the above paragraphs; and (b) a pharmaceutically acceptable excipient.
- the formulation is in a unit dosage form.
- the formulation is for oral or topical use.
- the invention provides a method of decreasing the release of a cytokine or a chemokine, the method comprising: contacting a cell with a compound according to any of the above paragraphs or a pharmaceutically acceptable salt thereof, wherein the release of the cytokine or chemokine by the cell is decreased.
- the cytokine is a member selected from IL- l ⁇ , IL-I ⁇ , IL-2, IL-3, IL-6, IL-7, IL-9, IL- 12, IL-17, IL-18, IL-23, TNF- ⁇ , LT, LIF, Oncostatin, IFN ⁇ , IFN ⁇ and IFN- ⁇ .
- the cytokine is a member selected from IL-l ⁇ , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL- 12, IL-23, TNF- ⁇ and IFN- ⁇ .
- the cytokine is a member selected from IL-2, IL-5, IL-10, IL- 12, IL-23, TNF- ⁇ and
- the chemokine is a member selected from IL-8, Gro- ⁇ , MIP-I, MCP-I, PGE2, ENA- 78, and RANTES.
- the invention provides a method of treating a condition, in an animal, the method comprising administering to the animal a therapeutically effective amount of a compound according to any of the above paragraphs, or a pharmaceutically acceptable salt thereof, thereby treating the condition.
- the condition is a member selected from arthritis, rheumatoid arthritis, an inflammatory bowel disease, psoriasis, a pulmonary disease, multiple sclerosis, a neurodegenerative disorder, congestive heart failure, stroke, aortic valve stenosis, kidney failure, lupus, pancreatitis, allergy, fibrosis, anemia, atherosclerosis, a metabolic disease, a bone disease, a cardiovascular disease, a chemotherapy/radiation related complication, diabetes type I, diabetes type II, a liver disease, a gastrointestinal disorder, an ophthamological disease, allergic conjunctivitis, diabetic retinopathy, Sjogren's syndrome, uvetitis, a pulmonary disorder, a renal disease, dermatitis, HIV-related cachexia, cerebral malaria, ankylosing spondolytis, leprosy, anemia and fibromyalgia.
- the condition is a member selected from psoriasis, atopic dermatitis, rheumatoid arthritis, an inflammatory bowel disease, asthma and chronic obstructive pulmonary disease.
- the condition is psoriasis
- said psoriasis is a member selected from plaque psoriasis, flexural psoriasis, Guttate psoriasis, pustular psoriasis, nail psoriasis and erythrodermic psoriasis .
- the psoriasis is a member selected from plaque psoriasis and nail psoriasis.
- the animal is a human.
- the animal is in need of treatment.
- the animal is a human.
- the animal is not already in need of treatment by the compound.
- the invention provides a method of inhibiting a phosphodiesterase (PDE), the method comprising: contacting the phosphodiesterase with a compound according to any of the above paragraphs, or a pharmaceutically acceptable salt thereof, thereby inhibiting the phosphodiesterase.
- PDE phosphodiesterase
- the phosphodiesterase is a member selected from phosphodiesterase4 (PD E4) and phosphodiesterase? (PDE7).
- Proton NMR are recorded on Varian AS 300 (300 MHz) or AS400 (400 MHz) spectrometer and chemical shifts are reported as ⁇ (ppm) down field from tetramethylsilane.
- Mass spectra are determined on Agilent 1200 series plus 6120 Quadrupole LC/MS, Micromass Quattro II or Waters MS consisting of an Alliance 2795 (LC) and Waters Micromass ZQ detector.
- the mass spectrometer was equipped with an electrospray ion source (ES) operated in a positive or negative mode.
- ES electrospray ion source
- aqueous is aq.
- O-(7- azabenzotriazol-l-yl)- ⁇ /, ⁇ /,N',N'-tetramethyluronium hexafluorophosphate is HATU
- m-CPBA 3- chloroperoxybenzoic acid is EDCI; equivalent is eq.
- diisopropyl azodicarboxylate is DIAD
- ⁇ /, ⁇ /-dimethylformamide is DMF
- dimethylsulfoxide is DMSO
- acetic acid is HOAc
- sodium cyanoborohydride is NaCNBH 3
- room temperature is r.t.
- overnight O/N
- tetrahydrofuran is THF
- Di-tert-buty ⁇ dicarbonate is BoC 2 O
- methanol is MeOH
- HPLC analyses were performed on a Water 600 Controller system with a Waters 717 Plus Autosampler and a Waters 2996 Photodiode Array Detector.
- the column used was an ACE C 18 , 5 ⁇ m, 4.6X150 mm.
- a linear gradient was applied, starting at 95 % A (A: 0.1% H 3 PO 4 in water) and ending at 90% B (B: MeCN) over 6 min and then maintained at 90% B until the 10 min mark.
- the column is then re- equilibrated over 3 min to 95:5 with a total run time of 20 min.
- the column temperature was at ambient temperature with the flow rate of 1.0 mL/min.
- the Diode Array Detector was scanned from 200-400 nm.
- TLC Thin layer chromatography
- Alugram ® Silica gel 60 F254 from Mancherey-Nagel and UV was typically used to visualize the spots. Additional visualization methods were also employed in some cases.
- the TLC plate was developed with iodine (generated by adding approximately 1 g of I 2 to 1O g silica gel and thoroughly mixing), vanillin (generated by dissolving about 1 g vanillin in 100 mL 10% H 2 SO 4 ), ninhydrin (available commercially from Aldrich), or Magic Stain (generated by thoroughly mixing 25 g (NH 4 ) 6 M ⁇ 7 ⁇ 24 4H 2 O, 5 g (NH 4 ) 2 Ce(IV)(N ⁇ 3) 6 in 450 mL water and 50 mL concentrated H 2 SO 4 ) to visualize the compound.
- iodine generated by adding approximately 1 g of I 2 to 1O g silica gel and thoroughly mixing
- vanillin generated by dissolving about 1 g vanillin in 100 mL
- Flash chromatography was preformed using typically 40 - 63 ⁇ m (230 - 400 mesh) silica gel from Silicycle following analogous techniques to those disclosed in Still, W.C.; Kahn, M.; and Mitra, M. Journal of Organic Chemistry, 1978, 43, 2923 - 2925.
- Typical solvents used for flash chromatography or thin layer chromatography were mixtures of chloroform/methanol, dichloromethane/methanol, ethyl acetate/methanol and hexanes/ethyl acetate.
- Reverse phase column chromatography were performed on a Biotage ® using a Biotage C 18 cartridges and a water/methanol gradient (typically eluting from 5% MeOH/H 2 O to 90% MeOH/H 2 O).
- Preparative chromatography was performed on either a Waters Prep LC 4000 System using a Waters 2487 Diode Array or on a Waters LC Module 1 plus.
- the column used was a Waters XTerra Prep C 18 , 5 ⁇ m, 30 X 100 mm or Phenomenex Luna C 18 , 5 ⁇ m, 21.6 X 250 mm or Phenomenex Gemini C 18 , 5 ⁇ m, 100 X 30 mm.
- Exemplary compounds of structure 3 prepared by the method above include: 1.2.a 2-Bromo-5-chlorobenzyl Alcohol; 1.2.b 2-Bromo-5-methoxybenzyl Alcohol.
- Additional examples of compounds which can be produced by this method include 2-bromo-4-(3-cyanophenoxy)benzyl alcohol; 2-bromo-4-(4- chlorophenoxy)benzyl alcohol; 2-bromo-4-phenoxybenzyl alcohol; 2-bromo-5-(3,4- dicyanophenoxy)benzyl alcohol; 2-(2-bromo-5-fluorophenyl)ethyl alcohol; 2-bromo- 5-fluorobenzyl alcohol; and l-bromo-2-naphthalenemethanol.
- Exemplary compounds of structure 4 prepared by the method above include: 3.2. a 2-Bromo-5-chloro-l-(methoxymethoxymethyl) benzene; 3.2.b 2-Bromo- 5-fluoro-l-[l-(methoxym,ethoxy)ethyll benzene; 3.2.c 2-Bromo-5-fluoro-l- [2 -(methoxymethoxy) ethyl] benzene; 3.2.
- Analytical data for exemplary compounds of structure I prepared by the method above include: 4.2. a 5-Chloro- 1 ,3-dihvdro-l -hvdroxy-2, 1-benzoxaborole (Cl); 4.2.b 1 ,3-Dihvdr o-l -hvdroxy-2, 1-benzoxaborole (C2); 4.2.c 5-Fluoro-l,3- dihvdro-l-hvdroxy-3-methyl-2, 1-benzoxaborole (C3); 4.2.d 6-Fluoro-l-hvdroxy- 1,2,3, 4-tetrahvdro-2 , 1-benzoxaborine (C4); 4.2.e 5, 6-Difluoro- 1 , 3-dihvdro- 1 - hvdroxy-2, 1-benzoxaborole (C5); 4.2.
- Exemplary compounds of structure 3 prepared by the method above include: 9.2. a 2-Bromo-5-cvanobenzyl Alcohol.
- Additional compounds can be produced by the methods described herein. By choosing the appropriate starting material such as 1 or 3, the methods described herein can be used to formulate the following compounds.
- Exemplary compounds of structure I are provided: 18a Ethyl 2-(l- hvdroxy- 1 ,3-dihvdrobenzo [c] [ 1 ,2] oxaborol-5-yloxy)acetate (C41); 18b 2-fl-hvdroxy- 1 ,3-dihvdrobenzo [cl 11 ,2) l oxaborol- 5 -yloxy) acetic acid (C42); 18c 6-(thiophen-2- ylthio)benzofc]fl.2]oxaborol-l ⁇ H)-ol (C43); 18d 6-(4-fluorovhenylthio) benzofc] [1 ,2] oxaborol-1 (3H)-ol (C44); 18e l-(3- ((
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17158536.7A EP3246034A1 (en) | 2008-03-06 | 2009-03-05 | Boron-containing small molecules as anti-inflammatory agents |
EP12178640.4A EP2564857B1 (en) | 2008-03-06 | 2009-03-05 | Boron-containing small molecules as anti-inflammatory agents |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3437108P | 2008-03-06 | 2008-03-06 | |
US5263708P | 2008-05-12 | 2008-05-12 | |
US9440608P | 2008-09-04 | 2008-09-04 | |
US10599008P | 2008-10-16 | 2008-10-16 | |
US11090308P | 2008-11-03 | 2008-11-03 | |
US14370009P | 2009-01-09 | 2009-01-09 | |
US14873109P | 2009-01-30 | 2009-01-30 | |
PCT/US2009/036250 WO2009111676A2 (en) | 2008-03-06 | 2009-03-05 | Boron-containing small molecules as anti-inflammatory agents |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17158536.7A Division EP3246034A1 (en) | 2008-03-06 | 2009-03-05 | Boron-containing small molecules as anti-inflammatory agents |
EP12178640.4A Division EP2564857B1 (en) | 2008-03-06 | 2009-03-05 | Boron-containing small molecules as anti-inflammatory agents |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2187893A2 true EP2187893A2 (en) | 2010-05-26 |
EP2187893A4 EP2187893A4 (en) | 2012-02-22 |
Family
ID=41056660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09700012A Withdrawn EP2187893A4 (en) | 2008-03-06 | 2009-03-05 | Boron-containing small molecules as anti-inflammatory agents |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2187893A4 (en) |
WO (1) | WO2009111676A2 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2343304T3 (en) | 2005-02-16 | 2015-06-29 | Anacor Pharmaceuticals Inc | BIOCIDE BORONOPHTHALIDE COMPOUNDS |
RU2008131324A (en) | 2005-12-30 | 2010-02-10 | Анакор Фармасьютикалз, Инк. (Us) | WOODEN SMALL MOLECULES |
CA2933994A1 (en) | 2006-02-16 | 2007-08-23 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-inflammatory agents |
RU2547441C2 (en) | 2008-03-06 | 2015-04-10 | Анакор Фармасьютикалз, Инк. | Boron-containing small molecules as anti-inflammatory agents |
WO2010028005A1 (en) | 2008-09-04 | 2010-03-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
EP2348863A4 (en) | 2008-09-04 | 2012-03-07 | Anacor Pharmaceuticals Inc | Boron-containing small molecules |
US9493489B2 (en) | 2008-10-15 | 2016-11-15 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agents |
BRPI0922566A2 (en) | 2008-12-17 | 2017-03-28 | Anacor Pharmaceuticals Inc | crystalline polymorph, pharmaceutical composition, compound, and methods for preparing a compound, and for treating a disease. |
WO2011017125A1 (en) | 2009-07-28 | 2011-02-10 | Anacor Pharmaceuticals, Inc. | Trisubstituted boron-containing molecules |
US9440994B2 (en) | 2009-08-14 | 2016-09-13 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules as antiprotozoal agents |
WO2011022337A1 (en) | 2009-08-19 | 2011-02-24 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
US9346834B2 (en) | 2009-10-20 | 2016-05-24 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
US8461134B2 (en) | 2009-11-11 | 2013-06-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
WO2011063293A1 (en) * | 2009-11-20 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antihelminth agents |
WO2011094450A1 (en) * | 2010-01-27 | 2011-08-04 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules |
AP2012006482A0 (en) | 2010-03-19 | 2012-10-31 | Anacor Pharmacueticals Inc | Boron-containing small molecules as anti-protozoalagent |
EA033311B1 (en) | 2010-09-07 | 2019-09-30 | Анакор Фармасьютикалс, Инк. | Benzoxaborole derivatives as antibacterial agents |
CN103732065B (en) | 2011-08-19 | 2016-10-26 | 葛兰素集团有限公司 | For treating the benzofuran compound of infection with hepatitis C virus |
US11039617B2 (en) | 2013-01-30 | 2021-06-22 | Agrofresh Inc. | Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness |
US9585396B2 (en) | 2013-01-30 | 2017-03-07 | Agrofresh Inc. | Volatile applications against pathogens |
MA38319A1 (en) | 2013-01-30 | 2016-08-31 | Dow Agrosciences Llc | Use of benzoxaboroles as volatile antimicrobials on meats, plants, or parts of plants |
US10070649B2 (en) | 2013-01-30 | 2018-09-11 | Agrofresh Inc. | Volatile applications against pathogens |
US8669207B1 (en) | 2013-01-30 | 2014-03-11 | Dow Agrosciences, Llc. | Compounds and compositions |
JP6605513B2 (en) | 2014-07-01 | 2019-11-13 | 第一三共株式会社 | Tricyclic benzoxabolol as an antibacterial agent |
WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
DK3383363T3 (en) | 2015-11-30 | 2021-01-18 | Anacor Pharmaceuticals Inc | Topical pharmaceutical formulations for the treatment of inflammatory-related conditions |
NZ745681A (en) | 2016-03-07 | 2022-05-27 | Agrofresh Inc | Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops |
US11447506B2 (en) | 2016-05-09 | 2022-09-20 | Anacor Pharmaceuticals, Inc. | Crystal forms of crisaborole in free form and preparation method and use thereof |
WO2017203514A1 (en) * | 2016-05-26 | 2017-11-30 | Perrigo Api Ltd | Polymorphs of crisaborole and production processes therefor |
WO2018160845A1 (en) | 2017-03-01 | 2018-09-07 | Anacor Pharmaceuticals, Inc. | Novel oxaborole analogs and uses thereof |
WO2018207216A1 (en) * | 2017-05-12 | 2018-11-15 | Biophore India Pharmaceuticals Pvt. Ltd. | Novel process for the preparation of 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl) oxy] benzonitrile (crisaborole) |
US10865217B2 (en) | 2017-05-23 | 2020-12-15 | Msn Laboratories Private Limited, R & D Center | Process for the preparation of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and polymorphs thereof |
JP2021505660A (en) | 2017-11-30 | 2021-02-18 | ボラゲン,インコーポレーテッド | Benzoxabolol compounds and their formulations |
BR112021003037A2 (en) | 2018-08-18 | 2021-05-11 | Boragen, Inc. | solid forms of substituted benzoxaborol and compositions thereof |
CR20210163A (en) | 2018-10-05 | 2021-06-24 | Pfizer | Boron containing pde4 inhibitors |
US20220185815A1 (en) | 2019-03-06 | 2022-06-16 | Daiichi Sankyo Company, Limited | Pyrrolopyrazole derivative |
CN112174989B (en) * | 2019-07-02 | 2023-06-20 | 江西同和药业股份有限公司 | Preparation method of clenbuterol |
US20230340530A1 (en) | 2020-08-31 | 2023-10-26 | Pfizer Inc. | Methods of Protecting RNA |
WO2024038090A1 (en) * | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
CN116239498B (en) * | 2023-05-11 | 2023-07-21 | 北京元延医药科技股份有限公司 | Method for preparing clenbuterol intermediate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060234981A1 (en) * | 2005-02-16 | 2006-10-19 | Anacor Pharmaceuticals | Boron-containing small molecules |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596985B2 (en) * | 2000-02-22 | 2003-07-22 | Rioch Company, Ltd. | Multi-beam scanning device, multi-beam scanning method, light source device, and image forming apparatus |
US20060229347A1 (en) * | 2005-03-30 | 2006-10-12 | Astion Development A/S | Treatment of eczemas |
CA2933994A1 (en) * | 2006-02-16 | 2007-08-23 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-inflammatory agents |
-
2009
- 2009-03-05 EP EP09700012A patent/EP2187893A4/en not_active Withdrawn
- 2009-03-05 WO PCT/US2009/036250 patent/WO2009111676A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060234981A1 (en) * | 2005-02-16 | 2006-10-19 | Anacor Pharmaceuticals | Boron-containing small molecules |
Non-Patent Citations (1)
Title |
---|
See also references of WO2009111676A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009111676A3 (en) | 2010-04-01 |
WO2009111676A2 (en) | 2009-09-11 |
WO2009111676A8 (en) | 2010-09-30 |
EP2187893A4 (en) | 2012-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9416146B2 (en) | Boron-containing small molecules as anti-inflammatory agents | |
WO2009111676A2 (en) | Boron-containing small molecules as anti-inflammatory agents | |
US9499570B2 (en) | Boron containing small molecules | |
US20200046745A1 (en) | Boron containing small molecules as anti-inflammatory agents | |
JP5745279B2 (en) | Boron-containing small molecules as anti-inflammatory agents | |
JP2017048198A (en) | Boron-containing small molecules as anti-inflammatory agents | |
AU2015202701A1 (en) | Boron-containing small molecules as anti-inflammatory agents | |
US20240358728A1 (en) | Boron containing small molecules as anti-inflammatory agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20090327 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1144260 Country of ref document: HK |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ALLEY, MICHAEL RICHARD KEVIN Inventor name: CHEN, DAITAO Inventor name: JACOBS, ROBERT Inventor name: SINGH, RAJESHWAR Inventor name: SHARMA, RASHMI Inventor name: SALES, MARCELO Inventor name: LU, XIAOSONG Inventor name: NIEMANN, JAMES A. Inventor name: BAKER, STEPHEN J. Inventor name: XIA, YI Inventor name: SANDERS, VIRGINIA Inventor name: FREUND, YVONNE Inventor name: MAPLES, KIRK R. Inventor name: PLATTNER, JACOB J. Inventor name: DING, CHARLES Z. Inventor name: ZHANG, YONG-KANG Inventor name: AKAMA, TSUTOMU |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120125 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07F 5/02 20060101ALI20120119BHEP Ipc: A61K 31/69 20060101AFI20120119BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120824 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1144260 Country of ref document: HK |